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ABSTRACT
Infectious diseases put an enormous burden on both children and the elderly in the forms 
of respiratory, gastrointestinal and oral infections. Th ere is evidence suggesting that specifi c 
probiotics may be antagonistic to pathogens and may enhance the immune system, but the 
clinical evidence is still too sparce to make general conclusions on the disease-preventive 
eff ects of probiotics. Th is thesis, consisting of four independent, double-blind, placebo-
controlled clinical trials, investigated whether Lactobacillus GG (LGG) or a specifi c probiotic 
combination containing LGG would reduce the risk of common infections or the prevalence 
of pathogens in healthy and infection-prone children and in independent and institutionalised 
elderly people.
 
In healthy day-care children, the 7-month consumption of probiotic milk containing 
Lactobacillus GG appeared to postpone the fi rst acute respiratory infection (ARI) by one week 
(p=0.03, adjusted p=0.16), and to reduce complicated infections (39% vs. 47%, p<0.05, adjusted 
p=0.13), as well as the need for antibiotic treatment (44% vs. 54%, p=0.03, adjusted p=0.08) and 
day-care absences (4.9 vs. 5.8 days, p=0.03, adjusted p=0.09) compared to the placebo milk. In 
infection-prone children, the 6-month consumption of a combination of four probiotic bacteria 
(LGG, L. rhamnosus LC705, Propionibacterium freudenreichii JS, Bifi dobacterium breve 99) 
taken in capsules appeared to reduce recurrent ARIs (72% vs. 82%, p<0.05; adjusted p=0.06), 
and the eff ect was particularly noticeable in a subgroup of children with allergic diseases 
(12% vs. 33%, p=0.03), although no eff ect on the presence of nasopharyngeal rhinovirus 
or enterovirus was seen. Th e 5-month consumption of the same probiotic combination did 
not show any benefi cial eff ects on the respiratory infections in frail, institutionalised elderly 
subjects. 
In healthy children receiving Lactobacillus GG, the reduction in complications resulted in a 
marginal reduction in the occurrence of acute otitis media (AOM) (31% vs. 39%, p=0.08; 
adjusted p=0.19), and the postponement of the fi rst AOM episode by 12 days (p=0.04; 
adjusted p=0.09). However, in otitis-prone children, a probiotic combination did not reduce 
the occurrence of AOM or the total prevalence of common AOM pathogens (Streptococcus 
pneumoniae, Haemophilus infl uenzae, Moraxella catarrhalis), except in the case of children with 
allergic diseases, in whom probiotics reduced recurrent AOM episodes (0% vs. 14%, p=0.03). 
In addition, interaction between probiotics and bacterial carriage was seen: probiotics reduced 
AOM in children who did not carry any bacterial pathogens (63% vs. 83%), but the eff ect was 
the reverse in children carrying bacteria in the nasopharynx (74% vs 62%) (p<0.05). 
Long-term probiotic treatment, either LGG given in milk to healthy children for 7 months or 
a combination of probiotics given in capsules to institutionalised elderly subjects for 5 months, 
did not reduce the occurrence of acute diarrhoea. However, when the probiotic combination 
(LGG, L. rhamnosus LC705, Propionibacterium JS) was given in cheese to independent elderly 
subjects for 4 months, the oral carriage of high Candida counts was reduced in the probiotic 
group vs. the placebo group (21% vs. 34%, p=0.01, adjusted p=0.004). Th e risk of hyposalivation 
was also reduced in the probiotic group (p=0.05). 
In conclusion, probiotics appear to slightly alleviate the severity of respiratory infections 
by postponing their appearance, by reducing complications and the need for antimicrobial 
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treatments. In addition, they appear to prevent recurrent infections in certain subgroups 
of children, such as in infection-prone children with allergic diseases. Alleviating ARI by 
probiotics may lead to a marginal reduction in the occurrence of AOM in healthy children but 
not in infection-prone children with disturbed nasopharyngeal microbiota. On the basis of 
these results it could be supposed that Lactobacillus GG or a specifi c combination containing 
LGG are eff ective against viral but not against bacterial otitis, and the mechanism is probably 
mediated through the stimulation of the immune system. A specifi c probiotic combination does 
not reduce respiratory infections in frail elderly subjects. Acute diarrhoea, either in children 
or in the elderly, is not prevented by the continuous, long-term consumption of probiotics, but 
the consumption of a specifi c probiotic combination in a food matrix is benefi cial to the oral 
health of the elderly, through the reduction of the carriage of Candida. 
ABSTRACT
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1   INTRODUCTION
Th e intestinal normal microbiota is a metabolically active organ, which plays a signifi cant 
role in the maturation and function of the immune system in the gut. Microbial colonisation 
begins at birth, is aff ected by the mode of delivery and the infant’s diet, and by the age of two 
years gradually alters to resemble that of an adult. Th e mature intestinal microbiota provides 
a physical and immunological barrier against microbial and other harmful exposures from 
the environment (Salminen et al., 2006). Th e microbiota is continuously interacting with the 
environment, including other bacteria, the gut epithelium, and the mucosal and endocrine 
systems. By means of these interactions the microbiota resists the colonisation of pathogens, 
participates in the elimination of foreign antigens, and regulates the immune responses. In a 
diseased state, the healthy host-microbe interaction is disturbed, leading to increased intestinal 
permeability, infl ammatory immune responses, and infection. 
Probiotic therapy is based on the concept of maintaining a healthy, balanced microbiota. 
Th e term ‘probiotic’, meaning ‘for life’, initially comes from the Greek. Probiotics, in the form 
of Streptococcus thermophilus and Lactobacillus bulgaricus in fermented milk, have been 
ingested by humans for thousands of years. Th e original concept of probiotics originated over 
a hundred years ago, when the Russian Nobel Prize winner Elie Metchnikoff  hypothesised 
that the longevity of Bulgarian peasants was the result of their consumption of fermented 
milk products. Since then, attention has increasingly been directed towards the possibilities 
of probiotic therapy for improving human health. Accumulating evidence suggests that 
administration of probiotics, either as mono- or mixed cultures, can be used to optimise the 
gut microbiota and to prevent and treat diff erent diseases.
Infectious diseases, including oral, respiratory and gastrointestinal infections, are a major 
health problem among children and the elderly. Th ey put a great health burden on patients and 
on their families, and an enormous economic burden on society in terms of consultations with 
doctors, direct medical costs, and the indirect costs of missed days from work or absences from 
school and day care (Bell et al., 1989; Nurmi et al., 1991; Fendrick et al., 2003). In children, 
acute respiratory infections, including their most prevalent complication, otitis media, account 
for 80% of all infectious diseases diagnosed in general practice (Rautakorpi et al., 2001). Viral 
gastroenteritis is the second most common infection (Rosenfeldt et al., 2005). Day-care 
attendance is known to be a major risk factor for infections in children (Louhiala et al., 1995). 
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In the elderly, respiratory infections account for approximately half (Rautakorpi et al., 2001), 
and gastroenteritis for one third, of all infections (Strausbaugh et al., 2003), while candidosis is 
the most common oral infection. As many as 75% of the elderly are known to harbour Candida 
in their oral cavity (Närhi et al., 1993).
Infectious diseases are widely treated with antimicrobials; for example, respiratory infections 
account for 80% of all antibiotic prescriptions in primary care (Rautakorpi et al., 1999). 
Although the prescription of antibiotics is lowest in northern Europe compared to southern 
and eastern parts (Goossens et al., 2005), the enormous consumption of antibiotics is evidently 
leading to emerging antibiotic resistance, a major public health problem worldwide. Th e failure 
of antibiotics to change the host receptivity of pathogen recurrences, and the dearth of any 
eff ective means of preventing infectious diseases, have inspired scientists to fi nd new alternative 
ways of reducing the risk of common infections, so the increased interest in probiotic bacteria is 
understandable. Nowadays, abundant experimental data support the hypothesis that probiotics 
aff ect the host benefi cially by balancing the indigenous microbiota (Madden et al., 2005), by 
hampering the growth of pathogenic microorganisms, and by boosting innate and aquired 
immunity (Maldonado Galdeano et al., 2007). Probiotics may thus have the potential to reduce 
the risk of infectious diseases. However, evidence of the clinical relevance of these eff ects is still 
scarce and needs to be proven in well controlled, clinical trials. 
Th e purpose of the present work was to evaluate the eff ect of specifi c probiotic bacteria 
in preventing common infections that occur in oral mucosa and in the respiratory and 
gastrointestinal tracts. To clarify these eff ects, four large-scale clinical studies, two with children 
and two with elderly subjects, were carried out.
INTRODUCTION
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2   REVIEW OF THE LITERATURE
2.1 Common infectious diseases in children and in the elderly 
2.1.1 Acute respiratory tract infections 
Acute respiratory infections (ARI) are the most common health problems among children and 
the elderly, though the incidence is high in all age groups. Th e majority of respiratory infections 
aff ect the upper respiratory tract, and are mild, self-limiting viral upper respiratory infections 
(URIs), also known as the common cold (for review, see Heikkinen and Järvinen, 2003). Th e 
frequency of respiratory infections shows clear seasonality; the occurrence increases rapidly 
in the autumn, reaching peak incidence during winter, and decreases in the spring (Butz et al., 
1990; Rautakorpi et al., 2006). 
In children, the prevalence of ARI is highest at the age of 2 years (Wald et al., 1991b). Children 
under 6 months of age experience less ARI than older children (Monto and Ullman, 1974), 
possibly due to antibodies originating from the mother. Based on population-based cohort 
studies, 1-2-year-old children experience an average of 3-8 ARI episodes per year, while children 
of over 3, an average of 4-6 episodes (Wald et al., 1991b). In addition to age, day-care attendance 
is known to be a major risk factor for ARI. Large numbers of children in close physical contact 
and the poor personal hygiene of infants and toddlers favour the transmission of infectious 
diseases. According to several population-based cross-sectional and cohort studies, the risk of 
respiratory infections and acute otitis media (AOM) is known to be 1.2-2.5 times higher (Bell 
et al., 1989; Wald et al., 1991a; Collet et al., 1994; Louhiala et al., 1995; Hernandez et al., 1999; 
Nafstad et al., 1999), and the risk of pneumonia as much as 9.7 times higher (Louhiala et al., 
1995) in children attending day-care centres than in children looked aft er at home or in small 
groups. Th us, day-care children experience an average of 6.3 respiratory infection episodes 
compared to 3.9 episodes in children in home care (Wald et al., 1988). Th e risk is particularly 
noticeable during the fi rst 6 months of enrolment in day care and in children under two years 
of age (Kamper-Jørgensen et al., 2006). 
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Approximately one quarter of children suff er from recurrent or prolonged infections (Nokso-
Koivisto et al., 2002b), usually defi ned as having 4-12 ARI episodes/year. In Finnish children, 
the incidence of ARI episodes was 4.5 per person-year in children suff ering from recurrent 
infections compared to 1.7 episodes in children without recurrences (Nokso-Koivisto et al., 
2002b). Socioeconomic and environmental risk factors, such as day-care attendance (Wald 
et al., 1991a), number of siblings, parental smoking in the household (Nokso-Koivisto et al., 
2002b), and short duration of breastfeeding (Douglas et al., 1994), have been associated with 
recurrent infections. Th e observation that boys experience recurrent infections more oft en 
than girls (Nokso-Koivisto et al., 2002b), suggests that genetic factors might account for a 
predisposition to infection. Defi ciencies in the innate immune system, such as in complement 
activation via mannanbinding lectin, or via the classical pathway through complement factor 
C4, have also been associated with increased risk of recurrent infections in children and 
chronic sinusitis in adults (Cedzynski et al., 2004; Seppänen et al., 2006). However, immune 
defi ciencies rarely explain susceptibility to infections at a population level. 
Elderly subjects living in long-term care facilities are also at increased risk of infection because 
of the physiological changes that occur with aging (such as less fl exible lungs and diminished 
clearance mechanisms for pulmonary secretions), because of underlying chronic diseases and 
the institutional environment where infections are easily transmitted (for review, see Garibaldi, 
1999). Respiratory infections, including both upper and lower respiratory tract infections, 
are known to account for 36-70% of all infectious diseases in long-term-care patients (Beck-
Sague et al., 1994; Orr et al., 1996; Engelhart et al., 2005). According to intervention trials, the 
incidence rate of URI in either the non-institutionalised elderly or elderly patients living in old 
people’s homes, varies from 0.8-1.2 infections per person-year (Nicholson et al., 1997; Graat 
et al., 2002; Meydani et al., 2004). Although the incidence rate of respiratory infections does 
not appear particularly alarming, the impact is greater because infections in the elderly are 
associated with increased mortality (Beck-Sague et al., 1994; Th ompson et al., 2006). Th ere is 
also growing evidence to show that common respiratory infections cause the exacerbation of 
asthma and chronic obstructive pulmonary diseases (COPD) (Proud and Chow, 2006).
Viral upper respiratory infections are sometimes accompanied by a bacterial complication, 
causing otitis media (see Chapter 2.1.2) and sinusitis in the upper respiratory tract, or 
bronchitis and pneumonia in the lower respiratory tract. Sinusitis is known to occur in 
0.5-2% of URI episodes (Heikkinen and Järvinen, 2003). However, in young children 
sinusitis is usually an extension of the common cold due to the spreading of infection to 
the paranasal sinuses, causing mucosal oedema and the accumulation of mucus without a 
bacterial co-infection (Kristo et al., 2003). Bronchiolitis and pneumonia are the most common 
manifestations of lower respiratory infections (LRIs) in infants. In the home-living elderly, 
as many as 65% of URIs are complicated by LRIs (Nicholson et al., 1997). LRIs represent 
about 60% of respiratory infections in the nursing-home elderly, acute bronchitis accounting 
for 84%, and pneumonia for 16% of the LRIs (Engelhart et al., 2005). Pneumonia is oft en 
a true bacterial complication, occurring with the prevalence of 0.3-5.8% (Garibaldi, 1999). 
In the Finnish population, the incidence of community-acquired pneumonia is known to 
be 12/1000 inhabitants per year, 36/1000 among children under 5, and 15-34/1000 among 
subjects over 60 years of age (Jokinen et al., 1993). Residents in long-term-care facilities are 
at particularly high risk of developing pneumonia.
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2.1.1.1 Etiology and pathogenesis 
Acute upper respiratory infections are mainly attributed to viruses. Viruses have been associated 
with two thirds of the common cold episodes (Mäkelä et al., 1998), and it is estimated that 
over 200 diff erent types of virus cause URI (for review, see Eccles, 2005). Th e proportions of 
diff erent viruses vary depending on the age of the subject, the season, and the methods of viral 
sampling and detection. Rhinoviruses are the largest group of viruses that cause URI, including 
at least 100 diff erent serotypes (for review, see Nokso-Koivisto et al., 2006). Rhinoviruses have 
been consistently found to be the most predominant cause in all age groups, accounting for 
about 30-63% of common colds (Nicholson et al., 1997; Mäkelä et al, 1998; Vesa et al., 2001; 
Nokso-Koivisto et al., 2002b). For the most part rhinoviruses attack during the early autumn 
and in the spring (Mäkelä et al., 1998; Vesa et al., 2001). Although they are generally thought 
to cause mild common colds, in children they are frequently associated with LRIs. Human 
coronaviruses are not common causes of URI in children, but account for about 10% of URI 
episodes later in life (Nicholson et al., 1997), followed by infl uenza, accounting for 4-10% of 
colds in children, and in community-living elderly people (Nicholson et al., 1997; Mäkelä et 
al., 1998; Nokso-Koivisto et al., 2002b; Peltola et al., 2005). Enteroviruses, frequently found in 
small children (Nokso-Koivisto et al., 2002a), used to be thought to cause mild disease, but 
recently they have also been associated with AOM (Nokso-Koivisto et al., 2006). Respiratory 
syncytial virus (RSV) has mainly been known as a primary cause of bronchiolitis in children 
(for review, see Hall, 1999), but is nowadays recognised as an important pathogen in adults 
as well (Hashem and Hall, 2003). In cohort studies RSV accounts for an annual incidence of 
3-7% of URIs in healthy, community-living elderly subjects (Nicholson et al., 1997; Falsey et 
al., 2005). Other causative viruses, such as parainfl uenza and adenoviruses, account for minor 
proportions of URIs (Nicholson et al., 1997; Heikkinen and Järvinen, 2003). Parainfl uenza 
viruses are most oft en associated with laryngitis, but can cause a broad spectrum of respiratory 
diseases, ranging from mild upper respiratory infections to pneumonia (Nokso-Koivisto et al., 
2006). Newly identifi ed human metapneumoviruses and bocaviruses have been found fairly 
frequently in children, each accounting for 5-6% of infections (Arden et al., 2006).
Th e pathogenetic mechanisms of various respiratory viruses diff er between the viruses 
themselves. Th e understanding of the pathogenetic events is mainly derived from rhinovirus 
infections. Rhinoviruses are transmitted mainly by small aerosol particles, and via direct or 
indirect contact with infected secretions.Virus titres peak 2-3 days aft er infection and may 
persist for as long as 3-6 weeks (Jartti et al., 2004). At the beginning of the infection, the 
rhinovirus invades the host by binding to the ICAM-1 receptor (intercellular adhesion receptor 
molecule 1), mainly located in the nasopharynx. Aft er intracellular invasion and replication, 
the virus spreads intranasally to the pharynx. Replication evokes infl ammatory and immune 
responses in the host, leading to vasodilatation, increased vascular permeability and cellular 
infi ltration, through the release of infl ammatory mediators. Elevated concentrations of 
proinfl ammatory cytokines, such as IL-1β, IL-6, TNF-α, and IFN-γ, in nasal lavage, result in a 
cascade of infl ammatory reaction necessary to eradicate the virus (van Kempen et al., 1999). 
Viral infections may pave the way for secondary bacterial infections (Peltola et al., 2006), 
leading to bacterial complications in the upper respiratory tract (such as otitis media and 
sinusitis), or in the lower respiratory tract (such as bronchitis and pneumonia). Viral infections 
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facilitate bacterial adherence and colonisation by upregulating the molecules that bacteria 
utilise as receptors (Hament et al., 1999; Peltola and McCullers, 2004). In addition, viruses cause 
physical damage to the respiratory epithelium and impair the local defence mechanisms, which 
leads to increased translocation of bacteria through the epithelial barrier of the respiratory cells 
(Hament et al., 1999; Peltola and McCullers, 2004). Mixed viral-bacterial infections seem to be 
relatively common in small children (Heikkinen et al., 2004), although bacterial co-infections 
in young adults have been found in only 4% of common cold events (Mäkelä et al., 1998). S. 
pneumoniae, H. infl uenzae or M. catarrhalis have been detected in 26% of young adults with 
sinusitis (Puhakka et al., 1998a), while viral infection has been detected in 82% of patients, 
with no signifi cant increase in the levels of antibodies to bacteria or the elevation of CRP 
(Puhakka et al. 1998a). Th e pathogenesis of acute otitis media, the most common bacterial 
complication of upper respiratory infection in children, is reviewed in more detail in Chapter 
2.1.2.1. Bronchiolitis in young children is mainly caused by viruses such as infl uenza, RSV, 
parainfl uenza and metapneumovirus, and to a lesser extent by adeno-, rhino- and enteroviruses, 
while the prevalence of bacterial pathogens increases with advancing age (van Woensel et al., 
2003; Klig, 2006). S. pneumoniae, H. infl uenzae, Moraxella catarrhalis, Chlamydia pneumoniae, 
Mycoplasma pneumoniae, and Staphylococcus aureus mixed with viruses, such as infl uenza and 
RSV, are important pathogens associated with pneumonia (for review, see Marrie, 2000). 
2.1.1.2 Clinical manifestation
Acute respiratory infections are diagnosed on the basis of symptomatology. However, not 
all infections lead to clinical illness; symptomatic diseases are known to develop in 75% of 
infected persons (Gwaltney and Hayden, 1992). Th e clinical expression of ARI is variable, and 
is modulated depending on the infective virus and on the age, physiological and immunological 
state of the host. Upper respiratory tract infection involves infl ammation of the respiratory 
mucosa from the nose to the lower respiratory tree, excluding the alveoli. URI causes localised 
symptoms such as cough, rhinitis, blocked nose, wheezing and sore throat, and systemic 
symptoms such as fever, malaise, headache and loss of appetite (for review, see Eccles, 2005). 
Understanding of the mechanisms behind the infection symptoms is poor, but it has been 
suggested that clinical symptoms might not be caused by the direct cytopathic eff ect of the 
viruses on the epithelial cells, but are primarily due to the infl ammatory response of the 
host (Eccles, 2005). Th e major cells protecting the host against the invasion of pathogens are 
macrophages, which produce cytokines, which lead to the recruitment of other immune cells 
and infl ammation. Th e complex mixture of proinfl ammatory cytokines is responsible for 
systemic symptoms such as fever, while the infl ammatory mediator, bradykinin, is believed 
to cause local symptoms. Symptoms arise aft er an incubation period that varies considerably 
between diff erent viruses, ranging from 10-12 hours in rhinovirus infection, to 1-7 days in 
infl uenza infection (for review, see Heikkinen and Järvinen, 2003). Th e symptoms usually peak 
2-3 days aft er infection and are resolved in 7-10 days, although in some patients symptoms can 
be present even for as long as 3 weeks (Eccles, 2005). 
Rhinovirus infection typically starts with a sore throat, soon followed by watery nasal discharge, 
and later by nasal congestion and cough, which may persist for 3 weeks or even longer (Eccless 
2005). In children, fever is oft en present during an acute respiratory infection (Putto et al., 
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1986), but in adults fever occurs less frequently (Puhakka et al., 1998b). Fever of at least 39°C 
in children has been mainly associated with adenovirus and infl uenza A and B, but not so oft en 
with parainfl uenza or RSV (Putto et al., 1986). Th e mean duration of fever varies from 3 to 5 days 
depending on the virus, and in one third of the children fever lasts fi ve days or longer (Putto et al., 
1986). However, high and prolonged fever does not diff er between viral and bacterial infections. 
Infl uenza is oft en considered to be a separate disease from the common cold. However, the 
clinical manifestations of infl uenza range from an asymptomatic infection to severe illness, and 
therefore cannot be distinguished on the basis of the symptoms. Cough and fever occurring 
within 48 hours of symptom onset have been found to be the best predictors of infl uenza (Monto 
et al., 2000), but the clinical diagnosis of infl uenza is still extremely diffi  cult. In a prospective 
outpatient study, fewer than 40% of all true cases were identifi ed, and only one third of all 
clinically diagnosed cases could be verifi ed by laboratory analysis (Peltola et al, 2005). Infl uenza, 
parainfl uenza and RSV cause more symptoms in the lower respiratory tract than rhino- and 
enteroviruses (for review, see Klig, 2006). Although diff erent viruses tend to have some variation 
in their typical clinical manifestation, it is not possible to identify the causative virus on the basis 
of symptoms. Lower respiratory infections are clinically characterised by a variety of symptoms, 
such as cough, fever, tachypnea, wheezing, chills and chest pain, but extrapulmonary symptoms 
such as nausea, vomiting and diarrhoea may also occur (for review, see Marrie, 2000). However, 
pneumonia, especially in the elderly, may also be latent and afebrile, or may manifest itself mainly 
as delirium with only a few respiratory symptoms. 
2.1.1.3 Treatment and prevention
Despite the fact that antibiotic treatment does not infl uence the clinical course of viral 
infection, uncomplicated respiratory infections are widely treated by antibiotics: In the USA, 
as many as 60% of patients with common colds receive antibiotic treatment unnecessarily 
(Mainous et al., 1996), the corresponding fi gure being 36% in Sweden (Andre et al., 2005) and 
7-12% in Finland (Rautakorpi et al., 2006). Treatment of the common cold is mainly based on 
symptom-relieving medications, such as antihistamines for reducing rhinitis, expectorants and 
mucolytic cough medication, and non-steroidal anti-infl ammatory drugs that reduce the fever. 
However, according to a recent review based on seven Cochrane reviews, these non-antibiotic 
treatments are mostly found to be ineff ective (Arroll, 2005). Antiviral medication, such as 
the M2 ion channel-blocking drugs, amantadine and rimantadine, and the neuraminidase 
inhibitors, zanamivir and oseltamivir, prevents approximately 60-80% of infl uenza cases, and 
shortens the duration of the fever by 1-2 days if the treatment is started within 48 hours of the 
onset of symptoms (Jeff erson et al., 2006). Despite intensive research and drug development, 
no eff ective antiviral medication is so far available against other common respiratory viruses. 
Preventive therapies against viral respiratory infections are also scarce. Preventive antimicrobial 
treatment has been shown to prevent the bacterial complications of URI in subjects carrying 
bacterial pathogens in the nasopharynx, but no benefi ts were seen in subjects without bacteria 
(Kaiser et al., 1996). However, antibiotic treatment did not improve the clinical course of acute 
sinusitis (van Buchem et al., 1997). Vaccine development against diff erent viruses has been 
ongoing without any real success. Th e prevention of rhinoviruses would be the most benefi cial, 
but because of its numerous diff erent serotypes, the development of a vaccine seems unlikely. At 
present, the only vaccines commercially available are against infl uenza. According to a recent 
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systematic review, the eff ectiveness of the infl uenza vaccination was modest (23%) against 
infl uenza-like illnesses in subjects aged 65 years or more residing in long-term-care facilities, 
and was not eff ective in the community-living elderly (Jeff erson et al., 2005a). However, 
vaccination seems to prevent pneumonia, hospital admission and death from infl uenza, 
pneumonia or cardiovascular diseases, as well as overall mortality. In children over two years 
of age, the eff ectiveness of live attenuated vaccines was 38%, and 28% for inactivated vaccines 
(Jeff erson et al., 2005b). Vaccines were  eff ective in reducing school absences, but had little 
eff ect on lower respiratory diseases, acute otitis media and hospital stay. Systematic reviews 
and a meta-analysis of the role of multivitamin and mineral supplementation in preventing 
infections in the elderly has showed a reduction of 18% in infections (El-Kadiki and Sutton, 
2005), and vitamin C supplements show small benefi ts in reducing the duration and severity 
of infections (Douglas et al., 2004). Th us, the evidence for routine use of vitamin supplements 
is still weak and confl icting. Improved hygiene practice programmes have also shown modest 
results: Infections, mainly upper respiratory infections, have been reduced by 9% (Uhari and 
Möttönen, 1999), and absences due to infections, by 26% in day-care children (Pönkä et al., 
2004), while the reduction of infections among long-term-care elderly subjects has been  34% 
(Makris et al., 2000). 
2.1.2 Acute otitis media 
Acute otitis media (AOM), infl ammation of the middle ear, is the most common complication 
of a viral respiratory infection, and the main reason for consulting a doctor and for antibiotic 
prescription in children (for review, see Klein, 2001). 30-43% of upper respiratory infections are 
associated with AOM (Wald et al., 1991b; Koivunen et al., 1999; Vesa et al., 2001). AOM places 
a great burden on children and their families. Untreated AOM may lead to perforation of the 
tympanic membrane, suppurative complications and impairment of hearing, which may result 
in speech and language delays in small children (for review, see Rovers et al., 2004). Direct and 
indirect costs are also high: in Finland, the total annual cost associated with AOM reaches $US 
138 M (Niemelä et al., 1999). Th e clinical picture of otitis media has changed over the past two 
decades: serious complications have decreased, while the incidence of recurrent infections 
has increased (Joki-Erkkilä et al., 2000). According to a cohort study in the Netherlands, the 
incidence rate of AOM and otitis media with eff usion (OME) declined during the years 1995-
2003 in children over two years of age, while the incidence rate in children under two increased 
by 46-66% (Plasschaert et al., 2006). Antibiotic prescriptions for AOM increased by 45% in all 
age groups.
Prospective cohort studies indicate that AOM peaks in children aged 6-11 months (Vesa et al., 
2001), and approximately every fi ft h child is known to experience at least one AOM episode 
during the fi rst year of its life (Aniansson et al., 1994). According to the Finnish Otitis Media 
(FinOM) cohort study, 62% of children experience at least one otitis media episode by the 
age of two, and 8% experience six or more recurrent episodes (Kilpi et al., 2001). When a 
child experiences at least three or more episodes of AOM within 6 months or at least four 
episodes within 12 months, s/he is considered prone to recurrent infections (Berman, 1997). 
Approximately 5-20% of the pediatric population suff ers from recurrent otitis media episodes 
(Alho, 1997; Pichichero, 2000; Faden, 2001). According to a meta-analysis, day care outside 
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the home, siblings, parental smoking and the use of a pacifi er were associated with increased 
risk of AOM, while breastfeeding for at least 3 months protected from AOM (Uhari et al., 
1996). In addition, the occurrence of the fi rst AOM episode during the fi rst 6 months of life, 
age under 3 years, male gender, allergies and anatomic abnormalities of the eustachian tube in 
children with cleft  palate or Down’s syndrome, are known to predispose to AOM (for review, 
see Klein, 2001). Studies have failed to demonstrate major immunological abnormalities in 
otitis-prone children, although diff erences, for instance in IgG2 antibody production between 
otitis-prone and healthy children, have been demonstrated (Faden, 2001). Th e prevalence of 
specifi c antibody defi ciences, such as an inadequate IgG response to polysaccharide antigens, 
is shown to be relatively common (15%) among children with recurrent infections (Boyle et 
al., 2006a).
2.1.2.1 Etiology and pathogenesis 
Respiratory viruses play a crucial role in the development of acute otitis media.  Viral 
respiratory infection precedes the development of AOM, which is frequently diagnosed on 
days 2-5 aft er the onset of acute upper respiratory symptoms (Koivunen et al., 1999). Viruses 
can be detected in 50-70% of AOM cases (Nokso-Koivisto et al., 2004; Ruohola et al., 2006), 
and in one fi ft h of the cases, virus has been the only pathogen found (Kleemola et al., 2006). 
Rhinoviruses, RSV and enteroviruses, in particular, have been found to be associated with a 
signifi cant proportion of AOM cases (Vesa et al., 2001; Nokso-Koivisto et al., 2004; Kleemola 
et al., 2006; Nokso-Koivisto et al., 2006). Th e pathogenesis of AOM is multifactorial, involving 
the innate and adaptive immune system and genetic and environmental factors, as well as 
Eustachian tube function and pathogen load. Viral infections induce a release of infl ammatory 
mediators from the nasopharyngeal cells, causing infl ammation of the mucosa, and this 
provokes the dysfunction of the eustachian tube – known to be the most important factor in 
the pathogenesis of acute otitis media. Eustachian dysfunction causes a negative middle ear 
pressure, leading to the accumulation of mucus and pathogens from the nasopharynx to the 
middle ear and to impaired ventilation (for review, see Hendley, 2002). Th is enhances bacterial 
replication in the fl uid of the middle ear, leading to bacterial otitis media. Two third of AOM 
cases are coinfections with both bacteria and viruses (Ruohola et al., 2006).
Streptococcus pneumoniae is the predominant bacterial pathogen associated with otitis 
media, followed by Haemophilus infl uenzae, Moraxella catarrhalis, Streptococcus pyogenes 
and Staphylococcus aureus (for review, see Faden, 2001). S. pneumoniae has been isolated as 
a causative agent in 22-26% of otitis events in Finnish children, M. catarrhalis in 17-23%, and 
H. infl uenzae in 13-23% of otitis cases (Kilpi et al., 2001; Kleemola et al., 2006). About 17% of 
the episodes remain etiologically obscure (Kilpi et al., 2001). On the basis of an intervention 
trial, the prevalence of S. pneumoniae carriage among Finnish day-care children varies 
between 27 and 46%, M. catarrhalis between 7 and 25%, and H. infl uenzae between 11 and 
16% (Kontiokari et al., 2005). Age is strongly associated with pathogen carriage: according 
to a FinOM cohort study, the prevalence of S. pneumonia in children aged 2 months to 2 
years gradually increases from 9% to 43% (Syrjänen et al., 2001). Approximately 50% of 
children carry S. pneumoniae at the age of 2 years, and the prevalence declines to 21% by the 
age of 7 (for review, see Harper, 1999). Colonisation stimulates the production of mucosal 
as well as serum antibodies against the pathogens. A specifi c IgA mucosal antibody limits 
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the frequency and duration of colonisation, while serum IgG mainly protects against the 
development of AOM but does not aff ect colonisation (Faden, 2001). Otitis-prone children 
probably fail to develop a broad-based immune response, and therefore experience repeated 
episodes of colonisation and infection. Th e nasopharyngeal carriage of bacterial pathogens 
is known to be higher in children with AOM than in children without AOM (Aniansson et 
al., 1994). Th e density of the bacteria in the nasopharynx and the adenoids is also higher in 
children with recurrent otitis than in non-otitis-prone children (Linder et al., 1997; Brook 
and Yocum, 1999; Brook and Gober, 2000). H. infl uenzae is known to be the major cause of 
recurrent AOM (Kilpi et al., 2001). 
2.1.2.2 Clinical manifestation 
Acute otitis media is defi ned as the presence of middle-ear eff usion in conjuction with the 
rapid onset of one or more signs or symptoms of infl ammation in the middle ear (for review, 
see Rovers et al., 2004). It is important to distinguish acute otitis media from otitis media with 
eff usion, which is defi ned as fl uid in the middle ear without local or systemic illness. Bacterial 
otitis media is characterised by a bulging eardrum that has purulent fl uid behind it. Infectious 
symptoms usually appear in 48 hours, and are revealed by local or systemic fi ndings such as 
earache, fever, rhinitis, cough, night restlessness, poor appetite, vomiting or diarrhoea. AOM 
is associated with common URI symptoms in 95% of cases, pain in 75%, and fever in 25% 
(Faden, 2001). However, symptoms of otitis media are considered non-specifi c. Earache has 
been most strongly associated with AOM, although as many as 40% of children with AOM 
might not have earache at all (Heikkinen and Ruuskanen, 1995; Kontiokari et al., 1998). Sore 
throat, night restlessness and fever have also been associated with AOM, especially in children 
of over two years of age, but they are of no value in distinguising AOM from uncomplicated 
URI (Heikkinen and Ruuskanen, 1995; Kontiokari et al., 1998). As the infection begins to 
resolve, symptoms such as pain and fever lessen within 2 to 3 days, and most children become 
asymptomatic by 7 days (for review, see Faden et al., 1998), although URI symptoms may last 
an average of 11 days (Koivunen et al., 1999). However, eff usion from the middle ear resolves 
relatively slowly: 40% of cases are resolved by 2 weeks, 60% by one month, but eff usion may 
persist for as long as three months (Faden et al., 1998).   
Myringotomy is considered the golden standard for diagnosing AOM. However, pneumatic 
otoscopy, which combines visual assessment of tympanic-membrane mobility and appearance, 
is widely used in general practice. Tympanometry, which is also used in clinical practise, is a 
simple and objective quantitative method of assessing tympanic mobility and function. Th e 
overdiagnosing of AOM is a common problem, especially among general practitioners, and 
there is only slight to moderate correlation between the diagnosis of paediatric residents and 
otolaryngologists (Steinbach et al., 2002). Although symptoms and signs associated with AOM 
have poor sensitivity and specifi city, parents have been able to predict the presence of AOM to 
a sensitivity of 71% and a specifi city of 80% (Kontiokari et al., 1998). 
2.1.2.3 Treatment and prevention 
Because the origin of acute otitis media may be viral or bacterial or a combination of the two, 
it is oft en unclear at the time of diagnosis whether antibiotic treatment will be eff ective or not. 
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According to a meta-analysis of randomised, placebo-controlled studies, AOM will resolve 
within a week without antibiotic therapy in more than 80% of children, and the benefi t of 
antibiotics is only 13.7% over a placebo (Rosenfeld et al., 1994). Th erefore the use of delayed 
antibiotic-prescribing strategy (waiting for 48 to 72 hours before prescribing antibiotics to see 
whether infection will resolve spontaneously) is appropriate (Spiro et al., 2006). On the basis of a 
recent meta-analysis, antibiotics seem to be benefi cial in relieving pain or fever in children under 
two years of age, and in children with AOM and otorrhoea (Rovers et al., 2006). However, the 
increasing prevalence of antibiotic-resistant micro-organisms makes the management of otitis 
media complex and diffi  cult (Goossens et al., 2005). During the last decades, multiresistance 
and macrolide resistance in S. pneumonia has increased remarkably (Pihlajamäki et al., 2002), 
and  has been clearly associated with the total use of β-lactam antibiotics (Wald et al., 2001; 
Nasrin et al., 2002), and macrolides (Bergman et al., 2006).  According to the Finnish Study 
Group for Antimicrobial Resistance (the FiRe), the erythromycin resistance of pneumococci 
doubled during the years 1999-2005, being around 20% at the moment (www.ktl.fi /portal/
english/projects/fi re/fi nres/fi nres_antimicrobial_resistance_statistics). In  general, 30-45% of 
H. infl uenzae and over 95% of M. catarrhalis are known to be β-lactamase  producers (Brook, 
1998). According to FiRe, the prevalence of ampicilloine-resistant H.infl uenza is around 20%, 
and of M. catarrhalis, around 90%. 
Because of diffi  culties in providing optimal treatment for otitis media, eff ective strategies for 
preventing the development of AOM would be of utmost importance. In that area, vaccine 
development against pneumococci has been extensive. Over 90 diff erent serotypes of S. 
pneumoniae, based on the capsular polysaccharide antigens, are currently known. Th e most 
frequent serotypes in Finnish children are 6B, 6A, 11, 14, 19F, and 23F (Syrjänen et al., 2001), 
and serotypes 6, 14, 19, and 23 have been shown to be responsible for a large proportion of 
both invasive and local pneumococcal diseases in children (Sniadack et al., 1995; Kilpi et al., 
2001). Th e fi rst 23-valent capsular polysaccharide vaccine has been constructed by using 23 
of the most common pneumococcal polysaccharide capsule serotypes, but its effi  cacy has 
been limited in children under 2 years of age, because polysaccharides are not immunogenic 
in small children (Bernatoniene and Finn, 2005). Conjugating polysaccharides to protein 
conjugates makes the combination more immunogenic. A seven-valent pneumococcal 
conjugate vaccine, consisting of capsular polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 
19F, and 23F, conjugated to a carrier protein, has been found to be highly eff ective against 
vaccine serotype invasive pneumococcal infections (Black et al., 2000; O’Brien et al., 2003; 
Whitney et al., 2006), and moderately against pneumonia (Black et al., 2002). Th e overall 
effi  cacy against AOM has only  been around 6-7% (Eskola et al., 2001), but effi  cacy against 
pneumococcal episodes and episodes due to vaccine serotypes has been higher: 35% and 57% 
respectively (Eskola et al., 2001). Th e major secondary advantages of vaccination include the 
reduction of the nasopharyngeal carriage of vaccine strains and antibiotic-resistant serotypes 
in vaccine recipients (Musher, 2006). In the USA, aft er introducing conjugate vaccine into 
the immunisation schedule, the total amount of invasive pneumococcal diseases decreased 
to about half, while the rate of antibiotic-resistant invasive pneumococcal infections caused 
by vaccine serotypes decreased by 87% among children under two years of age, but also 
signifi cantly among people 65 years of age or older (Kyaw et al., 2006). Th us the reduction in 
the carriage rate results in reduced spreading of infective strains to unvaccinated subjects, a 
phenomenon known as “the herd eff ect”. 
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2.1.3 Diarrhoea 
Acute diarrhoea is a non-specifi c response of the intestine to several diff erent factors and 
conditions. Infection is the most common cause of acute diarrhoea, but other conditions, such 
as drugs, functional bowel disorders or infl ammatory bowel diseases may also cause diarrhoea. 
Acute infectious diarrhoea remains a major cause of morbidity and mortality worldwide. In 
industrialised countries, infectious diarrhoea is mainly a problem of morbidity and has a major 
fi nancial impact on health care systems, but in terms of increased mortality, the burden is much 
heavier in developing countries. Th erefore, the prevention of diarrhoeal illnesses would have 
considerable public-health implications (for review, see Cheng et al., 2005).
In children, acute gastroenteritis is the second most common infectious disease aft er the 
common cold. In prospective cohort studies of children aged 6 months to 7 years attending 
day-care centres, 46-51% of the subjects developed acute gastroenteritis during a 6-12-month 
follow-up (Hjelt et al., 1987b; Rosenfeldt et al., 2005), the annual incidence of diarrhoea 
being 0.9-1.1 episodes per child (Hjelt et al., 1987b; Louhiala et al., 1997). Th e incidence is 
age-dependent and highest among children under two years of age (Rosenfeldt et al., 2005). 
Infants have been reported to have 3.6 diarrhoea episodes per year, decreasing to 1.3 episodes 
in children older than 18 months of age (Staat et al., 1991). Day-care attendance is a major 
risk factor for diarrhoea in children, and the incidence of diarrhoea seems to be higher in 
boys than in girls (Staat et al., 1991), while breastfeeding is known to be a protective factor in 
infants (Gianino et al., 2002). Children in day-care centres experience an average of 0.4-4.2 
diarrhoea episodes per year; the risk of acute diarrhoea being 1.2-3.5 times higher than in 
children taken care of at home (Th acker et al., 1992; Louhiala et al., 1997). Th e proportion of 
diarrhoeal episodes attributable to day-care centres is 49% in 1-year-olds and 37% in two-year-
olds (Louhiala et al., 1997). Th e peak incidence of diarrhoea occurs during the winter, between 
January and April (Hjelt et al., 1987b; Rosenfeldt et al., 2005).
Nursing-home facilities provide an ideal environment for the spreading of gastrointestinal 
infections, since residents share sources of air, food and water in crowded institutional settings. 
Age-related achlorhydria and the frequent use of antimicrobial agents predispose residents 
to gastrointestinal infections. Visitors, staff  and residents bring pathogens from the hospital 
and the community, and residents with dementia, incontinence or behavioural disturbances 
facilitate the person-to-person transmission of GI pathogens (Strausbaugh et al., 2003). Among 
institutionalised elderly patients, gastroenteritis is the second most common infection aft er 
respiratory infections, accounting for 20-35% of all infections (Li et al., 1996; Strausbaugh et al., 
2003; Engelhart et al., 2005). In a German nursing-home survey, the incidence of gastroenteritis 
during a one-year follow-up, was 1.2 per 1000 resident days (Strausbaugh et al., 2003). 
2.1.3.1 Etiology and pathogenesis
Although most cases of diarrhoea are the results of an infection, specifi c organisms can be 
identifi ed in only a minority of patients. More than 20 organisms that cause diarrhoea have 
been detected (for review, see Glass et al., 2006). In children, rotavirus is the most frequent cause 
of acute gastroenteritis, resulting in annual winter epidemics of high attack rates (over 50%), 
and predominantly aff ecting young children (Hjelt et al., 1987b; Waters et al., 2000; Rosenfeldt 
25
REVIEW OF THE LITERATURE
et al., 2005). It accounts for 24-40% of the diarrhoeal episodes in day-care centres, while bacterial 
pathogens are detected in only 6%, and parasites in 2% of the episodes (Hjelt et al., 1987b; Waters 
et al., 2000; Rosenfeldt et al., 2005). Rotavirus has been found to be more oft en the causative 
organism in children admitted to hospital with symptoms of acute diarrhoea (36%), than in 
the diarrhoeal episodes of children attending child-care centres (15%) (Waters et al., 2000). 
However, rotavirus infection does not necessarily lead to symptomatic infections: the incidence of 
nosocomial rotavirus infections in 420 Italian infants and toddlers was 28%, of which 17% were 
symptomatic and 11% remained asymptomatic (Gianino et al., 2002). Rotavirus is transmitted 
by the faecal-oral route with small infectious doses. During the incubation period of 18-36 hours, 
the virus enters the epithelial cells, where it elaborates toxin, causing diarrhoea. It continues to 
destroy the epithelium, leading to extensive damage and  the shedding of huge masses of virus in 
the stools (Glass et al., 2006). Other viruses commonly found as causative agents in community-
aquired diarrhoea among toddlers and children are sapporovirus (19% of outbreaks), astrovirus 
(7%), adenovirus (4%), torovirus (3%) and noroviruses (2%), (Mitchell et al., 1993; Waters et al., 
2000; Rosenfeldt et al., 2005). Among bacteria, Campylobacter jejuni and Clostridium diffi  cile 
have occasionally been found in children (Rosenfeldt et al., 2005). 
In institutionalised elderly subjects, the etiology of diarrhoea may sometimes be non-infectious, 
but epidemic diarrhoeal illnesses caused by a variety of bacterial and viral agents are also common 
(for review, see Garibaldi, 1999). Viruses cause the majority of outbreaks of GI infections in old 
people’s homes, the Caliciviridae family, including noroviruses, playing a dominant role (Marshall 
et al., 2003;  Strausbaugh et al., 2003). During recent years, a striking increase in norovirus 
outbreaks have been detected in Europe due to the emergence of a new predominant norovirus 
variant (genogroup II-4) (Lopman et al., 2004; Kroneman et al., 2006). Nine countries out of 11 
reported an increase of 2-3 times in the number of outbreaks (Kroneman et al., 2006), most of 
them occurring in hospitals (42%), homes for the elderly (31%), and locations with children (13%) 
(Krisztalovics et al., 2006). Norovirus was detected in 42% of outbreaks in aged-care facilities, 
while rotavirus accounted for 13% and astrovirus for 2% of outbreaks (Marshall et al., 2003). 
Norovirus is highly infectious because of the small infectious dose. Transmission occurs by the 
faecal-oral route and via aerosol sprays, as well as through the ingestion of contaminated food and 
water. Norovirus is very stable and resistant to many disinfectants, and may shed for prolonged 
periods of up to one month (for review, see Estes et al., 2006). Salmonella and toxigenic Escherichia 
coli are the major bacterial agents that cause diarrhoea, as well as Clostridium diffi  cile, which may 
be carried asymptomatically or may cause diarrhoea as a result of antibiotic therapy. Infectious 
nosocomial diarrhoea is mainly caused by C. diffi  cile. Th e prevalence of C. diffi  cile colonisation in 
long-term-care facilities in the absence of an outbreak has ranged between 4-20%, while up to 30% 
of residents have been found to harbour C. diffi  cile during outbreaks (Simor et al., 2002). Other 
infectious agents that have been occasionally detected in diarrhoeal outbreaks in nursing homes, 
include Shigella, Campylobacter, Aeromonas, and Yersinia, and parasite agents such as Entamoeba 
histolytica, Giardia lamblia and Cryptosporidium parvum (Strausbaugh et al., 2003).
2.1.3.2 Clinical manifestation
Diarrhoea is defi ned as an alteration in the normal bowel movement characterised by an 
increase in the water content, volume or frequency of stools. Acute diarrhoea is usually defi ned 
as the passage of three or more soft  or liquid stools/day lasting 14 days or less (for review, see 
26
REVIEW OF THE LITERATURE
Guerrant et al., 2001). It is considered persistent when it lasts more than 14 days, and chronic 
when it lasts over 30 days. Infectious diarrhoea is oft en accompanied by symptoms of nausea, 
vomiting and abdominal pain (Guerrant et al., 2001). Other symptoms, such as headache and 
myalgia, may also be present. Diarrhoea is generally a self-limiting illness lasting 5-7 days. Th e 
median duration of diarrhoea among day-care children has been 33 hours, ranging between 5-
169 hours (Rosenfeldt et al., 2005). Severe sequelae associated with acute diarrhoea are rare in 
developed countries, although dehydration may be a major problem in children, in the elderly, 
and in immunocompromised persons (for review, see Cheng et al., 2005). 
Rotavirus infection is associated with initial fever and vomiting for 2-3 days, especially in 
children under two years of age (Hjelt et al., 1987a), followed by profuse diarrhoea (Cheng 
et al., 2005). A norovirus outbreak is characterised by an illness of short duration, usually 
lasting 1-3 days, following a short incubation (24-48 hours) (Cheng et al., 2005). Th e most 
frequent symptoms observed in geriatric patients during a norovirus outbreak were nausea 
(82%), abdominal pain (80%), diarrhoea (71%), asthenia (68%) and vomiting (63%) (Odelin 
et al., 2006). Norovirus infections in hospitalised patients are more severe than those seen in 
otherwise healthy people, and subjects over 65 years of age are at greater risk of prolonged 
illness (Estes et al., 2006). Clinical manifestations of C. diffi  cile diarrhoea range from 
asymptomatic carriage to mild or moderate diarrhoea lasting less than 10 days in the majority 
of cases. However, one third of the patients may suff er from a prolonged duration of the disease 
and severe complications such as pseudomembranous colitis, toxic megacolon, dehydration, 
hypokalaemia, gastrointestinal bleeding or bowel perforation (Simor et al., 2002). Infl ammatory 
infectious diarrhoea, most commonly caused by Salmonella, Shigella and Campylobacter, is 
characterised by the presence of fever, systemic illness and blood or pus in the stools (Cheng 
et al., 2005).
2.1.3.3 Treatment and prevention
Th e management of diarrhoea is mainly directed toward symptomatic relief, the reduction 
of the duration of the illness and the correction of fl uid loss and electrolyte imbalance (for 
reviews, see Farthing, 2000; Cheng et al., 2005; Gadewar and Fasano, 2005). Th e development 
of an oral rehydration solution has provided a simple approach for maintaining hydration in 
children suff ering from acute watery diarrhoea. Anti-diarrhoeal drugs are widely used by adults 
to treat the condition, but are contra-indicated in young children. Motility-altering medication 
may even worsen the colonisation or invasion of infectious organisms by paralysing intestinal 
motility. Th ere is also a continuous search for agents that will reduce fl uid and electrolyte losses 
by directly inhibiting the intestinal secretory mechanisms. One candidate, racecadotril, has 
recently been proposed as a safe and eff ective anti-secretory drug (Farthing, 2006). Routine 
use of antimicrobial agents for treating diarrhoea is not recommended. However, appropriate 
antimicrobial therapy can shorten the illness and reduce morbidity in bacterial and parasitic 
infections, and can be life-saving in invasive infections (Farthing, 2000; Cheng et al., 2005; 
Gadewar and Fasano, 2005). 
Improving hygiene is the most eff ective way of preventing enteric illnesses. On the basis of a 
recent meta-analysis of 17 case-control and intervention trials, proper hand washing resulted in 
a 47% reduction in diarrhoea risk (Curtis and Cairncross, 2003). Vaccine development against 
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several pathogens including Salmonella typhi, Cholera, Campylobacter, Shigella, and rotavirus 
has also been under extensive study during the past decades (Gadewar and Fasano, 2005). 
Two live rotavirus vaccines (containing an attenuated human monostrain or a combination of 
fi ve bovine-human reassortant strains) are currently licensed in 35 countries in Europe and 
America (Glass et al., 2006). In Finland, both rotavirus vaccines are commercially available 
but are not yet included in a general immunisation schedule. Th e safety and effi  cacy of both 
vaccines have been proved in large-scale clinical trials (Ruiz-Palacios et al., 2006; Vesikari et 
al., 2006). A monovalent, live, attenuated human rotavirus vaccine showed an effi  cacy of 85% 
against any rotavirus diarrhoea and 100% against severe disease, in a large, multicentre trial 
of 63,000 infants in Latin America and Finland (Ruiz-Palacios et al., 2006). In a randomised 
clinical trial performed in 11 countries among 68,000 infants, the effi  cacy of a pentavalent 
human-bovine reassortant rotavirus vaccine, containing human serotypes G1, G2, G3, G4 and 
P, was 74% against G1-G4 rotavirus gastroenteritis, and 98% against severe gastroenteritis 
(Vesikari et al., 2006). Th e vaccine also reduced the need for hospitalisation and emergency 
department visits. Th e vaccination was found to be safe, since the cases of intussusception, 
a potential complication of vaccination, occurred similarily in the active and in the placebo 
groups in both vaccine trials.  
2.1.4 Oral Candida infections 
Candidosis is the most common infection involving oral mucosal tissues in the elderly. As 
many as 75% of elderly people in Finland harbour oral yeast (Närhi et al., 1993). Th e prevalence 
of oral candidosis, based on clinical signs and symptoms or high yeast counts, ranges between 
37 and 51% in geriatric patients (Wilkieson et al., 1991; Budtz-Jørgensen et al., 1996; Paillaud 
et al., 2004). Th e level of Candida in non-institutionalised elderly people is known to be lower 
than in the institutionalised elderly (Honda, 2001). Th e elderly are vulnerable to Candida 
infection provoked by chronic diseases, medication, poor oral hygiene, reduced salivary fl ow 
or the impairment of the immune system (for review, see Shay et al., 1997). Studies have 
consistently demonstrated a higher frequency of Candida carriage among subjects using full or 
partial dentures and among those suff ering from hyposalivation, both common factors in the 
elderly (Wilkieson et al., 1991; Närhi et al., 1993; Närhi et al., 1999; Ikebe et al., 2006). Other 
factors predisposing to oral candidosis include age itself, diabetes mellitus and treatment with 
antibiotics and corticosteroids (Peterson, 1992; Shay et al., 1997; Paillaud et al., 2004; Fanello 
et al., 2006). Oral candidosis also appears to be related to malnutrition, and mucosal lesions 
resulting from candidosis may lead to reduced energy intake and further worsening of the 
nutritional status (Paillaud et al., 2004). 
2.1.4.1 Etiology and pathogenesis
Candida species are usually harmless commensals of the digestive tract, but under optimal 
circumstances benign colonisation of this opportunistic organism may be transformed into 
a pathological state (for reviews, see Peterson, 1992; Shay et al., 1997). Candidosis thus 
originates mainly from endogenous microbiota (Fanello et al., 2006). A normal, healthy oral 
mucosa protects against Candida infection by the clearance of micro-organisms through the 
shedding of the surface layer and by maintaining a chemical barrier which inhibits compounds 
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from penetrating the epithelium (Peterson, 1992). Antibiotic usage disturbs the resident oral 
microbiota, in particular anaerobes, which can compete with Candida for the same host 
receptor sites, resulting in the overgrowth of endogenous yeasts (Payne et al., 2003). In the 
oral cavity, Candida adheres to salivary proteins, which are absorbed by the oral surfaces of the 
host cells (for review, see Calderone et al., 2000). Th e conversion of yeast cells to fi lamentous 
hyphae growth is essential for virulence. Th us, the deleterious action of Candida has been 
attributed to the ability of the fungal hyphae to grow within the oral epithelium, releasing their 
virulence factors, including hydrolytic enzymes such as proteinases (for review, see Cannon 
et al., 1995). Candidosis is most commonly caused by Candida albicans, and to a lesser extent 
by  C. glabrata, C. tropicalis and C. parapsilosis (Wilkieson et al., 1991; Budtz-Jørgensen et al., 
2000). Th e normal carriage of Candida is less than 1000 cfu/mL, whereas in infected individuals 
counts range between 4000 and 20,000 cfu/mL (Farah et al., 2000).
Th e ability of Candida to colonise, penetrate and damage host tissues depends on the 
imbalances between Candida virulence attributes and specifi c defects in host immune 
defences. According to animal models, host resistance to Candida infection in the oral 
mucosa is mainly due to T-cell proliferation, cytokine production and nitric oxide production 
(Elahi et al., 2000;  2001; Farah et al., 2001;  2002). Th e essential role of CD4+ T cells in oral 
infection has been demonstrated in an immunodefi cient mouse model (Farah et al., 2002). 
Th e reconstitution of immunodefi cient mice with naive CD4+ but not CD8+ T cells reduced 
the oral colonisation of yeast. However, T cells alone are not able to kill Candida - phagocytic 
neutrophils and macrophages are needed for the clearance of oral yeasts. Th eir anticandidal 
activity, on the other hand, is dependent on Th 1-type cytokines, such as IL-12 and IFN-γ, 
produced by T cells (Farah et al., 2001). Th e early production of IL-12 and IFN-γ, and also 
of the Th 2-type cytokine, IL-4, together with the accumulation of T cells in the regional 
lymph nodes, correlates with the rapid elimination of Candida in mice (Elahi et al., 2000). 
Th ese results suggest that a balanced Th 1 and Th 2 helper-cell response, characterised by 
the production of both IFN-γ and IL-4, is important in mucosal protection against oral 
infection. Vaccination against Candida in mice produces high levels of IFN-γ and IL-4 and 
also fi ve times higher levels of NO in the saliva (Elahi et al., 2000). IL-4 thus appears to act 
through the paracrine enhancement of NO production by macrophages (Elahi et al., 2001). 
Nitric oxide, an antimicrobial compound, on the other hand, is associated with macrophage 
candidacidal activity, and is thus involved in controlling the oral colonisation of Candida 
(Elahi et al., 2001). Serum IgG and salivary IgA antibodies have been shown to increase in 
mice suff ering from oral candidosis, but only aft er the infection has been cleared, indicating 
that antibodies do not play a signifi cant role in the mucosal clearance of Candida (Elahi et 
al., 2000). 
2.1.4.2. Clinical manifestation
Even though colonisation by Candida may be asymptomatic, heavy growth usually leads to 
local candidosis with various types of mucosal lesions and symptoms (for review, see Shay et 
al., 1997). Th us colonisation of Candida is a signifi cant predictive factor for yeast infections 
(Fanello et al., 2006). Symptoms associated with infection include burning, sensitivity, altered 
taste and a change in the sense of smell. Oral mucosal candidosis can be classifi ed as 1) acute, 
asymptomatic pseudomembranous candidosis with white patches that can be wiped off  
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(the classical form of candidosis, so-called “trush”); 2) acute atrophic candidosis with a burning 
sensation in the mouth or on the tongue, the aff ected tissues being bright red; 3) chronic, 
asymptomatic hyperplastic candidosis  with non-removable white lesions in the buccal 
mucosa or on the tongue (“leucoplakia”); 4) chronic, atrophic candidosis usually localised 
in the maxillary alveolus and hard palate, which can be asymptomatic or cause burning, 
itching and sometimes a salty taste (“denture stomatitis”); 5) median rhomboid glossitis, oft en 
asymptomatic or associated with vague complaints of an aching tongue; and 6) angular cheilitis 
in the form of erythematous fi ssuring at the corners of the mouth, which can be asymptomatic, 
itching or painful (“perleche”) (Shay et al., 1997). In compromised aged persons, whose 
immune competence is reduced and salivary function diminished, oral mucosal lesions may 
enhance localised candidal growth and possibly lead to systemic consequences. In general, 
oral health is known to be associated with systemic diseases and thus with general well-being 
(Meurman and Hämäläinen, 2006). Th erefore, the management of oral Candida carriage in the 
elderly is of primary importance. 
2.1.4.3 Treatment and prevention
Th e management of oral candidosis requires a concurrent resolution of the underlying 
predisposing systemic conditions. Cases of oral candidosis that appear not to be complicated 
by systemic factors are generally managed through the improvement of oral hygiene and the 
use of topical antifungal rinses (Shay et al., 1997; Farah et al., 2000). Th e most commonly-
used rinse is nystatin. Nystatin oral suspension, four times a day for 7-14 days, is usually 
suffi  cient to allow the oral microbiota to return to normal, although it is relatively ineff ective 
if the candidosis is complicated by diabetes, steroid use or an immunocompromised state 
(Farah et al., 2000). Clorhexidine-gluconate oral rinses may be eff ective in uncomplicated 
cases when appropriate attention is paid to denture hygiene. A 6-week daily or weekly 
treatment with clorhexidine solution resulted in a 20% reduction in the proportion of 
subjects carrying Candida (Persson et al., 1991), and treatment with clorhexidine-xylitol 
chewing-gum, in a 22% reduction in Candida counts (Simons et al., 1997). Clotrimazole 
troches are eff ective in cases that do not resolve with nystatin. Systemic antigungal drugs, 
such as fl uconazole and itraconazole, may be advantageous when topically-delivered 
medications are administered concurrently. A two-week treatment with fl uconazole reduced 
Candida counts by approximately 50% in patients with denture stomatitis (Budtz-Jørgensen 
et al., 1988). However, partial relapse occurred 2-4 weeks aft er termination of the treatment. 
Topical or systemic antifungal therapy may result in the resolution of symptoms and lesions, 
but unfortunately many cases of candidosis are refractory to therapy, and lesions recur if 
underlying factors are not erased. Th erefore, antifungal prophylaxis is indicated to prevent 
colonisation or multiplication, especially in susceptible subjects. However, there is only a 
limited number of preventive means of reducing Candida carriage. Improving oral hygiene is 
the most effi  cient non-pharmacological method. It has been possible to reduce high Candida 
carriage by approximately 50% by improving oral and dental care practices (Budtz-Jørgensen 
et al., 2000).
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2.2 Probiotics in the prevention of infectious diseases 
2.2.1 Probiotics and their health eff ects
According to the working group convened by the FAO/WHO, probiotics are defi ned as 
“Live micro-organisms which, when administered in adequate amounts, confer a health benefi t 
to the host” (FAO/WHO, 2001). Probiotics should fulfi l several basic criteria: they must be 
able to survive in the gastrointestinal tract and to proliferate in the gut, which means that 
they must be resistant to gastric juices and bile; in addition, they should exert benefi ts to the 
host through growth and/or activity in the human body. Obviously, probiotics must be non-
pathogenic and non-toxic. To confer health benefi ts, they should protect against pathogenic 
micro-organisms by means of multiple mechanisms (FAO/WHO, 2001). Th e consumption 
of 1x106 – 1x1010 viable cells per day is usually required for benefi cial eff ects to be seen (for 
review, see Bernardeau et al., 2006), although higher doses of 109 –1010 are needed for faecal 
recovery (Saxelin et al., 1993). All existing evidence, including genomic data, suggests that 
health eff ects are strain-specifi c. It is therefore of importance to identify the genus and species 
of the probiotic strains. Th e probiotic species most oft en investigated and most widely used in 
food products are mainly the lactic acid bacteria, Lactobacillus ssp., and Bifi dobacterium ssp., 
although several other species such as Propionibacterium, Streptococcus, Bacillus, Enterococcus 
and E.coli, as well as yeasts, have been used. 
Probiotics have been advocated for the prevention and treatment of a diverse range of 
disorders. Table 1 summarises the proposed targets and possible health eff ects, based on 
recent reviews or meta-analyses. Lactobacillus rhamnosus GG (LGG), discovered by professors 
Goldin and Gorbach (Goldin et al., 1992), is by far the most extensively studied probiotic 
strain (research evidence of LGG is illustrated in Figure 1). Although LGG seems to have 
multifunctional activities against a wide range of health problems, it has become evident that 
multistrain probiotics (containing several strains of the same genera) or multispecies probiotics 
(containing strains of diff erent genera) may have advantages over monostrains (for review, 
see Timmerman et al., 2004). Since probiotics are expected to control multi-factorial diseases 
demanding a variety of probiotic properties, the synergistic actions or additive eff ects of 
several strains may be advantageous. Recently, a multispecies combination of Lactobacillus 
GG with three other species - L. rhamnosus LC 705, Propionibacterium freudenreichii ssp. 
shermanii JS, and Bifi dobacterium breve 99 - has been shown to be eff ective, especially against 
certain gastrointestinal disorders; for instance, in improving the eradication of Helicobacter 
pylori (Myllyluoma et al., 2005) and alleviating IBS symptoms (Kajander et al., 2005), while 
LGG alone has not been particularly effi  cient in those conditions (Cremonini et al., 2002; 
Bausserman and Michail, 2005). Th e effi  cacy of multistrain probiotics could be due to their 
more effi  cient ability to colonise several niches in the GI tract. For example, the adhesion of 
Bifi dobacterium Bb-12 and Propionibacterium JS to intestinal cells was more than double in 
the presence of LGG (Ouwehand et al., 2000; Ouwehand et al., 2002). Furthermore, strains 
from diff erent genera of Lactobacillus, Streptococcus, Bifi dobacterium and Propionibacterium 
show symbiotic relationships to each other which enhance their growth and metabolic activity 
(Timmerman et al., 2004). However, in some indications such as in the treatment of atopic 
eczema, the same probiotic combination has not been eff ective while LGG alone has (Viljanen 
et al., 2005c). It has, however, shown benefi cial eff ects in the prevention of atopic eczema when 
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probiotics were administered from birth (Kukkonen et al., 2007). Th is supports the idea of using 
multispecies probiotics specifi cally selected for a certain application, particularly in conditions 
with identifi ed microbiota aberrancies or at the time when the microbiota is still developing, or 
in situations where an enhanced multispecies colonisation (which creates a probiotic niche) or 
synergistic actions against pathogens, may have a major impact on the disease. However, this 
does not necessarily mean that multispecies are superior for every indication.
Figure 1. Research areas of Lactobacillus rhamnosus GG (ATCC 53103) during the years 1987-2007 
(Modifi ed from Bernardeau et al., 2006). 
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Table 1. Proposed targets and possible health eff ects of probiotics.
Target organ Indication Health eff ect Reference
Oral cavity Dental health Reduced risk of caries due to inhibition of 
salivary Streptococcus mutans
(Meurman, 2005)
Stomach Helicobacter pylori / 
gastritis
Increased eradication of H. pylori when 
combined with antibiotics
Diminished adverse eﬀ ects of antibiotics
(Gotteland et al., 2006)
Intestine Acute gastroenteritis Reduced duration of rotavirus 
diarrhoea in children
(Huang et al., 2002)
Traveller’s diarrhoea Prevention of traveller’s diarrhoea (McFarland, 2007)
Antibiotic-associated 
diarrhoea (AAD)
Reduced duration of ADD (Hawrelak et al., 2005)
(Szajewska et al., 2006)
Irritable bowel 
syndrome (IBS)
Alleviation of IBS symptoms (Kajander and Korpela, 
2006)
Inﬂ ammatory bowel 
diseases 
Enhancement of mucosal immune responses, 
improvement of intestinal permeability, 
lowered disease activity and reduced 
relapse rates
(Shanahan, 2004)
Lactose intolerance Increased tolerance of lactose due to microbial 
hydrolysis 
(Levri et al., 2005)
Constipation Shortening of intestinal transit time through 
modulation of colonic microbiota
(Hamilton-Miller, 2004)
Colorectal cancer Down-regulation of intestinal microbial 
enzyme activities and the conversion of 
precarcinogens to carcinogens 
(Commane et al., 2005)
Microbiota deviations Combating aberrant microbiota (Isolauri et al., 2002)
Urogenital 
tract
Urinary tract infections Inhibition of the growth of E. coli by 
restoration of vaginal lactobacilli microbiota 
(Falagas et al., 2006b)
Bacterial vaginitis /
Vaginal candidosis 
Inhibition of the growth of pathogenic bacteria/ 
Candida by establishing the vaginal 
lactobacilli microbiota
(Falagas et al., 2006a)
(Reid and Bocking, 
2003)
Systemic 
eﬀ ects
Allergy/atopy Alleviation of symptoms and reduction of 
risk of atopic eczema 
(Rautava et al., 2005)
Respiratory infections Prevention of viral respiratory infections 
by enhancement of immunity, 
reduction of the carriage of bacterial 
pathogens
(de Vrese and 
Schrezenmeir, 2002)
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2.2.2 Normal microbiota against pathogens
Th e commensal microbiota, which consists of micro-organisms present on mucosal surfaces 
covered by epithelial cells in the oral, gastrointestinal and respiratory tracts, plays an important 
role in protecting the body against pathogenic organisms (for review, see Tlaskalova-Hogenova 
et al., 2004). Th e normal indigenous microbiota, with an intact epithelium, creates a barrier 
(colonisation resistance) against pathogens by competing for nutrients and available adhesion 
sites on the mucosa, as well as by producing metabolic and regulatory substances, such as lactic 
acid, short-chain fatty acids, hydrogen peroxide and bacteriocins (for review, see Lu and Walker, 
2001). Commensal microbes are in close “cross-talk” with the epithelial cells, and are able to 
induce an immunological response which may prevent infection (for review, see Corthesy 
et al., 2007). Environmental pressures such as changes in the diet or the use of antimicrobials 
can dramatically alter the composition of microbiota (Madden et al., 2005), leading to enhanced 
growth of pathogens or opportunistic pathogens. 
Th e mucosal parts of the oral cavity (lips, cheek, tongue, palate) and non-shedding surfaces 
(teeth) contain approximately 108-1010 bacteria/mL, consisting of facultative, micro-aerophilic 
and obligate anaerobic species (for review, see Marsh, 2000) (Figure 2). Th e development of the 
resident oral microbiota starts at birth and changes during the time of teeth eruption, eventually 
leading to a relatively stable situation in adulthood, with broad species diversity. However, 
transient fl uctuations in the oral ecosystem are caused by aging, the type of food ingested, 
medication, and the composition and rate of fl ow of saliva. Candida albicans is also a commensal 
organism, but can be converted to a pathogen when the normal microbiota is reduced as a result 
of antimicrobials, or the host defence mechanisms are impaired. 
A large number of bacterial species colonise the upper respiratory tract, while the lower respiratory 
tract is virtually free of micro-organisms. Th e nasopharynx of healthy children is predominantly 
colonised by non-pathogenic organisms, some of which have the ability to inhibit the growth of 
potential otitis pathogens (Tano et al., 1999) (Figure 2). Th ese interfering organisms include the 
aerobic α- and γ-haemolytic streptococci (Brook and Gober, 2000). α-haemolytic streptococci have 
been shown to inhibit the colonisation or the growth of potential pathogens in the adenoids of otitis-
prone children (Brook and Yocum, 1999), and in the nasopharynx of sinusitis-prone children (Brook 
and Gober, 1999; 2000) possibly by producing inhibitory substances and through pH reduction. Th e 
normal microbiota and the interfering activity of α-haemolytic streptococci against S. pneumoniae, 
S. pyogenes, H. infl uenzae and Staphylococcus aureus have been shown to be lower in children with 
recurrent otitis media than in healthy children (Bernstein et al., 1993; Fujimori et al., 1996; Tano et 
al., 2000). Th is may be due to the wide use of broad-spectrum antimicrobials, such as amoxicillin-
clavulanate, which disturb the normal microbiota more than narrow-spectrum antimicrobials 
(Brook and Gober, 2005), and is associated with prolonged absence of normal microbiota and rapid 
colonisation with pathogens (Brook and Gober, 2005), which probably leads to recurrent infections. 
Restoring the normal microbiota of the nasopharynx aft er antibiotic treatment, by replacement of 
α-streptococci, has been benefi cial in reducing the clinical recurrences of acute and secretory otitis 
(Roos et al., 2001) and streptococcal pharyngotonsillitis (Roos et al., 1996). 
It has been estimated that the adult gut microbiota is composed of 400-1000 species, the majority 
of which are strict anaerobes (97%), and only 3% belong to aerobes (for reviews, see Salminen 
et al., 1998; Noverr and Huff nagle, 2004a). Th ere is a high degree of variability between the small 
intestine and the colon in terms of numbers and bacterial species (Figure 2). Th e small intestine 
harbours bacteria in numbers of 104-107 cfu/g, increasing rapidly to 1010-1012 cfu/g in the colon 
(Salminen et al., 1998). However, the new metagenomics analysis, based on 16S ribosomal DNA 
sequence-based enumeration used for sequencing the whole human intestinal microbiome, has 
resulted in the total number of 1013-1014 microorganisms (Gill et al., 2006). Th e composition 
of individual microbiota is relatively constant, but may fl uctuate under some circumstances, 
for instance during intestinal illnesses or antibiotic treatment, and to a lesser extent by dietary 
changes (Noverr and Huff nagle, 2004a). Th e wide diversity and inter-subject variability of the 
intestinal microbiota have been recently highlighted by the microbial sequence analysis of gut 
mucosal tissue and faecal samples derived from healthy subjects (Eckburg et al., 2005). Of the 
395 bacterial phylotypes, 62% of the sequences were found to be novel and 80% were from 
species that have not been cultivated. Th is indicates that the bacterial diversity within humans 
is far greater than previously described. Th e intestinal microbiota plays an important part in the 
development and functioning of the immune system, as is clearly shown in studies on germ-free 
animals (for review, see Cebra, 1999). Th e development of the immune system is impaired in 
germ-free animals, as refl ected by decreased numbers of lymphocytes in gut-associated lymphoid 
tissues and less diversifi ed immunoglobulins. 
Figure 2. Composition of the microbiota in the oral cavity, in the nasopharynx and in the gut. 
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2.2.3 Probiotic mechanisms
2.2.3.1 Antagonism to pathogens
Mucosal epithelial surfaces cover an enormous area of the body, and those in the mouth and 
gastrointestinal and respiratory tracts are constantly exposed to numerous micro-organisms 
and serve as primary ports of entry for most infectious agents. In the gut, altered intestinal 
permeability of the epithelium facilitates the invasion of pathogens. Permeability is increased 
in infl ammatory conditions as a result of mucosal dysfunction caused by viruses, bacteria or 
dietary antigens (for review, see Lu and Walker, 2001). One possible mechanism of probiotic 
therapy is the promotion of this non-immunological gut defence barrier by normalising 
increased permeability and disturbed gut microecology (Isolauri et al., 1993). Probiotics 
may strengthen the epithelial barrier by promoting the recovery of the intestinal epithelium, 
as suggested by a study showing the prevention of cytokine-induced apoptosis in mouse or 
human epithelial cells in the presence of Lactobacillus GG (Yan and Polk, 2002). Lactobacillus 
GG has also been shown to increase the rate of mitoses in the small intestine of rats, resulting 
in increased numbers of cells in the villi, suggesting that probiotics may enhance mucosal 
regeneration (Banasaz et al., 2002). An enhanced epithelial barrier could prevent microbial 
translocation into the epithelium, as shown in an experimental study in which L. acidophilus, 
L. rhamnosus, or L. plantarum administered rectally to animals reduced bacterial translocation 
to the liver and mesenteric lymph nodes in an acute liver injury model (Adawi et al., 2001). 
A probiotic mixture (VSL#3) containing four lactobacilli, three bifi dobacteria and one 
Streptococcus, and their bacterial cell lysates, also increased transepithelial resistance in HT-29 
intestinal epithelial cells, stabilised the tight junctions and prevented the decrease in resistance 
induced by pathogenic Salmonella (Otte and Podolsky, 2004). 
 
Bacterial adhesion to host cells or mucosal surfaces is always the essential fi rst step in the 
disease process, and therefore interruption of the pathogen adhesion could be of benefi t to 
the host. On the other hand, the adhesion of probiotics to mucosal surfaces is considered 
one of the main properties by which probiotics exert their health eff ects. Adherence 
to mucosal surfaces can be mediated by diff erent mechanisms, such as electrostatic, 
hydrophobic, hydrophilic, capsular and fi mbrial ones, and a wide range of mammalian 
cell surface constituents, such as glycoproteins and glycolipids, can act as receptors for 
bacterial attachment (Lu and Walker, 2001). Specifi c adhesin-receptor interaction involves 
carbohydrate moieties on the mucosal surface and carbohydrate-binding adhesins on the 
bacterial surface. Th e adhesion of pathogens can be inhibited by steric hindrance, by which 
a large number of benefi cial bacteria may cover receptor sites in a non-specifi c manner, 
or by competing for specifi c carbohydrate receptors. It has been suggested that lactobacilli 
such as Lactobacillus rhamnosus GG are able to compete with E. coli and Salmonella through 
steric hindrance (Lee and Puong, 2002). Mucosal surfaces are also protected by luminal 
secretions such as mucus, glycolipids, protective peptides and antibiotic-like substances such 
as defensins. Intestinal mucins (high-molecular-weight glycoproteins secreted by epithelial 
goblet cells) may protect epithelial cells from pathogens by providing a physico-chemical 
barrier, or by binding to pathogens through specifi c mucin-bacterial/viral interaction, 
thereby inhibiting their adherence to epithelial cells (Deplancke and Gaskins, 2001). 
Lactobacillus GG, L. plantarum 299V and a VSL#3 combination of probiotic strains has 
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inhibited the in vitro adherence of enteropathogenic E. coli to HT-29 intestinal epithelial cells 
by inducing the epithelial expression of mucin genes (Mack et al., 1999; 2003). In in vitro 
assays, a specifi c probiotic combination, containing L.rhamnosus GG, L. rhamnosus LC705, 
Propionibacterium freudenreichii ssp. shermanii JS and Bifi dobacterium breve 99 or B. lactis 
Bb12, has displaced already adhered pathogens (E.coli, Bacteroides, Clostridium, Listeria, 
Salmonella and Staphylococcus) and has competitively excluded these (Collado et al., 2006). 
However, the adhesion inhibition, displacement activity and competitive exclusion ability 
do not correlate, suggesting that diff erent mechanisms are responsible for these phenomena. 
Th e ability of probiotics to inhibit adhesion and to displace pathogens seems to be strain-
dependent. It is likely that the diff erences in the adhesion of probiotics themselves - caused 
by diff erent surface molecules such as carbohydrates – may play a role in the inhibition or 
displacement of pathogens (Gueimonde et al., 2007).
In addition to the competitive inhibition of the mucosal adherence of pathogens, lactobacilli 
and bifi dobacteria also show direct antimicrobial activity against pathogens by producing 
antimicrobial substances such as organic acids, hydrogen peroxide, diacetyl, short chain fatty 
acids, biosurfactants and bacteriocins (for review, see Servin, 2004). Bacteriocins are 
bactericidal proteinaceous molecules which have a relatively narrow killing spectrum and 
are only toxic to bacteria closely related to the strain which produces them. Bacteriocins, 
produced by lactobacilli or bifi dobacteria, are eff ective against the Lactococcus, Streptococcus, 
Staphylococcus, Listeria and Mycobacterium species. Several in vitro studies have shown 
growth inhibition against numerous pathogens, such as Clostridium, Bacteroides, Bacillus, 
Enterobacteriaeae, Pseudomonas, Staphylococcus, Streptococcus, Salmonella and E. coli, 
achieved by diff erent antimicrobial substances produced by probiotics (Silva et al., 1987; 
Huttunen et al., 1995; Hudault et al., 1997; Ocana et al., 1999; Lievin et al., 2000; Lee and 
Puong, 2002; Hutt et al., 2006). Th e antibacterial activity of Lactobacillus strains has been 
shown to be mainly due to lactic acid (De Keersmaecker et al., 2006), but for some strains 
evidence of an unknown inhibitory substance exists (Makras et al., 2006). Th e antagonistic 
activity of Lactobacillus GG against Salmonella typhimurium seems to be dependent on the 
acidic environment (Hudault et al., 1997). Th e growth inhibition may also result from a 
coaggregation phenomenon. In this event, lactobacilli and pathogens, through their specifi c 
surface properties, develop large contact areas (“a microenvironment”), where the activity of 
inhibitory metabolites is exacerbated leading to reduced growth capacity of pathogens 
(Drago et al., 1997). 
2.2.3.2 Immunomodulatory eff ects 
An optimally functioning immune system is fundamentally important for protection against 
infectious diseases. Stimulation of the immune system has been suggested as one possible 
probiotic mechanism that provides protection against infections. Probiotic immunomodulation 
seems to be induced by bacterial patterns such as cell wall components (e.g. peptidoglycans in 
gram-negative and gram-positive bacteria, capsular polysaccharides and lipoteichoic acid in 
gram-positive, and lipopolysaccharide present in gram-negative groups), which are recognised 
by Toll-like receptors expressed in intestinal and immune cells (Pena and Versalovic, 2003). 
Lactobacilli have been shown to up-regulate the expression of TLR-2 transcripts, suggesting 
that lactobacilli deliver signals in dendritic cells through TLR-2, and thereby promote the 
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activation of these antigen-presenting cells (Miettinen et al., 1998; Foligne et al., 2007). Th e 
activation of immune cells, such as macrophages, neutrophils and dendritic cells, by bacterial 
cell wall components leads to the release of diff erent immune mediators, cytokines and 
chemokines. 
Peripheral blood mononuclear cells (PBMC) of humans and experimental animals have 
been found to secrete increased amounts of cytokines following in vitro stimulation 
with lactobacilli or bifi dobacteria (Miettinen et al., 1996; Menard et al., 2004). Th e eff ect 
is mediated through the activation of the transcription factors, NF-κB and STAT by 
lipopolysaccharides, leading to enhanced gene expression and protein synthesis (Miettinen 
et al., 2000; Ishida-Fujii et al., 2007). Lactobacillus GG has induced cytokine production 
in human macrophages (Veckman et al., 2003), but the induction in dendritic cells has 
only been weak (Veckman et al., 2004). Th e eff ect, although much weaker, has also been 
shown in non-viable lactobacilli and bifi dobacteria strains (Miettinen, 1998). Lactobacilli 
have mainly induced pro-infl ammatory cytokines (such as IL-1β, IL-6, IL-12, TNF-α and 
IFN-γ), and  the eff ect on anti-infl ammatory cytokines (IL-4, IL-10 or TGF-β) has been 
weak or non-existent (Miettinen et al., 1996; 1998) (Table 2). However, under infl ammatory 
conditions, lactobacilli have reduced the production of pro-infl ammatory cytokines and 
induced anti-infl ammatory cytokines (Pena and Versalovic, 2003; Hart et al., 2004; Jijon et 
al., 2004; Menard et al., 2004; Zhang et al., 2005), although there is a wide diversity between 
individual strains (Hart et al., 2004). Immunomodulation also seems to be diff erent in in 
vitro and ex vivo conditions (Flinterman et al., 2007). Based on in vivo trials, the probiotic 
eff ect on Th 1/Th 2 balance seems to be dependent on the immunological status of the 
subject. In healthy adults and patients with an infl ammatory condition, lactobacilli have 
mainly reduced the production of proinfl ammatory cytokines (Schultz et al., 2003; Braat et 
al., 2004), but in healthy elderly subjects (Arunachalam et al., 2000; Matsumoto et al., 2007) 
and in children with atopic diseases (Prescott et al., 2005; Viljanen et al., 2005b; Flinterman 
et al., 2007), probiotics have mainly enhanced the Th 1 response by increasing the production 
of proinfl ammatory cytokines. However, the in vivo eff ect on anti-infl ammatory cytokines 
seems to be controversial.  
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Table 2. Eff ect of diff erent probiotic bacteria on cytokine production in experimental in vitro assays 
and in clinical interventions.
Probiotic strains Model/
Study design
Assessment Outcome Reference
L. rhamnosus GG
L. rhamnosus E509
L. acidophilus 
L. paracasei 
L. plantarum
Lactococcus lactis 
B. longum
B. animalis 
In vitro Cytokine production by 
human PBMC
IL-6, TNF-α ↑
IL-10 (↑)
best inducers:
L. rhamnosus GG, 
B. animalis, 
L. acidophilus
(Miettinen 
et al., 1996)
L. rhamnosus GG
L. rhamnosus E509, 
L. bulgaricus 
In vitro Cytokine production by 
human PBMC
IL-1β, IL-6, TNF-α, 
IL-12, IFN-γ, IL-18 ↑
IL-10 (↑)
IL-4 ↔
(Miettinen et al., 
1998)
L. rhamnosus GG In vitro Maturation of human 
monocyte-derived DCs 
by induction of 
co-stimulatory molecules 
and production of 
pro-inﬂ ammatory 
cytokines by DCs
Expression of co-stimulatory 
molecules (↑) / ↔
TNF-α (↑)
IL-2, IL-12, IL-23, IL-27 ↔
(Veckman et al., 
2004)
L. rhamnosus GG In vitro: 
inﬂ ammatory 
conditions 
induced by LPS 
or LTA 
Cytokine production by 
murine macrophages
TNF-α ↓
IL-10 ↔
(Pena and 
Versalovic, 2003)
L. rhamnosus GG:
live or heat-killed 
In vitro:
inﬂ ammatory 
conditions 
induced by TNF-α
Cytokine production 
by Caco2 intestinal 
epithelial cells
IL-8 ↑ for live LGG
IL-8 (↑) for  heat-killed LGG
Th e eﬀ ect was dose-dependent.
(Zhang et al., 
2005)
B. breve BbC50
S. thermophilus 
St065 
In vitro:
inﬂ ammatory 
conditions induced 
by LPS or LTA
Cytokine production 
by human PBMC and 
intestinal cell monolayers
TNF-α ↓ for both strains
IL-10 ↑  for B. breve
IL-10 ↓  for S. thermoph.
(Menard et al., 
2004)
L. casei I-5 Ex vivo:
inﬂ ammatory 
conditions 
induced by 
E. coli
Cytokine levels in rat 
peripheral blood
TNF-α, IL-12 ↑
IL-6 ↔
(Ishida-Fujii 
et al., 2007)
Combination of 
8 strains (VSL#3) 
L. acidophilus 
L. delbrueckii
L. casei
L. plantarum
B. longum
B. infantis
B. breve
S. salivarius
In vitro
inﬂ ammatory 
conditions 
induced by LPS
Cytokine production by 
human blood dendritic 
cells and intestinal 
lamina propria 
mononuclear cells 
IL-12, IFN-γ  ↓
IL-10 ↑
Individual bacteria displayed 
diﬀ erent eﬀ ects than combination:
lactobacilli: IL-10 ↓ / ↔
biﬁ dobacteria: IL-10 ↑
(Hart et al., 
2004)
Combination of 
8 strains (VSL#3) 
In vitro 
inﬂ ammatory 
conditions induced 
by E. coli
Cytokine production 
by murine colonic cells, 
splenocytes and 
HT-29 cells
IFN-γ, TNF-α ↓ in colonic cells
IL-8 ↓ in HT-29 cells
(Jijon et al., 
2004)
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Probiotic strains Model/
Study design
Assessment Outcome Reference
L. rhamnosus GG 
in capsules
5-week oral suppl.
n=10 healthy 
adults
Cytokine production by 
PBMC
TNF-α, IL-6, IFN-γ ↓
IL-10, IL-4 ↑
(Schultz et al., 
2003)
L. rhamnosus in 
lyophilised powder
2-week oral 
suppl.
n=6 healthy 
volunteers and
6 Crohn’s disease 
patients
Cytokine production 
by PBMC
IL-2, IL-4, IL-10 ↓ 
in healthy subjects
IL-2, IFN-γ, IL-10  ↓  
in Crohn’s patients
IL-4 ↔ 
in Crohn’s patients
(Braat et al., 
2004)
B. lactis HN019 or 
placebo in milk
DBPC
6-week oral 
suppl.
n=25 healthy 
elderly 
subjects
Cytokine production 
by PBMC
IFN-α ↑ (Arunachalam 
et al., 2000)
B. animalis 
ssp. lactis 
LKM512 in yoghurt 
or placebo
PC 2-week 
oral suppl.
n=6 elderly 
subjects
In vitro stimulation of 
murine macrophage-line 
cells by faecal precipitates 
from elderly subjects 
aft er oral consumption of 
B. animalis
TNF-α ↑
IL-1α, IL-10 ↔
(Matsumoto 
et al., 2007)
L. rhamnosus GG 
or a probiotic 
mixture 
containing 
L. rhamnosus GG, 
LC705, 
B. breve 99, 
Propionibacterium 
JS or placebo in 
capsules
DBPC
4-week oral 
suppl.
n=230 infants with 
atopic eczema
Plasma levels of 
cytokines
IL-6 ↑ for LGG
IL-10 ↑ for mixture
IL-2, IL-4, TGF-β, IFN-γ ↔
(Viljanen et al., 
2005b)
L. fermentum in 
freeze-dried powder 
or placebo 
DBPC
8-week oral 
suppl.
n=53 infants with 
atopic dermatitis
Cytokine production 
by PBMC
TNF-α, IFN-γ  ↑
IL-13 ↓
IL-10, TGF-β ↔
(Prescott et al., 
2005)
Probiotic bacteria
or placebo
DBPC
12-week oral 
suppl.
n=13 infants with 
food allergy
In vitro and ex vivo 
cytokine production 
by PBMC
In vitro:
TNF-α, IFN-γ, IL-10  ↑
Ex vivo:
TNF-α, IL-10, IL-6  ↓
(Flinterman 
et al., 2007)
PBMC = Peripheral blood mononuclear cells, DCs = dendritic cells
DBPC = double-blind, placebo-controlled intervention
LTA=lipoteichoic acid, LPS=lipopolysaccharide
↑ =  increased 
(↑) = only a slight increase
↓ = decreased 
↔ = no eﬀ ect
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Table 3. Eff ect of diff erent probiotic bacteria on immune cell activity in experimental animal studies 
and in clinical interventions. 
Probiotic strains Model/
Study design
Assessment Outcome Reference
B. longum
L. bulgaricus
L. casei
L. helveticus
S. cremoris
S. lactis
S. thermophilus
In vivo mice: 
gastric intubation 
of probiotics for 
8 days
Pulmonary 
alveolar 
macrophages
Phagocytic activity of 
alveolar macrophages ↑ 
for L. casei, 
B. longum, 
L. helveticus
(Moineau, 
1991)
L. fermentum
L. plantarum
In vivo mice: 
gastric intubation 
of probiotics for 
3 weeks
Phagocytic activity 
of peritoneal 
leucocytes
Ex vivo phagocytic 
capacity of leucocytes ↑
(Lee and Lee, 
2005)
L. casei 
L. paracasei
L. acidophilus
In vivo mice: 
gastric intubation 
of probiotics for 
2 days 
NK-cells activity in 
spleen mononuclear 
cells
NK-cell activity ↑ (Ogawa et al., 
2006)
L. casei I-5 In vivo rats: 
oral administration 
of probiotics for 
10  days 
Phagocytic activity 
of rat peritoneal 
macrophages and 
NK-cell cytotoxicity
Phagocytic activity ↑ 
NK-cell activity ↔ 
(Ishida-Fujii 
et al., 2007)
9 lactobacillus 
strains of
Lactobacillus ssp.
L. plantarum
L. bulgaricus
Rat small intestinal 
mucus incubated 
with lactobacilli
Phagocytic activity 
of Peyer’s patches’ 
macrophages
Strain speciﬁ c enhancement 
of phagocytic activity of 
macrophages, which 
was correlated with the 
ingestion of lactobacilli 
by macrophages.
(Sun et al., 
2007)
Th e main function of pro-infl ammatory cytokines and interferons is to attract phagocytic cells 
to the site of infection, and to stimulate cytotoxic T cells, monocytes, macrophages and NK 
cells. Experimental animal studies have shown that lactobacilli and bifi dobacteria enhance the 
ex-vivo phagocytic activity of blood leucocytes and peritoneal or pulmonary macrophages, 
and increase the activity of NK cells  (Moineau, 1991; Lee and Lee, 2005; Ogawa et al., 2006; 
Ishida-Fujii et al., 2007; Sun et al., 2007) (Table 3). In healthy adults, oral consumption of 
diff erent lactobacilli or bifi dobacteria has  increased the ex-vivo phagocytic capacity of 
polymorphonuclear cells, and increased the NK cell-killing activity (Schiff rin et al., 1997; 
Arunachalam et al., 2000; Gill et al., 2001a; Gill et al., 2001b; Sheih et al., 2001; Parra et al., 
2004). However, contrary results also exist (Spanhaak et al., 1998).  Th e immuno-stimulatory 
eff ects of probiotics thus seem to be species- and strain-dependent, and may also depend on 
the viability of the bacteria. Th e enhancement of the immune system may also depend on age, 
since subjects over 70 years of age have experienced greater increases in NK-cell activity (Gill et 
al., 2001a). Th e immunological status of the host may also play a role: for instance, Lactobacillus 
GG has down-regulated the phagocytic activity of neutophiles in milk-hypersensitive adults, 
but has increased the activity in healthy subjects (Pelto et al., 1998). 
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Probiotic strains Model/
Study design
Assessment Outcome Reference
L. acidophilus La1 
or B. bifi dum Bb12 
in fermented milk
3-week oral suppl.
n=28 healthy 
volunteers
Lymphocyte subsets 
and leucocyte 
phagocytic activity
Lymphocyte subsets ↔, 
Phagocytic activity of 
granulocytes and 
monocytes ↑
(Schiﬀ rin et al., 
1997)
L. casei DN114001 
or placebo in 
fermented milk
DBPC 8-week 
oral suppl.
n=45 healthy 
volunteers
Lymphocyte subsets, 
NK-cell tumoricidal 
activity, phagocyte 
functions
Lymphocyte subsets ↔
NK-cell activity ↑
Oxidative burst  ↑
capacity of monocytes ↑
(Parra et al., 
2004)
B. lactis HN019 
or placebo in milk
DBPC 6-week 
oral suppl.
n=25 healthy 
elderly volunteers
Phagocytic 
activity of PMN
Phagocytic capacity ↑ (Arunachalam 
et al., 2000)
L. rhamnosus 
HN001 or
B. lactis HN019
 in milk
3-week oral suppl.
n=27 healthy 
elderly volunteers
Proportion of 
CD56+ lymphocytes, 
ex vivo tumoricidal 
activity of PBMC
PBMC tumoricidal activity ↑: 
101% for L. rhamnosus, 
62% for B. lactis
NK-cell activity ↑
(Gill et al., 
2001a)
B. lactis HN019
in milk
3-week oral suppl. 
n=30 healthy 
elderly volunteers
Ex vivo leucocyte 
phagocytic activity,
NK cell tumour-  
killing activity, 
leucocyte subsets
Phagocytic activity of 
phagocytes ↑
NK-cell activity ↑
CD4+ and CD25+ cells ↑
(Gill et al., 
2001b)
L. rhamnosus 
HN001 or placebo 
in powder 
DBPC 3-week 
oral suppl. 
n=52 healthy 
volunteers
Ex vivo phagocytic 
activity of PMN, 
NK-cell tumour-  
killing activity
Phagocytic activity of 
phagocytes ↑ 
NK-cell activity ↑
(Sheih et al., 
2001)
L. casei Shirota 
or placebo 
in fermented 
milk
DBPC 4-week 
oral suppl. 
n=20 healthy 
volunteers
Lymphocyte subsets, 
NK-cell activity, 
phagocyte functions
Lymphocyte subsets ↔
NK-cell activity ↔
Phagocytosis ↔
(Spanhaak 
et al., 1998)
L. rhamnosus GG  
or placebo 
in milk
DBPC 1-week oral 
suppl.
n=17 volunteers 
(9 healthy, 8 milk-
hypersensitive)
Expression of 
phagocytosis 
receptors on 
neutrophiles and 
monocytes 
Receptor expression in 
neutrophiles ↑ in healthy
Receptor expression in 
neutrophiles ↓  
in hypersensitivesubjects
(Pelto et al., 
1998)
PMN = Peripheral polymorphonuclear leucocyte
PBMC = Peripheral blood mononuclear cells
DBPC = double-blind, placebo-controlled intervention
↑ =  increased 
↓ = decreased 
↔ = no eﬀ ect
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Lactobacilli have also been shown to enhance cell-mediated immune responses and T cell 
development through the modulation of dendritic cell functions (Smits et al., 2005). Human 
myeloid DCs, activated by live or heat-killed lactobacilli, clearly skewed to T helper 1 and Tc1 
polarisation, leading to the enhancement of proliferation of  CD4+ and CD8+ T cells (Miettinen 
et al., 1998) (Table 4). In animal studies, the proliferative activity of T and B lymphocytes 
has increased in murine lymphocytes aft er feeding with lactobacilli or Propionibacterium 
(Kirjavainen et al. 1999). In humans, the eff ect of oral supplementation with lactobacilli on T 
and B cell proliferative activity seems to depend on the immunological status of the subject: 
duodenal B lymphocyte numbers and CD4+ T lymphocytes seem to increase in healthy 
subjects (Schultz et al., 2003) and ileostomy patients (Valeur et al., 2004). However, in patients 
with an infl ammatory condition such as Crohn’s disease, an oral supplementation of lactobacilli 
has resulted in decreased T cell proliferation (Braat et al., 2004). 
Table 4. Eff ect of diff erent probiotic bacteria on the proliferative activity of B and T lymphocytes 
in experimental animal studies and in clinical interventions.  
Probiotic strains Model/
Study design
Assessment Outcome Reference
L. rhamnosus GG,
Propionibacterium 
freudenreichii JS
In vivo mice: 
peroral treatment 
with  probiotics 
for 7 days
Proliferative 
activity of 
murine 
lymphocytes
B cell proliferation ↑ 
+57% for LGG
B cell proliferation ↑ 
+82% for PJS
T cell proliferation ↑ 
+ 69% for LGG 
T cell proliferation ↑ 
+ 84% for PJS 
(Kirjavainen 
et al. 1999)
L. rhamnosus GG 5-week oral suppl.
n=10 healthy 
volunteers
CD4+ T 
lymphocyte 
activation
CD4+ T cell 
activation ↑
(Schultz et al., 
2003)
L. reuteri 4-week oral suppl.
n=10 healthy 
volunteers and 
9 ileostomy patients
Cell counts in 
mucosal biopsy 
specimens
Duodenal B 
lymphocytes ↑
Ileal CD4+ T cell ↑
Duodenal and 
stomach T cells ↔
(Valeur et al., 
2004)
L. rhamnosus 2-week oral suppl.
n=6 healthy 
volunteers and 
6 Crohn’s patients
T cell 
proliferation
Expression of 
CD4+ T cells ↓
(Braat et al., 
2004)
↑ =  increased 
↓ = decreased 
↔ = no eﬀ ect
To summarise, probiotic bacteria are able to stimulate the immune system in several ways. 
Probiotics induce cytokine release from immune cells, mainly towards Th 1 polarization. 
Th rough increased cytokine production, probiotics are able to stimulate diff erent immune cells, 
including phagocytic cells, NK cells, and T and B cells. However, the eff ects are highly strain-
dependent, and a combination of several strains may show synergistic as well as antagonistic 
eff ects. In addition, a probiotic eff ect in vivo seems to rely largely on the immunological status 
and possibly on the age of the subject. 
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2.2.3.3 Mucosal defence mechanisms
Oral ingestion of antigens produces IgA synthesis locally in the gut. Aft er antigenic 
stimulation, T and B lymphocytes activated in the Peyer’s patches travel via the blood and 
enter the secondary lymphatic organs in the distal mucosal eff ector sites of the GI and 
respiratory tracts, or in the salivary glands (so-called mucosa-associated lymphoid tissue, 
MALT), where B cells diff erentiate into immunoglobulin-producing plasma cells. Th is 
provides one logical mechanism whereby orally-ingested probiotic bacteria may initiate an 
immune response in the gut, which then leads to enhanced responses at other mucosal 
surfaces.
Data from animal studies strongly indicate that several specifi c lactic acid and bifi dobacteria 
strains induce the synthesis of antigen-specifi c IgA in intestinal secretions, in Peyer’s patch 
cells and in serum (Perdigon et al., 1990). It has been proposed that the possible underlying 
mechanism in triggering antibody secretion may be the enhanced secretion of IL-6 (He et 
al., 2005), which stimulates the growth of antibody-producing B lymphocytes. Metabolites 
of lactic acid bacteria, such as peptides derived from milk fermented with L. helveticus, have 
also increased the number of IgA-producing B cells in the lamina propria, and enhanced the 
secretory and systemic IgA levels in mice following E. coli challenge (Leblanc et al., 2004). 
In clinical studies, oral bacteriotherapy with Lactobacillus GG has increased the numbers of 
specifi c antibody-secreting cells against dietary β-lactalbumin and casein in patients with 
Crohn’s disease (Malin et al., 1996), antibody-secreting cells producing rotavirus-specifi c 
IgA antibodies in children with rotavirus gastroenteritis (Kaila et al., 1992; Majamaa et 
al., 1995), and faecal IgA in children with cow’s milk allergy (Viljanen et al., 2005a). In 
breast-fed infants, whose mothers consumed Lactobacillus GG before childbirth, and who 
were themselves supplemented with LGG aft er the birth, the total number of circulating 
IgM-, IgA- and IgG-secreting cells in peripheral blood was higher than in children without 
probiotic supplementation (Rinne et al., 2005). Th e results suggested that early treatment with 
probiotics with breastfeeding benefi cially infl uences the maturation of gut humoral immunity. 
However, traditional yoghurt strains (Streptococcus thermophilus and L. bulgaricus) induced 
only a weak activity of salivary IgA to yoghurt cultures (Carlsson and Bratthall, 1985). Nor 
did the consumption of a fermented milk product containing L. johnsonii La1 increase the 
secretion of jejunal IgA against La 1, although serum IgA concentrations increased slightly 
(Marteau et al., 1997).  L. plantarum 299v had no eff ect on the concentration of plasma cells, 
IgA or IgM positive cells in the lamina propria in patients undergoing abdominal surgery 
(Woodcock et al., 2004). Th e eff ectiviness of probiotics in enhancing the immunogenicity of 
oral vaccines in healthy humans has also been reported (Link-Amster et al., 1994). In these 
studies, Lactobacillus GG or L. fermentum have increased the formation of poliovirus-specifi c 
IgA and IgG in serum (de Vrese et al., 2005a), the numbers of IgA antibody-secreting cells 
against Salmonella typhi (He et al., 2000) the numbers of rotavirus-specifi c IgM-producing 
cells (Isolauri et al., 1995) and the level of infl uenza-specifi c IgA in serum (Olivares et al., 
2007), suggesting that orally-ingested lactic acid bacteria have an adjuvant-like eff ect on the 
humoral responses. 
Th e possible mechanisms by which probiotics may infl uence the growth of pathogens or 
stimulate mucosal innate and acquired immunity are presented in Figure 3.
●
●
●
●
●
●
●
●
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Figure 3. Probiotics may prevent infections through several mechanisms: 
1. By inhibiting the adhesion of pathogens to the epithelium in a non-specifi c manner 
 or by competing for specifi c receptors and nutrients,
2. by producing antimicrobial agents against pathogens,
3. by inducing mucin (MUC2 and -3) production in the epithelial cells,
4. by strengthening the mucosal barrier by promoting the regeneration of epithelial cells 
 and by reducing permeability,
5. by modulating the immune system through the antigen-presenting cells (macrophages and dendritic cells),
6. by inducing pro-infl ammatory cytokine production from epithelial and immune cells, 
 resulting in enhanced cell-mediated immune responses and the activation of cytotoxic T cells, 
 phagocytic cells and NK cells,
7. by increasing the proliferation of B cells through the induction of Th 2 cytokines, which travel to 
 secondary lymphatic organs in mucosa-associated lymphoid tissue (MALT) and diff erentiate into
  immunoglobulin-producing plasma cells and may return to gut-associated lymphoid tissue (GALT), 
8. by inducing the production of specifi c antibodies such as secretory IgA.
IL
LU
ST
R
A
TO
R
:  
SO
LE
 L
Ä
T
TI
45
REVIEW OF THE LITERATURE
2.2.4 Clinical eff ects of probiotics against infectious diseases 
2.2.4.1 Respiratory infections
Th e mucosal surfaces of the upper respiratory tract are functionally linked to other mucosal 
surfaces of the common mucosal-associated lymphoid tissue, and the respiratory tract is 
therefore an appropriate area for probiotic immuno-stimulation. Th ere are some clinical 
studies that have examined the eff ects of probiotics on respiratory infections in basically 
healthy subjects. No positive eff ect of probiotics on the rate or duration of respiratory 
infections was seen in infants who consumed an infant formula with Lactobacillus reuteri 
or Bifi dobacterium lactis for 12-weeks (Weizman et al., 2005) (Table 5). Th e probiotic 
groups, however, had fewer febrile and diarrhoea episodes than the placebo group, and 
L. reuteri seemed to be more eff ective than Bifi dobacterium. In schoolchildren, continuous 
consumption of Lactobacillus casei for 20 weeks reduced the occurrence of lower respiratory 
tract infections, while no eff ect was seen on the duration of the respiratory infections 
(Cobo Sanz et al., 2006). However, the same probiotic did not reduce the incidence of 
either respiratory or gastrointestinal infections in independent elderly subjects during 
a 3-week consumption, but the duration of all infections, including gastrointestinal infections, 
was 20% shorter in the probiotic group than in the control group (Turchet et al., 2003). 
In healthy adults, the consumption of a dietary supplement containing L. gasseri, B. longum and 
B. bifi dum combined with several vitamins and minerals, over a period of at least three months, 
reduced the incidence of respiratory tract infections, the number of days with fever and the 
symptoms of infl uenza, but did not have any eff ect on the duration of infections (Winkler et 
al., 2005). However, on the basis of the results, it is diffi  cult to separate the eff ect of probiotics 
from the possible benefi cial eff ects of vitamins and minerals. When the eff ect of the supplement 
containing probiotics with vitamins and minerals was compared with the vitamin-mineral 
supplement alone, the probiotics signifi cantly reduced the severity of symptoms, the duration of 
the common cold episodes and the number of days with fever, although no infl uence was seen 
on the overall incidence of respiratory tract infections (de Vrese et al., 2005b). Consumption 
of a Lactobacillus reuteri drink for 80 days reduced the frequency of days off  sick in Swedish 
employees, but no data were available on the actual incidence of infections (Tubelius et al., 2005). 
Some studies suggest that probiotics might also be used as a supportive therapy in more serious 
conditions. In a non-controlled, pilot study among 7 paediatric patients suff ering from respiratory 
distress, synbiotic therapy (containing B. breve, L. casei Shirota and galactooligosaccharides) 
from between 8 months and several years showed improvement in the intestinal microbiota 
which probably led to the improvement of intestinal functions and the suppression of bacterial 
translocation and thereby lessened the risk of severe bacterial infections in the lungs (Kanamori 
et al., 2006). In patients with cystic fi brosis, colonised by Pseudomonas, a 6-month therapy with 
Lactobacillus GG reduced pulmonary exacerbation episodes, suggesting that probiotics might 
delay respiratory impairment in these patients (Bruzzese et al., 2007).
Although there are some clinical data suggesting that probiotics may reduce either the 
occurrence or the duration of respiratory infections, only a few trials have made an attempt 
to clarify the mechanisms behind the positive eff ects. Th e groups of de Vrese and colleagues 
(2005, 2006), and Winkler and colleagues (2005) have shown that the acute cellular immune 
response before and 14 days aft er the probiotic supplementation increased the cell counts 
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Table 5. Clinical interventions on probiotics in the prevention of respiratory infections.
Study design 
and settings
Subjects Probiotics used and 
length of the intervention
Main ﬁ ndings:
probiotic vs. placebo*
Reference
RDBPC
in day-care 
centres
201 healthy 
infants
age: 4-10 mo
L. reuteri SD 2112 or 
B. lactis BB-12 or 
placebo in infant formula 
for 12 weeks
Rate and duration of ARI ↔ 
Febrile episodes ↓
0.11 for L. reuteri vs. 
0.27 B. lactis, 0.41 placebo
Absences from day care ↓
0.14 for L. reuteri vs. 0.41, 0.43
Antibiotics ↓
0.06 for L. reuteri vs. 0.21, 0.19
(Weizman et al., 
2005)
RDBPC
in schools
251 healthy 
children
age: 3-12 y
L. casei 
DN-114 001 or placebo 
in fermented milk 
for 20 weeks
Incidence of ARI ↔
Duration of ARI ↔
Incidence of LRI ↓ 32 vs. 49%
Incidence of fatigue ↓ 3 vs. 13%
(Cobo Sanz 
et al., 2006)
RC
free-living 
subjects
260 subject 
age: > 60 y
L. casei 
DN-114 001 
in fermented milk 
for 3 weeks vs.
a control group
Incidence of infl uenza 
or GI inf. ↔
Duration of ARI and GI inf. ↓ 
7 vs. 8.7 days
Fever ↓ 38.3 vs. 38.5
(Turchet et al., 
2003)
RDBPC
free-living 
subjects
477 healthy 
adults
age: 18-70 y
L. gasseri PA16/8+
B. longum SP07/3+
B. bifi dum MF 20/5 + 
vitamin. + miner. or 
placebo in tablet 
for 3-5.5 mo
Incidence of ARI ↔ 13.6% (n.s.)
Duration of ARI ↔ (n.s.)
ARI symptoms ↓ 19% (n.s.)
Days with fever ↓ 0.3 vs. 0.7
(Winkler et al., 
2005)
RDBPC
free-living 
subjects
479 healthy 
adults
age: 18-67 y
L. gasseri PA16/8+
B. longum SP07/3+
B. bifi dum MF 20/5
or placebo in tablet 
for 3 mo
Incidence of ARI ↔
Duration of ARI ↓ 7.0 vs. 8.9
Symptom score ↓ 79 vs. 103
Days with fever ↓ 0.2 vs. 1.0
(de Vrese et al., 
2005b)
RDBPC
free-living 
subjects
479 healthy 
adults
age: 18-67 y
L. gasseri PA16/8+
B. longum SP07/3+
B. bifi dum MF 20/5 + 
vitamin. + miner. 
or placebo in tablet 
for 3-5 mo
Incidence of ARI ↔
Duration of ARI ↓ 7.0 vs. 8.9
Symptom score ↓ 
(de Vrese et al., 
2006)
RDBPC
work-place 
262 
employees
age: 18-65 y
L. reuteri or
placebo through 
a drinking straw 
for 80 days
Sick-leave ↓ 10 vs. 26%
Percentage of sick-days ↓ 
0.4 vs.0.9
(Tubelius et al., 
2005)
Pilot study 7 pediatric 
patients 
with severe
respiratory 
distress
B. breve + L. casei Shirota 
+ galactooligosaccharides 
admin. orally or 
via a nasogastric tube
for varying time periods 
(8 mo-6 y)
Improvement of the intestinal 
microbiota
Antibiotics treatments ↓
Risk of bacteremia ↓
(Kanamori 
et al., 2006)
RPC 19 children 
with cystic 
ﬁ brosis
L. rhamnosus GG dissolved 
in ORS for 6 mo
Pulmonary exacerbations ↓
Hospital admissions ↓
Pulmonary function ↑
(Bruzzese et al., 
2007)
RDBPC = Randomised, double-blind, placebo-controlled; RPC = Randomised, placebo-controlled; RD = Randomised, controlled
ARI= Acute respiratory infection; LRI= Lower respiratory infection; GI= Gastrointestinal
* signiﬁ cant diﬀ erence unless otherwise stated
↑ =  increased 
↓ = decreased 
↔ = no eﬀ ect
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of total leucocytes, lymphocytes, CD4+ T helper cells, sytotoxic and suppressor CD8+ T 
cells, and monocytes. Another probiotic mechanism suggested is their antagonistic eff ects 
against pathogens. A combination of Lactobacillus GG, Bifi dobacterium, L. acidophilus and S. 
thermophilus given in fermented millk reduced the nasal colonisation of potentially pathogenic 
bacteria in healthy adults (Glück and Gebbers, 2003). Th e mechanism has been postulated to 
be mediated by the stimulation of B lymphocytes in gut-associated lymphoid tissue. Th is may 
have resulted in lymptocyte migration to the upper respiratory immune system, resulting in 
the production of antibodies. 
To sum up the probiotic eff ect on respiratory infections: there is increasing evidence that specifi c 
probiotics may reduce infections outside the gastrointestinal tract, too. However, the eff ect seems 
to be mild or modest, and is mainly seen in the reduction of the severity or duration of infections. 
Th e probiotic mechanisms are probably mediated through the systemic immune system, but 
growth inhibition of pathogens may also occur locally in the upper respiratory tract. 
2.2.4.2 Infectious diarrhoea 
Th e most extensively studied health benefi ts of probiotics are to be found in diarrhoeal studies. 
Th e rationale for using probiotics to treat and prevent diarrhoeal diseases is based on the 
assumption that they modify the colonic microbiota and act against enteric pathogens. Several 
studies among children, using diff erent Lactobacillus species (such as L. rhamnosus and reuteri), 
have shown a reduced duration of acute diarrhoea mainly caused by rotavirus, reduced excretion 
of rotavirus and reduced length of hospitalisation (Guarino et al., 1997; Rosenfeldt et al., 2002a; 
Szymanski et al., 2006). In a multicentre trial conducted by the Working Group of the European 
Society for Paediatric Gastroenterology, Hepatology and Nutrition, with 287 hospitalised children 
suff ering from acute diarrhoea, Lactobacillus GG administered with an oral rehydration solution 
reduced the duration of diarrhoea from 71 to 58 hours, and in rotavirus-positive patients even 
more markedly, from 77 to 56 hours (Guandalini et al., 2000). Th e number of watery stools 
and the risk of a prolonged course of disease were also reduced. Th e eff ect was evident among 
rotavirus-positive children and among those with diarrhoea of unknown etiology, but not 
among those with invasive diarrhoea caused by Salmonella, Shigella, Campylobacter, Yersinia 
or Entamoeba (Guandalini et al., 2000). Nor did Lactobacillus GG administered with an oral 
rehydration solution reduce the duration of diarrhoea in Brazilian or Peruvian children with 
severe dehydrating diarrhoea (Costa-Ribeiro et al., 2003; Salazar-Lindo et al., 2004), when EPEC, 
Vibrio cholera, Campylobacter and Shigella or mixed species were causative pathogens in addition 
to rotavirus. It thus seems that the eff ect of probiotics in treating acute rotavirus diarrhoea is well 
established, but the effi  cacy in ameliorating invasive bacterial enteritis is not. Diff erences between 
studies might also result from the diff erent degrees of severity of the disease. Th e benefi cial eff ects 
of probiotics in the treatment of acute diarrhoea have also been shown in systematic reviews and 
meta-analyses carried out among hospitalised children (Szajewska and Mrukowicz, 2001; Huang 
et al., 2002) (Table 6). Th e risk of prolonged diarrhoea has been reduced by 57% by the probiotic 
therapy (Szajewska and Mrukowicz, 2001). 
Several systematic reviews or meta-analyses of probiotic therapy for preventing or treating 
Clostridium diffi  cile-associated diarrhoea (CDAD), or antibiotic-associated diarrhoea (AAD)
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Table 6. Meta-analyses or systematic reviews on the eff ect of probiotics on the treatment or prevention of 
diarrhoeal illnesses. 
Design Studies 
included 
Inclusion 
criteria
Subjects Probiotics used Main fi ndings:
probiotic vs. placebo*
Reference
Systematic 
review
13 RDBPC 
studies:
10 treatment,
3 prevention
Acute 
diarrhoea 
deﬁ ned as 
> 3 loose or 
watery 
stools /d
Children 
or infants
n=731 
/ 773
L. rhamnosus GG
L. reuteri 
L. acidophilus 
S. thermophilus 
Saccharomyces 
boulardii
RR = 0.43 for diarrhoea 
lasting > 3 days. 
Only LGG showed 
a consistent eﬀ ect.
Duration of diarrhoea ↓
-18.2 h for all
-24.8 h for LGG and 
L. reuteri.
Eﬃ  cacy in prevention 
IRR:
0.17
0.23 (n.s.)
0.97(n.s.)
(Szajewska 
and 
Mrukowicz, 
2001) 
Meta-analysis 18 RPC 
treatment 
studies
Acute 
diarrhoea, 
duration of 
diarrhoea 
reported
Healthy 
children 
< 5 years
n=1917
Coadministration of 
L. rhamnosus GG 
L. reuteri 
L. acidophilus 
L. bulgaricus
S. thermophilus 
Sacch.boulardii 
Enterococcus 
B. subtilis with 
rehydration therapy
Duration of 
diarrhoea ↓
- 0.8 day
-1.2 days withLGG
- 0.6 day with other 
lactobacilli
(Huang et al., 
2002)
Systematic 
review
8 RPC 
prevention or 
treatment
studies: 4 CDAD 
4 AAD 
CDAD or 
AAD
Adults
n=not 
known
Sacch. boulardii 
L. rhamnosus GG 
L. plantarum 
L. acidophilus + 
B. bifi dum
Risk diff erence ↓ 
in 2/8 studies
(Dendukuri 
et al., 2005)
Systematic 
review
6 RPC 
prevention
studies
AAD Children 
and adults
n=692
L. rhamnosus GG RR ↓ in 4/6 studies: 
0.13
0.17 (n.s.)
0.29
0.32 (n.s.)
Number of days with 
diarrhoea ↓ 2 vs. 8 days
(Hawrelak 
et al., 2005)
Meta-analysis 6 RPC 
prevention 
trials
AAD,
incidence of 
diarrhoea 
available
Children
n=707
L. rhamnosus GG, 
L. acidophilus + 
B. infantis, 
L. acidophilus + 
L. bulgaricus,
L. sporogens, 
Sacch. boulardii
RR = 0.43 
for AAD 
(Johnston 
et al., 2006)
Meta-analysis 25 RPC 
studies
AAD 
deﬁ ned as 
> 3 loose 
or watery 
stools/d 
for at least 
2 days
Children 
and adults
n=3164
L. rhamnosus GG, 
L. acidophilus 
B. longum
C. butyricum
Bacillus clausii 
Sacch. boulardii
Enterococcus faecium
RR = 0.43 for AAD
RR = 0.59  for CDAD  
(only Sacch. boulardii) 
RR = 0.31 for LGG 
RR = 0.37 for 
Saccharomyces 
(McFarland, 
2006)
Meta-analysis 6 RPC 
treatment
studies
AAD or 
CDAD
Children
n=766
L. rhamnosus GG, 
L. acidophilus + 
B. infantis, 
L. acidophilus + 
L. bulgaricus,
B. lactis +
S. thermophilus, 
Sacch. boulardii 
RR = 0.44 for AAD 
RR = 0.48 for 
B. lactis + S. thermop. 
RR = 0.30 for LGG 
RR = 0.20 for 
Saccharomyces 
RR = 0.38 (n.s.)
for CDAD  
(Szajewska 
et al., 2006)
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Design Studies 
included 
Inclusion 
criteria
Subjects Probiotics used Main fi ndings:
probiotic vs. placebo*
Reference
Meta-analysis 34 RPC 
prevention 
trials
Risk of 
diarrhoea 
available: 
travellers’ /  
AAD /  
acute 
infectious / 
nosocomial 
diarrhoea
Children 
and adults
n=4886
L. rhamnosus GG 
L. reuteri 
L. casei
L. acidophilus 
L. bulgaricus
S. thermophilus 
Sacch. boulardii 
Enterococcus 
B. longum
B. bifi dum
B. lactis  and 
combinations
RR = 0.65 
RR = 0.48 for AAD 
RR = 0.92 (n.s.) for 
travellers’ diarrhoea 
RR = 0.43 for 
children 
RR = 0.74 for adults 
RR = 0.83 (n.s.) for 
single strains 
RR = 0.48 for 
combinations 
(Sazawal 
et al., 2006)
Meta-analysis 12 RBPC 
prevention 
trials
Traveller’s 
diarrhoea 
deﬁ ned as 
≥ 3 loose 
stools/d 
for at least 
2 days
n=4709 L. rhamnosus GG, 
L. fermentum,
L. acidophilus +
L. bulgaricus +
S. thermophilus +
B. bifi dum,
 Sacch. boulardii,
heat-killed 
Salmonella + Shigella 
+ E. coli 
RR = 0.85 (McFarland, 
2007)
RDBPC = Randomised, double-blind, placebo-controlled; RPC = Randomised, placebo-controlled
AAD = antibiotic-associated diarrhoea; CDAD = Clostridium diffi  cile associated diarrhoea
* signiﬁ cant diﬀ erence unless otherwise stated
RR=relative risk; IRR=incidence rate ratio
have been performed  among children and adult patients (Dendukuri et al., 2005; Hawrelak et 
al., 2005; Johnston et al., 2006; McFarland, 2006; Szajewska et al., 2006) (Table 6). Th e pooled 
risk ratio (RR) for ADD has been around 0.4 in the probiotic treatment groups, and for the most 
eff ective strains, such as L. rhamnosus GG or Saccharomyces boulardii, even lower, around 0.2-0.3. 
Th e incidence of ADD, for example, has varied between 3 and 8% in the LGG groups, while in the 
placebo groups it was 16-30%, indicating a 0.17-0.32 relative risk (Hawrelak et al., 2005).
Although there is fairly convincing evidence of the therapeutic benefi ts of probiotics in treating 
viral and antibiotic-associated diarrhoea, especially in children, the evidence of probiotics in 
actually preventing infectious diarrhoea is still sparce. According to a recent meta-analysis of 34 
randomised, placebo-controlled diarrhoeal prevention trials carried out among both children and 
adults, probiotic treatment showed a signifi cant protective eff ect - a 35% reduction in the risk of 
diarrhoea (Sazawal et al., 2006) (Table 6). Th e eff ect varied according to the type of diarrhoea:  it 
was most pronounced in preventing ADD, while the reduction of traveller’s diarrhoea was non-
signifi cant, although a separate meta-analysis on traveller’s diarrhoea showed a 15% reduction in the 
incidence (McFarland, 2007). According to Sazawal and colleagues, the eff ect was higher in children 
than in adults, probably as a result of the diff erences between the colonisation and gut microbiota 
of children and adults. A few studies that examined the preventive eff ect of probiotics on hospital-
acquired diarrhoea in children during their hospital stay and shortly aft er discharge reported the 
incidence of nosocomial diarrhoea as being approximately 7% in the probiotic groups compared 
50
REVIEW OF THE LITERATURE
to 31-33% in the control groups, indicating a relative risk of 0.20 (Saavedra et al., 1994; Szajewska et 
al., 2001). However, there are also studies reporting no preventive eff ects (Mastretta et al., 2002). 
Apart from hospital-acquired diarrhoea, only a few studies have examined the preventive eff ect 
of probiotics on the occurrence of community-acquired diarrhoea among a healthy population 
(Oberhelman et al., 1999; Pedone et al., 1999;  2000; Chouraqui et al., 2004; Th ibault et al., 
2004; Weizman et al., 2005) (Table 7). Th ree studies have examined the eff ect of an infant 
formula containing bifi dobacteria or lactobacilli on the incidence of diarrhoea in infants. 
Consumption of an infant formula containing Bifi dobacterium or Lactobacillus has reduced 
Table 7. Randomised, controlled trials on probiotics in preventing community-aquired diarrhoea 
in healthy children and in adults. 
Study design 
and settings
Subjects Probiotics used and 
length of the intervention
Main fi ndings:
probiotic vs. placebo*
Reference
RDBPC
Peri-urban 
Peruvian 
town 
204 under-
nourished  
infants and 
children
age: 6-24 mo
L. rhamnosus GG or 
placebo in gelatine capsules 
for 15 mo
Diarrhoea episodes ↓
5.2 vs. 6.0 
Incidence of diarrhoea ↓ 
in nonbreastfed 4.7 vs. 5.9 
Duration of diarrhoea ↔
(Oberhelman 
et al., 1999)
RPC
Day-care 
centres
287  infants 
and children 
age:
mean 19 mo
L. casei DN-114001 
or placebo in fermented 
milk for 6 mo
Incidence of diarrhoea ↔
Duration of diarrhoea ↓
4.3 vs. 8.0 days 
(Pedone et al., 
1999)
RDBPC
Multicentre
928  infants 
and children
age: 6-24 mo
L. casei DN-114001 
or placebo in fermented 
milk for 4 mo
Incidence of diarrhoea ↓
16% vs. 22% 
(Pedone et al., 
2000)
RDBPC
Multicentre
residential 
care settings
90 infants 
age < 8 mo
B. lactis Bb-12 or 
placebo in infant 
formula for 4.5 mo
Incidence of diarrhoea ↔ 
28% vs. 39% (ns.)
Duration of diarrhoea ↓
1.2 vs. 2.3 days 
(Chouraqui et al., 
2004)
RDBPC
Pediatric 
centres
971 infants
age: 4-6 mo
B. breve + 
S. thermophilus or 
placebo in infant formula 
for 5 mo
Incidence or duration of 
diarrhoea, hospital 
admissions ↔
Medical consultations ↓ 
46% vs. 57% 
Need for dehydration ↓
2.5% vs. 6.1% 
ORS presriptions ↓ 
42% vs. 52% 
(Th ibault et al., 
2004)
RDBPC
Day-care 
centres
201 infants
age: 4-10 mo
B. lactis Bb-12 or 
L. reuteri or placebo 
in infant formula 
for 3 mo
Diarrhoeal episodes ↓:
0.02 for B. lactis group 
0.13 for L. reuteri group
0.31 for controls
Duration of episodes ↓:
0.15 vs. 0.37 vs. 0.59 
(Weizman et al., 
2005)
RPC
Military 
camps
502 military 
men
L. casei DN-114001 
or placebo in yogurt for
2 mo
Incidence of diarrhoea ↔ 
12% vs. 16% (ns.)
Duration of diarrhoea ↔
(Pereg et al., 
2005)
RDBPC = Randomised, double-blind, placebo-controlled; RPC = Randomised, placebo-controlled 
* signiﬁ cant diﬀ erence unless otherwise stated
↑ =  increased 
↓ = decreased 
↔ = no eﬀ ect
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diarrhoeal episodes and the duration of diarrhoea, but no diff erences were seen in stool 
pathogens as regards rotavirus or bacterial cultures (Weizman et al., 2005). However, studies 
by Th ibault et al., (2004) and Chouraqui et al., (2004) could not show any benefi cial eff ect of a 
Bifi dobacterium infant formula on the incidence or duration of diarrhoea, but the severity of 
infections (e.g. the need for rehydration), was reduced (Th ibault et al., 2004). Lactobacillus GG 
(Oberhelman et al., 1999) and  L. casei  (Pedone et al., 1999; 2000) have reduced  the incidence 
and the severity of diarrhoea in infants and small children but not in young military men (Pereg 
et al., 2005). Although some studies suggest benefi cial eff ects of probiotics in the prevention 
of diarrhoea in healthy infants and children, the data on adults is sparce, and virtually no data 
among the elderly exists so far. 
Taken together, specifi c probiotics seem to be eff ective in reducing the duration of acute 
diarrhoea, especially rotavirus diarrhoea in children. Specifi c probiotic strains may protect 
from antibiotic-associated and nosocomial diarrhoea in both children and adults. Probiotics 
have also shown a modest eff ect in preventing community-aquired infectious diarrhoea in 
healthy infants and children, but the evidence is weak on the prevention of diarrhoea among 
adults and non-existant among the elderly. 
2.2.4.3 Candida infections 
It has been shown in animal studies that Candida albicans colonises germ-free animals more 
easily than conventional animals, suggesting that normal anaerobic microbiota in the oral 
cavity, digestive tract or vagina suppresses the growth of Candida in vitro (for review, see 
Kerr, 1999). Th e importance of the normal gut microbiota in suppressing the growth of C. 
albicans has been clearly demonstrated in an in vitro model of the human colon (Payne et 
al., 2003). In that particular model, tetracycline distrupted the composition of the normal 
bacterial population by decreasing the total numbers of anaerobes, bifi dobacteria, lactobacilli, 
bacteroides and clostridia, while the amount of yeasts increased. Th e addition of Lactobacillus 
plantarum to the model noticeably reduced the growth of Candida.  
Clinical evidence of the antifungal properties of probiotics in humans is sparce, and comes 
mainly from studies examining the prophylactic eff ects of lactobacilli on vaginal candidosis 
(Hilton et al., 1992; Shalev et al., 1996). Long-term consumption of yoghurt containing 
Lactobacillus acidophilus reduced both vaginal candidal colonisation and infection compared to 
the period without yoghurt consumption (Hilton et al., 1992).Th e mechanism in the prevention 
of vaginal candidosis has been postulated as being due to the production of hydrogen peroxide 
by the lactobacilli, since the most eff ective strains have been H2O2-producers (Hilton et al., 
1992; Shalev et al., 1996). Normalisation of vaginal microbiota has also been postulated as 
a possible mechanism, since Lactobacillus species are the predominant micro-organisms in 
the vaginal microbiota, and orally-consumed strains have been found in faeces and vaginal 
secretions (Hilton et al., 1992; Shalev et al., 1996). However, yeasts and lactobacilli can co-
exist in the vagina, and there are also contradictory results on the eff ect of lactobacilli on 
vaginal candidosis. No benefi cial eff ects on candidal vaginitis were observed when a 4-month 
consumption of yoghurt containing live L. acidophilus was compared to pasteurised yoghurt 
(Shalev et al., 1996). Nor did a short-term treatment of lactobacilli simultaneously with 
antibiotics reduce the incidence of post-antibiotic vulvovaginitis (Pirotta et al. 2004). Although 
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the oral administration of diff erent Lactobacillus strains can result in restoration of normal 
vaginal microbiota (Reid et al., 2003), and some probiotic strains can be recovered from the 
vagina aft er oral consumption (Vasquez, 2005), the protective role of lactobacilli in preventing 
Candida vaginitis still remains unproven. Th ere are only a very few clinical trials showing the 
benefi cial eff ects of probiotics on oral or gastrointestinal Candida. Th e consumption of cheese 
containing Lactobacillus GG and L. rhamnosus LC705 showed a tendency to reduce salivary 
yeasts in healthy adults (Ahola et al., 2002). Recently, Lactobacillus GG has also been shown 
to reduce the enteric colonisation of Candida in very-low-birth-weight preterm neonates, 
measured by colonies isolated from oropharyngeal, gastric aspirate, stool and faecal specimens 
(Manzoni et al., 2006). 
In vivo animal studies have shown that the oral administration of live L. acidophilus and 
fermentum has shortened the duration of oral colonisation by Candida in mice (Elahi 
et al., 2005). Diff erent Lactobacillus species (L. acidophilus, reuteri, and rhamnosus GG) 
and Bifi dibacterium animalis have also reduced the incidence of systemic candidiasis in 
immunodefi cient mice (Wagner et al., 1997a). Probiotics also reduced the number of Candida 
in the alimentary tract, but Bifi dobacterium was the only one to reduce the severity of orogastric 
candidiasis. All the strains were seen to colonise and persist in the alimentary tract (Wagner 
et al., 1997b). However, the viability of probiotics does not seem necessary for reducing the 
number of Candida, since also heat-killed Lactobacillus GG, too, induces limited protection 
against candidiasis in immunodefi cient mice; LGG suppresses the severity of candidiasis in 
the stomach, oesophagus, tongue and hard palate of mice with dysfunctional phagocytic cells, 
defi cient NK-cell activity, and missing T cells (Wagner et al., 2000). Heat-killed Lactobacillus 
GG and L. acidophilus were both able to inhibit systemic candidiasis in Candida-resistant mice; 
it was hypothesised that the adherence of Candida was blocked by the surface components of 
the heat-killed lactobacilli which stimulated the immune system (Wagner et al., 2000). 
To summarise, lactobacilli may have antagonistic eff ects against Candida. Th e clinical evidence 
on the eff ect of probiotics comes mainly from vaginal candidosis studies. However, several 
animal trials suggest that lactobacilli are able to suppress the growth of Candida in diff erent 
parts of the alimentary tract.
2.2.5 Safety of probiotics 
Th e increasingly widespread use of probiotics, in addition to the fact that probiotics are live 
bacteria, has raised the question of their possible health risks. Although probiotic therapy 
is generally considered harmless, rare case reports have been published on the ability of 
lactobacilli to cause endocarditis and bacteraemia (for review, see Boyle et al., 2006b). Few 
cases have been linked to the ingestion of probiotic supplements, or else bacteria found in 
blood cultures could not have been distinguished from the strains used in food or probiotic 
supplements. However, all the cases have occurred in patients with underlying severe chronic 
diseases (Boyle et al., 2006b). Immunosuppression, prior prolonged hospitalisation and surgical 
operations have been identifi ed as major predisposing factors for Lactobacillus bacteremia 
(Salminen et al., 2004a). However, no reports have described bacteremia related to probiotic 
use in otherwise healthy people. Nor does published evidence suggests that the consumption 
of probiotics containing lactobacilli or bifi dobacteria increases the risk of opportunistic 
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infections in immunocompromised subjects. In fact, probiotics have been proved to be safe 
and well-tolerated in immunocompromised patients with HIV (Wolf et al., 1998; Salminen et 
al., 2004b) and also in children, including pre-term neonates (Agarwal et al., 2003; Bin-Nun 
et al., 2005).
In Finland, the safety of L. rhamnosus GG, a widely used probiotic strain, has been followed 
nationwide since the year 1990, when the probiotic LGG was introduced to the market. Despite 
the marked increase in the use of probiotic foods containing LGG since then, no signifi cant 
increase in Lactobacillus bacteremia attributable to probiotics has been observed (Salminen et 
al., 2002). During the years 1990-2000, all Lactobacillus isolates from blood culture specimens 
were collected, and lactobacilli were isolated in 0.02% of all the blood cultures and 0.2% 
of all the positive blood cultures. Th e annual incidence of Lactobacillus bacteremia in the 
Finnish population was 0.3 cases / 100,000 inhabitants (Salminen et al., 2002). Lactobacilli and 
bifi dobacteria belong to the normal intestestinal microbiota; lactobacillemia may thus occur 
naturally, without exogenous administration. Th ere is also no evidence that ingested probiotic 
lactobacilli or bifi dobacteria pose any higher risk of infection than the risk associated with 
commensal strains (Borriello et al., 2003). A workshop panel consisting of experts on probiotics 
has concluded that on the basis of current scientifi c and medical evidence, the consumption of 
probiotic products presents a negligible risk to consumers, including immunocompromised 
subjects (Borriello et al., 2003). Th e European Food Safety Authority (EFSA) has also proposed 
a QPS status (Qualifi ed Presumption of Safety) for Lactobacillus (including L. rhamnosus), 
Bifi dobacterium and Propionibacterium (particularly P. freudenreichii ssp. shermanii) species 
(EFSA, 2006). EFSA concludes that “there are apparently no specifi c safety concerns regarding 
a number of Lactobacillus, Bifi dobacterium and Propionibacterium species, which have a long 
history of safe use in food.” 
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3   AIMS OF THE STUDY
Th e main objective of this thesis was to evaluate whether long-term treatment with a specifi c 
probiotic or a specifi c probiotic combination would prevent the clinical appearance of common 
infections in children, and also in the elderly, who are at increased risk of infection. To resolve 
the main question, four studies among children and the elderly were performed, in which the 
specifi c aims were:  
To examine whether a specifi c probiotic supplementation would reduce 
the risk /occurrence of:
1. acute respiratory infections and their complications in healthy children (I), 
 in otitis-prone children (II), and in the institutionalised elderly (III), and to
 consider the possible mechanisms of probiotics by investigating whether
  probiotics reduce the prevalence of common viral respiratory pathogens (II),
2. acute otitis media in healthy children (I) and in otitis-prone children (II), and to
 consider the possible mechanisms of probiotics by investigating whether
 probiotics reduce the carriage of the main bacterial otitis pathogens (II),
3. diarrhoea in healthy children (I) and in the institutionalised elderly (III) and
4. high oral yeast carriage in independent elderly subjects (IV). 
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4   MATERIALS AND METHODS 
4.1 Subjects and study designs (I-IV) 
Th e description of the study settings, subjects and interventions in each study are shown in 
Table 8, the individual study designs, in Figure 4.
All the studies were randomised, double-blind, placebo-controlled clinical intervention studies 
with two parallel groups (probiotic and placebo). Th e required sample size for each study was 
calculated on the basis of previous probiotic studies examining the incidence of respiratory 
infections (II) or diarrhoea (III). If there were no previous probiotic studies available, other 
non-pharmacological intervention studies were used as a reference (I, IV). Estimated sample 
sizes were increased by 10-30%, depending on the study population, in order to compensate 
for the anticipated drop-out rates. A total of 500 (I), 380 (II), 216 (III) and 216 (IV) subjects 
completing the study were needed for the expected diff erences between the groups to be 
detected. Th e exact sample size calculations are presented in the original articles.
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4.1.1 Respiratory and gastrointestinal infections in healthy children (I)
Healthy children aged 1-6 years and attending day-care centres, were recruited through meetings 
with parents. Th ose with severe chronic diseases, cow´s milk allergy, lactose intolerance or 
severe food allergy were excluded. Th e children were considered to have a slightly increased 
risk of infections because of their day-care attendance. 
During the 7-month intervention (October 1998 to April 1999), data on the occurrence and 
duration of respiratory and gastrointestinal infections, medication, absences from day-care 
centre and doctor’s diagnoses, were gathered by means of symptom diaries fi lled in daily by 
the parents. Information on the demographic data, home environment, the child’s nutrition 
habits and history of illnesses was collected at baseline. No scheduled clinical examinations 
were carried out during the study. Th e children used either municipal health care services, or 
private doctors whenever necessary. All the diagnoses and visits to doctors were reported in 
the study diaries either by the doctor or by the parents. Faecal samples were collected at the 
beginning, in the middle and at the end of the study to determine the recovery of Lactobacillus 
GG. Th e parents were also instructed to contact the researchers each time their child had 
Table 8. Characterisation of the study settings, interventions and subjects.
Study Settings Subjects Intervention
Risk level of 
infectious 
diseases
Numbers starting/ 
completing the study 
(%)
Probiotic* / Placebo
treatment
I 18 day-care 
centres
Healthy children 
attending day-care 
centres: 
slightly increased 
risk
571 / 513 (90%) Low-fat milk containing 
LGG
Low-fat milk without 
probiotics
7 mo
II 1 study centre Otitis-prone 
children:
moderately 
increased risk  
309 / 269 (87%) Capsules containing    
LGG, LC705, PJS, Bb99
Placebo capsules
6 mo
III 2 old people’s 
homes
1 hospital
Institutionalised 
elderly subjects:
moderately 
increased risk  
265 / 226 (85%) Capsules containing    
LGG, LC705, PJS, Bb99
Placebo capsules
5 mo
IV 12 old people’s 
homes
37 sheltered 
housing units
Independent 
elderly subjects:
slightly increased 
risk
 
276 / 192 (70%) Low-fat cheese containing 
LGG, LC705, PJS
Low-fat cheese without 
probiotics
4 mo
*LGG = Lactobacillus rhamnosus GG (ATCC 53103) 
LC705 = Lactobacillus rhamnosus LC705 (DSM 7061) 
PJS = Propionibacterium freudenrechii ssp. shermanii JS (DSM 7067) 
Bb99 = Bifi dobacterium breve 99 (DSM 13692) 
Duration
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diarrhoea, and to collect a faecal sample for pathogen analysis. However, although there were 
179 diarrhoeal episodes during the study, only 31 faecal samples were obtained, and therefore 
these results have been omitted.
4.1.2 Respiratory infections and acute otitis media in otitis-prone children (II)
Otitis-prone children, aged 10 months to 6 years, who had experienced at least four episodes 
of acute otitis media during the preceding 12 months or at least three episodes during the 
preceding 6 months, were recruited by advertisements in newspapers and through primary 
healthcare and day-care centres. Th ese children were considered to be at moderately increased 
risk of infection because of their history of recurrent otitis media. Children on regular 
medication, with chronic illnesses, Down’s syndrome, lip or palatal cleft , otitis media with 
eff usion, or who were scheduled for tympanostomy or adenoidectomy during the study were 
excluded. 
Th e study consisted of a four-week run-in period followed by a 6-month intervention (carried 
out between September 2001 and April 2002), during which period the occurrences of acute 
respiratory infections and AOM episodes were registered. Th e children were examined by a 
full-time physician, a senior resident in otorhinolaryngology, three times during the study. 
Th ese visits were made at baseline, in the middle (3 months) and at the end (6 months) of 
the study, and scheduled at times when the child was free of respiratory symptoms and free 
of AOM. At each visit, the physician carried out a general physical examination, including 
inspection of the child’s ears with a pneumatic otoscope and a tympanometry (GSI 37 Auto-
Tymp, Grason-Stadler, Milford, NH, USA). In addition, a nasopharyngeal sample for the 
culture of potential bacterial pathogens (S. pneumoniae, H. infl uenzae, M. catarrhalis and 
S. pyogenes) and the detection of viral pathogens (rhinovirus and enterovirus), and a saliva 
sample for analysis of anti-pneumococcal IgA antibodies were taken during these “healthy 
visits”. Each time the parents suspected AOM, they were instructed to bring their child to 
the study clinic. During these illness visits, a physical examination, a pneumatic otoscope 
and a tympanometry were carried out by the same doctor, but no samples were taken. If the 
child visited any doctor other than the study physician, the diagnosis was double-checked 
as soon as possible by the study physician. Th e parents kept a daily diary of the symptoms 
of acute respiratory infections, the use of medication, and visits to doctors other than the 
study physician.
4.1.3 Respiratory and gastrointestinal infections in the institutionalised 
elderly (III)
Institutionalised elderly people aged 65 years or over were recruited from the long-term care 
units in the municipal hospital of the City of Jyväskylä and from two old people’s homes in 
Jyväskylä. Patients with chronic gastrointestinal disorders and those who were expected to 
move to other residential care units during the study were excluded. Because nurses participated 
actively in the study, no attempt was made to exclude patients with dementia. Subjects were 
considered to have moderately increased risk of infectious diseases because of their frail health 
status and the need for long-term care.  
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Th e study consisted of a two-week run-in period followed by a 5-month intervention (January 
to May 2001). During both the run-in period and the intervention, personal nurses evaluated 
the overall health status of the subjects daily. Information on the occurrence of respiratory and 
gastrointestinal infections, fever (≥ 38º C) and the use of antimicrobial agents was reported in 
a study diary by nurses on a daily basis. Th e number of bowel movements, stool consistency, 
and the use of laxatives were also recorded daily. Th e health status of the patients was evaluated 
at a routine doctor’s examination, fi ve times a week in the hospital and once a week in the 
old people’s homes. Baseline information on medical history was obtained from the hospital 
medical records. Functional capacity was evaluated on the basis of the Barthel Index score 
(Mahoney and Barthel, 1965), weight and height were measured, and the body mass index 
(BMI) was calculated at baseline.  
4.1.4 Oral Candida in the independent elderly (IV) 
Independent elderly people aged 65 years or over living in old people’s homes or sheltered 
housing units and who were mentally able to understand and follow the study protocol were 
recruited through informational meetings about the study. Th ose with current oral yeast 
medication, or dementia according to the Mini Mental State (MMS) test (Folstein et al., 
1975), were excluded. Th e subjects who participated were considered to represent the average 
elderly population with a slightly increased risk of infections due to age-related diseases and 
medication.
Th e study consisted of a three-week run-in period followed by a 4-month intervention and 
was carried out during diff erent periods between January 2001 and March 2002. Baseline 
information on health status was gathered by interviewing the subjects, and on the use of 
medication, from medication prescriptions. Oral yeast samples were taken by research assistants 
four times during the study. Th e fi rst sample at the beginning of the run-in period was taken in 
order to form a stratifying factor for the randomisation. Th e next three samples were taken on 
scheduled clinical examinations (at 0, 2 and 4 months). Stimulated and unstimulated salivary 
secretion rates and salivary buff ering capacity were measured (by the Dentobuff  ® Strip method; 
Orion Diagnostica, Espoo, Finland) at baseline and at the end of the intervention. Th e subjects 
were interviewed fi ve times (at 0, 1, 2, 3 and 4 months) about their general health, changes 
in medication and subjective feelings of oral pain and dry mouth. Th e oral and dental status 
of the subjects was examined according to WHO criteria (WHO, 1997) by an experienced 
dentist, at baseline and at the end of the intervention. Periodontal conditions, the presence of 
mucosal lesions and the number of decayed, missing and fi lled teeth or the number and type of 
prosthetic appliances were recorded. Mucosal lesions were recorded as leukoplakia (white oral 
lesions, hyperkeratotic areas that are not removable by scraping), erythroplakia (erythematous, 
red oral lesions), hyperplasia (white plaques, not easily removed), ulceration and pigmented 
oral lesions. 
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Figure 4. Study designs. 
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4.2 Administration and doses of probiotics (I-IV) 
Th e subjects were randomly allocated to the probiotic or placebo groups according to a 
computer-generated random permuted block method. A block size of four was used and the 
randomisation was stratifi ed according to the suspected factors aff ecting the susceptibility 
of infections: in Study I, according to age and the individual day-care centre; in Study II, 
according to age, gender and the form of day care; in Study III, according to the health-care 
unit; and in Study IV, according to the baseline yeast count. 
Probiotic treatment was given either in food (Studies I and IV) or in capsules (Studies II and 
III). In Study I, the probiotic Lactobacillus rhamnosus GG (ATCC 53103) was given in milk 
(Gefi lus®, Valio Ltd, Riihimäki, Finland). Th e children drank the milk during their attendance 
at day care, fi ve days a week and three times a day, at an average of 260 mL/day. Th e milk 
contained 1% of fat and 5-10 x 105 cfu/mL (colony-forming units) of strain LGG®. Th us the 
average amount of LGG was approximately 1-3 x 108 cfu/day. Th e control milk was similar, 
but without the LGG. In Study IV, a probiotic combination of the strains L. rhamnosus GG, L. 
rhamnosus LC705 (DSM 7061) and Propionibacterium freudenreichii ssp. shermanii JS (DSM 
7067) was given in low-fat cheese. Th e daily dose of cheese was 50g, containing 15% of fat and 
107 cfu/g of each probiotic strain. Th e average quantity of probiotics was 1.5 x 109 cfu/day. Th e 
placebo cheese contained 17% of fat and no probiotics. Th e placebo products were blinded by 
using coded packages.
Th e gelatine capsules consumed in Studies II and III contained a mixture of probiotic 
strains (L. rhamnosus  GG, L. rhamnosus LC 705, Bifi dobacterium breve 99 (DSM 13692), 
Propionibacterium JS, Valio Ltd, Helsinki, Finland), 8-9 x 109 cfu/capsule of each strain. Th e 
placebo capsules were identical in appearance, with cellulose microcrystalline as a fi lling 
material. Otitis-prone children (II) consumed one capsule (daily dose of 3-6 x 1010 cfu) and 
the institutionalised elderly (III), two capsules per day (daily dose of 6 x 1010 – 1.2 x 1011 cfu). 
Th e subjects were instructed to consume the capsules in the morning with breakfast. Th ey were 
allowed to swallow the capsules, or if they were not able to swallow, the capsules were opened 
and the powder was blended with a cold drink or food, preferably a milk product.  
Th e amount of milk or cheese eaten, or the number of probiotic capsules consumed, was 
recorded in the study diary. Compliance (%) was measured as 100*(the amount of milk or 
cheese or capsules eaten/ total amount). Th e use of other products containing probiotic bacteria 
was forbidden for one month preceding the interventions (I and II), during the run-in periods 
(III and IV) and throughout the interventions. Th e study products were obtained from the 
Research and Development Centre of Valio, Ltd, Helsinki, Finland.
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4.3 Diagnostics of infectious diseases 
4.3.1 Acute respiratory tract infections (I-III)
In Studies I and II, the symptoms of acute respiratory infections (ARI) (fever, rhinitis, sore 
throat, cough, wheezing, earache, otorrhoea), and other illness-related symptoms such as 
irritability, night-restlessness and poor appetite, were recorded on a daily basis in a symptom 
diary by the children’s parents. Acute respiratory infection was defi ned when at least one 
respiratory symptom was present for at least two consecutive days or at least two symptoms 
were present for at least one day. In Study III, “the common cold” was recorded in a study 
diary by a personal nurse on the basis of common respiratory symptoms (rhinitis, cough, 
sore throat and wheezing). Th e duration of ARI episodes was counted from the study diaries. 
In all the studies, a new ARI episode was defi ned as occurring aft er at least 7 asymptomatic 
days. 
Respiratory infections with complications (bronchitis, pneumonia, sinusitis) were diagnosed 
by a doctor on the basis of commonly accepted clinical criteria. In Study I, the diagnoses were 
made by municipal or private physicians, in Study II, by a study doctor, and in Study III, by 
hospital doctors. A new bronchitis and sinusitis episode was defi ned as one aft er at least 7 
symptom-free days, and a new pneumonia episode, aft er at least 14 symptom-free days. Th e use 
of antimicrobials for treating respiratory infections was recorded in the study diaries.
4.3.2. Acute otitis media (I-II)
In Study I, the diagnosis of acute otitis media (AOM) was made by municipal or private doctors 
on the basis of commonly accepted criteria. In Study II, 69% of all AOM diagnoses were made 
by a study doctor, a senior resident in otorhinolaryngology, and the remainder by municipal 
or private doctors. 
In Study II, AOM was defi ned as the simultaneous presence of middle ear eff usion, 
abnormalities of the tympanic membrane indicating an infl ammation, and at least one 
symptom of an acute infection (fever, earache, otorrhoea, cough, rhinitis, sore throat, wheezing, 
irritability, poor appetite, vomiting or diarrhoea). Th e presence of middle ear eff usion was 
detected in pneumatic otoscopy by a combination of abnormal colour (haemorrhagic, pale 
or yellow), reduced or absent mobility or a bulging position of the tympanic membrane, and 
a B-type, fl at  tympanogram curve. Th e duration of AOM was calculated on the basis of the 
doctor’s diagnosis, and the presence of infection symptoms recorded in the study diaries. Th e 
AOM episode was considered to have lasted as long as the child had respiratory infection 
symptoms aft er the AOM diagnosis. A new episode of AOM was diagnosed when there was at 
least one day without any respiratory symptoms since the previous episode. If the child visited 
the doctor again because of the extension of the symptoms and the criteria of AOM were 
fulfi lled but the child had been asymptomatic for at least one day in between, the AOM was 
diagnosed as a new episode. Otherwise, if the child had suff ered from symptoms continuously, 
the “newly” diagnosed AOM was considered to be part of the same episode. Otitis media was 
treated on the basis of the audit of the Finnish Medical Societies, amoxicillin being the fi rst-line 
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antibiotic (Puhakka et al., 1999), and the use of non-steroidal anti-infl ammatory drugs being 
recommended when needed. Th e use of antimicrobials for treating AOM was recorded in the 
study diaries (I, II).
4.3.3 Diarrhoea and gastrointestinal infections (I, III)
Gastrointestinal symptoms - diarrhoea, vomiting and abdominal pain - were recorded on a 
daily basis in the symptom diaries by the children’s parents (I) or by personal nurses (III). In 
the children (I), diarrhoea was defi ned as abnormal loose or watery stools during at least one 
day. In the elderly (III), personal nurses evaluated the consistency of stools (hard, normal/
soft , loose, watery). Loose or watery stools indicated diarrhoea. Th e defi nition of diarrhoea 
also included abstention from the use of laxatives on the same or on the previous day. In 
both children and the elderly, gastrointestinal (GI) infection was defi ned as diarrhoea and/or 
vomiting lasting at least one day. A new diarrhoea or GI-infection episode was defi ned as 
one occurring aft er at least 14 days without any gastrointestinal symptoms. Th e duration of 
diarrhoea and GI infections was assessed from the study diaries. 
4.4 Bacteriological and serological methods 
4.4.1 Detection of nasopharyngeal rhino- and enteroviruses (II)
Nasopharyngeal samples were taken three times during the study. A senior resident in 
otorhinolaryngology took the samples from the nasopharynx with a fl exible calcium alginate 
swab via the nostril. Th e swab was immediately immersed in a tube containing 1 mL of STGG 
transport medium (20 g skimmed milk powder, 30 g Oxoid tryptone soya broth, 5 g glucose, 
100 mL glycerol, 1 L distilled water). Th e STGG tube containing the swab was vortexed 
immediately, stored in a refrigerator for not more than 8 hours, and frozen at –70°C until 
analysis. Samples were sent in dry ice for analysis to the Department of Viral Diseases and 
Immunology, National Public Health Institute, Helsinki, Finland. Th ey were thawed and a 
multiplex reverse-transcription PCR-hybridisation assay for rhino- and enteroviruses was 
carried out as described in earlier studies  (Blomqvist et al., 1999). 
4.4.2 Cultivation of nasopharyngeal bacterial pathogens (II)
Nasopharyngeal samples were cultured for potential otitis pathogens (Streptococcus 
pneumoniae, Haemophilus infl uenzae, Moraxella catarrhalis and Streptococcus pyogenes) at the 
Laboratory for Chlamydia and Respiratory Tract Bacteria, National Public Health Institute, 
Oulu, Finland. Th e samples were thawed and vortexed before being inoculated on sheep’s blood 
agar, sheep’s blood agar with gentamicin (5 mg/L), and chocolate agar plates. Th e plates were 
incubated overnight in 5% CO2 at +37°C, and colonies suspected of being S. pneumoniae, H. 
infl uenzae, M. catarrhalis and S. pyogenes were identifi ed using generally accepted methods 
(Kilpi et al., 2001). Th e number of bacterial colonies were recorded semiquantitatively: negative 
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(no colonies), + (1-10 colonies), ++ (11-100 colonies) and +++ (>100 colonies). Th e serotyping 
of pneumococcal isolates was performed by latex agglutination and counterimmuno-
electrophoresis and if necessary confi rmed by a capsular swelling test using commercial 
pneumococcal antisera purchased from the Statens Serum Institute, Copenhagen, Denmark 
(Kilpi et al., 2001).
4.4.3 Salivary pneumococcal IgA antibodies (II)
Saliva samples were aspirated with a plastic pipette into an Eppendorf tube. Th e samples were 
stored in a refrigerator for not more than 8 hours and then frozen at –70°C. Aft er thawing, 
the samples were centrifuged at 15,000 rpm for 10 minutes and the supernatant was used for 
assay. Th e salivary IgA antibodies against pneumococcal proteins (PspA1, PspA2 and PhtD) 
and polysaccharides (6B and 19F) were measured by enzyme immunoassay (EIA), as described 
by Nurkka et al., (2004), with a few modifi cations. Th e antigens used were PspA family 1 
(Pneumococcal surface protein A) recombinant protein from the Rx1 strain and  PspA family 
2 from the V24 strain (University of Alabama, Birmingham, USA), the full-length protein of 
PhtD  (Pneumococcal histidine triad) (GSK, Rixensart, Belgium), and polysaccharides 6B and 
19F  (ATCC, Rockville, Maryland, USA). Analyses were performed in the Vaccine Immunology 
Laboratory, National Public Health Institute, Helsinki, Finland.
4.4.4 Cultivation of oral Candida (IV) 
Oral yeast samples were taken three times during the study. Th e research assistant obtained 
the yeast samples by rotating a cotton stick in the oral mucosa of the cheeks and tongue, and 
the gingival margin (dentate subjects) or alveolar ridge (edentate subjects), and immediately 
inoculating it onto a Dentocult® CA slide (Orion Diagnostica, Espoo, Finland). Aft er 
incubation for 48 hours at +37°C, the growth was assessed semiquantitatively according to 
the manufacturer’s visual scale, using the following categories: negative (no visible colonies), 
+ (equivalent to a colony density of 103cfu/mL), ++ (equivalent to 104cfu/mL), +++ (equivalent 
to 105cfu/mL), and ++++ (equivalent to 106cfu/mL). Th e growth category “+” was used to 
distinguish between patients with low (<104cfu/mL) and high (≥ 104cfu/mL) counts. Further 
identifi cation of the yeast species was made by subculturing them onto CHROMAgar Candida 
(Becton Dickenson, Franklin Lakes, New Jersey, USA), which permitted the presumptive 
identifi cation of C. albicans, C. glabrata, C. krusei and C. tropicalis. Th e cultivations were made 
in the Department of Bacteriology and Immunology, University of Helsinki, Finland. 
4.4.5 Lactobacillus GG in faeces (I) 
Faecal samples, taken three times during the study, were delivered from the day-care centres 
to Valio Research & Development Centre, where they were immediately frozen at -45°C until 
analysis. One hundred samples (51 probiotic + 49 placebo) were randomly selected to study the 
recovery of Lactobacillus GG in the faeces in order to confi rm compliance. Th e thawed samples 
were diluted in phosphate buff ered saline (pH 7.2, 10 mM phosphate) and the dilutions were 
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spread on MRS agar supplemented with vancomycin (50 mg/L). Th e plates were incubated 
aerobically for 48 hours at +37°C, and the typical colonies of Lactobacillus GG were purifi ed 
to check for cell morphology and lactose fermentation. Analyses were performed in the 
microbiological laboratory of Valio Ltd, R&D. 
4.5 Statistical methods 
Statistical analyses were performed by using SPSS for Windows versions 9.0-14.0 (SPSS Inc, 
Chicago, IL, USA). All the analyses were based on the intention to treat (ITT) population. 
However, to avoid any inaccuracy in estimating missing values for the number of episodes 
and other variables describing the counts of incidents, only those children who completed the 
study were included in the primary analysis. Baseline health status and demographic factors 
were compared between the probiotic and the placebo groups by the t test, or in the case of 
skewed distribution, by the non-parametric Mann-Whitney U test or by the χ2-test, when the 
proportions of the groups were being compared (I-IV). 
Th e occurrence of infections (ARI, AOM, diarrhoea), recurrent infections, complicated 
infections and the proportion of subjects on antimicrobial treatment, were dichotomised 
(at least one / at least two, etc.), and the diff erences between the intervention groups were 
analysed by the χ2-test, or by Fisher’s exact test when appropriate (I-III). A logistic regression 
analysis was used to study the association between the intervention and the outcome; the 
factors that based on previous studies were strongly associated with the outcome, and possible 
confounding factors were included as covariates. In Study I, age (as years) for the analysis of 
respiratory infections, and age, gender and the number of diarrhoea or GI infections during 
the preceding 12 months for the analysis of GI infections, were included as covariates. Th e 
corresponding factors in Study II were: age (<3; ≥3 years), gender, form of day care (home 
care/small group; large group/day-care centre), and the number of AOM episodes during the 
preceding 6 months, and in Study III, the number of chronic diseases, type of care, Barthel-
index and chronic respiratory diseases (analysis of respiratory infections), and the number 
of chronic diseases and type of care (analysis of GI infections). All the results of the logistic 
regression models are presented as odds ratios (OR) with 95% confi dence intervals (95% CI). 
Th e number and duration of infection episodes and the days with respiratory symptoms 
were skewed to the right, and diff erences between the intervention groups were tested by the 
Mann Whitney U test (I-III). Th e results are presented as medians with inter-quartile range 
(IQR), except for the number of ARI episodes, which was almost normally distributed, and 
are presented as means (SD). In Study I, the days of absence from day-care centre were skewed 
to the right and were logarithmically transformed before analysis, and the geometric mean 
was tested using the t test. To control for the confounding factor (age), analysis of covariance 
(ANCOVA) was carried out, and age was included as a continuous covariate.  
Th e Kaplan-Meier method was used to estimate the time free of the fi rst infection episode 
(ARI, AOM, diarrhoea) (I-III), and the Log rank test was used to compare the groups. In these 
analyses all the randomised subjects were included, and the missing values due to premature 
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withdrawal were treated as censored observations. Cox’s regression analyses were performed 
to adjust for other explanatory factors. For respiratory infection-free time these were: age (I); 
age, gender and AOM episodes during the preceding 6 months (II); chronic diseases and 
antibiotic treatments during the preceding 12 months (III); for AOM-free time: age, gender, 
AOM episodes during the preceding 12 months (I); age, gender, AOM episodes during the 
preceding 6 months (II); and for diarrhoea-free time: age (I); type of care (III). Results are 
presented as Hazard ratios (HR) with 95% confi dence intervals (95% CI). 
Th e association between the intervention and the frequency of nasopharyngeal viruses and 
bacterial carriage, as well as the proportion of subjects positive to anti-pneumococcal IgA, 
were analysed by logistic regression analysis (II). Age, gender, form of day care, the number 
of AOM during the preceding 6 months, and the corresponding baseline pathogen carriage or 
IgA were included as covariates. Th e levels of IgA antibody concentrations were analysed by the 
repeated measures of variance (ANOVA), in which the baseline concentration was included as a 
covariate. Th e IgA distributions were skewed to the right and were logarithmically transformed 
before the analysis; the concentrations are presented as geometric means. Th e results are given 
as ratios (Probiotic/Placebo) with 95% confi dence intervals.Th e interaction between the 
probiotic treatment, virus positivity and the occurrence of recurrent ARI, as well as between 
the probiotic treatment, bacterial positivity and the occurrence of AOM, was studied by the 
Mantel-Haenszel method. Th e homogeneity of the odds ratios for the occurrence of infections 
among pathogen-negative (all samples negative for all the pathogens) and pathogen-positive 
(at least one pathogen-positive sample during the study) subjects was tested by the Breslow-
Day test.
In Study IV, logistic regression analysis was used to study the association between the 
intervention and the proportion of subjects with high yeast counts. Th e baseline yeast count 
(positive/negative) was included as a categorical covariate. Th e other explanatory factors (e.g. 
age, gender, baseline diseases such as diabetes, the amount of medication, salivary fl ow rate and 
buff ering capacity, denture wearing, and the type of housing) were introduced to the stepwise 
multivariable regression model with an entry criterion of p<0.15. Th e results were adjusted 
with salivary buff ering capacity and denture wearing, which reached the statistical signifi cance 
level of p<0.15. Changes in the yeast counts between the baseline and the end were analysed 
by the χ2-test among those who carried low counts and high counts at baseline. Th e eff ect of 
probiotics on the salivary fl ow rate and mucosal lesions was analysed using the separate logistic 
regression analysis, including the corresponding baseline value as a categorical covariate. 
4.6 Ethics 
Th e study protocols were approved by the Ethics Committee of Helsinki City Health 
Department (Study I), the Ethics Committee of Helsinki University Central Hospital (Studies 
II and IV), and the Ethics Committee of Central Finland Health Care District (Study III). Th e 
subjects themselves (III, IV), or their parents (I, II), or near relatives (III) gave their written 
informed consent. All the data were treated confi dentially.
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5.1 Baseline characteristics (I-IV)
Th e baseline characteristics of the children participating in Studies I and II are presented in 
Table 9. No statistically signifi cant diff erences were seen in demographic characteristics or 
health status between the intervention groups within each study. However, the prognostic value 
of each baseline variable was evaluated and if, according to previous studies, the variable was 
related to the outcome, it was included as a covariate. Overall, the otitis-prone children in Study 
II were younger and had had more infectious diseases and antimicrobial treatments during the 
preceding 12 months than the basically healthy children in Study I. Of the healthy children, 
96% had experienced at least one respiratory infection, 43% at least one AOM, and 15% at least 
one bronchitis episode during the preceding 12 months. Th e corresponding fi gures in otitis-
prone children were 98% for respiratory infections, 100% for AOM, and 30% for bronchitis. 
Th e children in Study I are considered as having a slightly increased risk of infection because 
of day-care attendance, whereas the children in Study II, as having a moderately increased risk 
of infection. 
Baseline characteristics of the elderly subjects participating in Studies III and IV are presented 
in Table 10. No signifi cant diff erences were seen between the intervention groups in either 
study, with the exception of chronic respiratory diseases in the institutionalised elderly (III). By 
chance, the prevalence of chronic respiratory diseases was higher in the probiotic group. Again, 
the prognostic value of each baseline variable was evaluated, and if the variable was considered 
a possible confounding factor, it was included as a covariate. Overall, the institutionalised 
subjects were older, had lower BMI, used antimicrobials, and had mental and neurological 
diseases more oft en than the independently-living elderly subjects. Th e institutionalised elderly 
are thus considered to have moderately increased risk of infection. Cardiovascular, respiratory, 
gastrointestinal and metabolic diseases seemed to be more common among the independent 
than the institutionalised elderly. Th e independent elderly are considered to have slightly 
increased risk of infection because of age-related chronic diseases. 
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Table 9. Baseline characteristics of healthy children (I) and otitis-prone children (II).
Characteristics Study I
Healthy children: 
slightly increased 
risk of  infection
Study II
Otitis-prone children: 
moderately increased 
risk of infection
Probiotic 
(n=282)
Placebo 
(n=289)
Probiotic 
(n= 155)
Placebo 
(n=154)
Boys, % 54 48 57 58
Mean age, years (range) 4.6 (1.3-6.8) 4.4 (1.3-6.7) 2.4 (0.8-6.0) 2.4 (0.9-5.6)
     < 3 years, % 18 19 72 74
     ≥ 3 years, % 82 81 28 26
Siblings  (%) 82 77 64 72
Median duration of total breast-feeding, 
mo (range)
6.0  (0-32) 7.0 (0-30) 6.5 (0-44) 6.0 (0-26)
Parental smoking, % 32 34 37 40
Atopic diseases, %* 25 28 14 12
Food allergy, %† 9 10 6 5
History of infectious diseases‡
    Mean no of ARI (range) 2.9 (0-12) 3.2 (0-20) 6.5 (0-16) 6.8 (0-15)
    Mean no of AOM (range) 0.9 (0-12) 1.0 (0-11) 6.0 (3-16) 5.9 (3-13)
    Mean no of GI infections (range) 0.9 (0-3) 1.0 (1-10) NA NA
Median number of antimicrobial 
treatments† (range)
        0%
        1-3%
        ≥ 4%
1 (0-12)
40
50
10
1 (0-9)
37
51
11
6 (1-16)
0
7
93
6 (3-13)
0
6
94
Tympanostomy, % 26 24 28 25
Adenoidectomy, % 33 30 32 28
Regular use of probiotic products, % 26 23 47 56
Use of paciﬁ er, % 9 8 32 33
Regular use of xylitol, % 43 38 42 42
*Atopic diseases diagnosed by a doctor, including atopic eczema /asthma /allergic rhinitis /allergic eye symptoms.
†Food allergies diagnosed by a doctor, including milk allergy /cereal allergy / other food hypersensitivities  
‡ During preceding 12 months 
NA = not analysed
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Characteristics Study III
Institutionalised elderly
subjects: 
moderately increased 
risk  of infection
Study IV
Independent  elderly
subjects:
slightly increased 
risk of infection
Probiotic 
(n=135)
Placebo 
(n=130)
Probiotic 
(n= 136)
Placebo 
(n=140)
Male, % 24 27 27 21
Mean age, years (range) 83
(65-102)
83
(69-103)
79
(59-95)
79
(65-95)
Type of housing,  %
Sheltering housing unit 0 0 74 77
Old people’s home 54 55 26 23
Hospital 46 45 0 0
Median duration of residence, years 
(range) 
1.7 (0-16) 1.6 (0-16) 3.0 (1-15) 4.0 (0-15)
BMI, mean (range) 24.4
(15.0-43.7)
25.1
(16.3-37.8)
27.9
(17.9-46.6)
27.6
(18.8-41.0)
    < 20% 16 12 2 2
    20-24.9% 42 42 26 28
    25-29.9% 28 24 43 41
    ≥ 30% 10 19 30 28
Smoking (%) 
    Non-smoking 51 53 65 64
    Former smoker 9 6 32 32
    Yes 2 3 3 4
    No information available 38 38 - -
Chronic diseases, %
    Cardiovascular diseases 53 53 69 65
    Respiratory diseases* 11 1 12 17
    Gastrointestinal diseases 4 2 15 19
    Mental disorders 15 12 4 3 
    Neurological disorders 41 32 17 20
    Metabolic disorders 17 22 45 41
    Musculoskeletal diseases 26 28 38 42
Median number of diseases (range) 3 (1-8) 3 (1-7) 3 (0-10) 3 (0-9)
Median number of medications (range) 6 (0-19) 6 (0-15) 4 (0-18) 4 (0-25)
Use of prophylactic antimicrobials, % 21 14 8 4
Use of probiotic products, % NA NA 37 38
Mean Barthel index (range) 22.3 (0-90) 24.2 (0-95) NA NA
* Diﬀ erence between groups: 15 subjects (11%) in probiotic  vs. 1 subject (1%) in placebo group
NA = not analysed
Table 10. Baseline characteristics of institutionalised (III) and independent elderly subjects (IV). 
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5.2 Th e eff ect of probiotics on acute respiratory infections (ARI) 
(I-III)
5.2.1 Occurrence of ARI (including unpublished results) 
Th e occurrence of acute respiratory infections (ARI) during probiotic interventions in healthy 
children, otitis-prone children and the institutionalised elderly is presented in Table 11, and 
the corresponding adjusted odds ratios (with 95% confi dence intervals) resulting from logistic 
regression models are shown in Figure 5. No signifi cant diff erences between the probiotic and 
placebo interventions were seen in the occurrence of at least one ARI episode or recurrent ARI 
episodes in healthy children (I) or in the institutionalised elderly (III), although the odds ratios 
were constantly in favour of the probiotic group (OR less than 1) (Figure 5). 
In otitis-prone children (II), the occurrence of recurrent ARI episodes (at least 4) was 
reduced in the probiotic group (72%) compared to the control group (82%) (OR=0.56, 95% 
CI 0.31 to 0.99, p=0.046, adjusted OR=0.55, 95% CI 0.30 to 1.02, p=0.06). Th e occurrence 
of at least six episodes was also almost signifi cantly reduced (20% vs. 30%; OR=0.59, 95% 
CI 0.34 to 1.03, p= 0.06, adjusted OR=0.58, 95% CI 0.32 to 1.04, p=0.07). As a secondary 
observation, it was noted that the preventive eff ect of probiotics in reducing recurrent ARI 
episodes was more pronounced in the allergic children. In the probiotic group, 12% (4/34) 
of those with a history of allergic disease or with a current allergic disease experienced at 
least 6 ARI episodes, while the corresponding fi gure in the placebo group was 33% (14/42) 
(p=0.03).
 
Table 11. Occurrence of acute respiratory infections during interventions in Studies I-III. Only subjects 
who completed the study are included in the analysis.
Study I
Healthy children 
 
  Study II
   Otitis-prone children 
 
   Study III
    Institutionalised elderly 
     subjects
No of 
ARI 
Probiotic
n=252
% 
Placebo
n=261
% 
p* Probioticn=135
% 
Placebo
n=134
% 
p† Probiotic
n=117
% 
Placebo
n=109
% 
p‡ 
≥ 1 95 96 0.44 99 100 NA 40 39 0.92
≥ 2 85 89 0.13 97 99 0.58 10 10 0.68
Recurrent 
≥ 3 
≥ 4 56 61 0.21 72 82 0.06
3 6 0.18
Extreme 
≥ 6 22 24 0.77 20 30 0.07 NA NA NA
 Adjusted for:
     * age
     † age, gender, form of day care, number of AOM episodes during preceding 6 months 
     ‡ number of chronic diseases, type of care, Barthel index 
NA = not analysed
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Figure 5. Adjusted odds ratios (with 95% confi dence intervals) for the occurrence of at least one, 
at least two, and recurrent (≥ 4 in Studies I and II; ≥ 3 in Study III) respiratory infections in healthy 
children (I), otitis-prone children (II) and institutionalised elderly subjects (III) are shown on 
a logarithmic scale.
In otitis-prone children (II), the mean number of ARI episodes was 4.3 days in the probiotic group 
compared to 4.6 days in the placebo group (p=0.08; Table 12). In healthy children (I) on probiotic 
treatment, the number of days with fever was reduced (p=0.03, age-adjusted p=0.07) and fewer 
antimicrobials for respiratory infections were needed than in the placebo group (p=0.03, age-
adjusted OR=0.72, 95% CI 0.50 to 1.03, p=0.08). In addition, the healthy children had 16% fewer 
days of absence from day care because of illness (4.9 vs. 5.8 days, p=0.03; 11% less when age-adjusted, 
p=0.09) than the placebo group. In the elderly, the duration of respiratory infections was signifi cantly 
longer in the probiotic group (8.8 days) than in the placebo group (4.3 days) (p=0.01).  
Probiotic treatment postponed the fi rst respiratory infection in healthy children (I): the median 
infection-free time from the beginning of the study was 5 weeks (95% CI 4.1-5.9) in the probiotic 
group and 4 weeks (95% CI 3.5 to 4.6) in the placebo group (Log-rank test p=0.03; adjusted 
HR=0.86, 95% CI 0.70 to 1.06, p=0.16) (Figure 6). Probiotic treatment did not signifi cantly aff ect 
the infection-free time in otitis-prone children (II) (probiotic: 13 days vs. placebo: 11 days, Log-
rank test p=0.55), nor in the elderly (III) (107 vs. 104 days respectively, Log-rank test p=0.71).
Healthy children
Oititis-prone children
Institutionalised elderly subjects
Recurrent
At least two
At least one
Recurrent
At least two
At least one
Recurrent
At least two
At least one
0.1 0.25 0.5 1 2 3 4 5
0.1 0.25 0.5 1 2 3 4 5
0.1 0.25 0.5 1 2 3 4 5
Odds ratio
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Table 12. Number and duration of acute respiratory infections (ARI), number of days with respiratory 
symptoms, and proportion of subjects with at least one antimicrobial treatment during interventions 
in Studies I-III. Only subjects who completed the study are included in the analysis.
Study I
Healthy children 
Study II
Otitis-prone children 
Study III
Institutionalised elderly subjects
Probiotic
n=252
Placebo
n=261
p Probiotic
n=135
Placebo
n=134
p Probiotic
n=117
Placebo
n=109
p 
ARI episodes
Number, mean (SD)/ 
median* (IQR)       3.8(2.1)
4.0
(2.0)
0.24 4.3
(1.4)
4.6
(1.4)
0.08 0*
(0, 1) 
0*
(0, 1) 
0.85
Duration,  
median (IQR) 
6.6
(4.0, 9.5)
6.8
(4.6, 10.0)
0.41 12.3
(8.4, 18.8)
11.6
(8.0, 15.9)
0.33 8.8
(2.0, 12.0)
4.3
(1.5, 6.6)
0.01
Respiratory 
symptoms
Days with symptoms,
median (IQR)
23
(11, 43)
25
(13, 45)
0.24 51
(33, 74)
49
(34, 72)
0.96
 
0
(0, 7.5)
0
(0, 4.0)
0.76
Days with  fever, 
median (IQR)
2.0
(0, 5.0)
3.0
(1.0, 6.0)
0.03 4.0
(2.0, 7.0)
3.0
(1.0, 6.0)
0.18 NA NA NA
Antimicrobial 
courses
Subjects with 
≥ 1 course,  % 
44 54 0.03 77 69 0.16 15 14 0.66 
Number of courses,  
median (IQR)
0
(0, 1)
1
(0, 2)
0.03 1
(1, 3)
1
(0, 2)
0.28 NA NA
NA = not analysed
   
0 1 2 3 4 5 6 7
Study I
1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 3 4 5
Months
Probiotic
Placebo
Study III
Pr
op
or
tio
n 
of
 su
bj
ec
ts
 w
ith
 A
RI
0 1 2 3 4 5 6
Study II
Figure 6. Cumulative incidence of the fi rst ARI episode during the 7-month intervention with healthy 
children (I), during the 6-month intervention with otitis-prone children (II), and during the 5-month 
intervention with the institutionalised elderly (III).
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5.2.2 Prevalence of rhinovirus and enterovirus (II, unpublished results)
Th e prevalences of rhino- and enterovirus-positive children are presented in Table 13. 
Rhinovirus positivity decreased in both intervention groups from the baseline to 3 months, and 
increased again from 3 to 6 months. Th e prevalence of enterovirus positivity at the baseline in 
the probiotic group was by chance more than double that of the placebo group. Th e prevalence 
decreased in the probiotic group from the baseline to 3 and 6 months, and in the placebo group 
from the baseline to 6 months. No signifi cant diff erences between the groups were seen in virus 
positivity during the study.
Table 13. Prevalence of rhinovirus and enterovirus positivity in the nasopharynx of otitis-prone 
children during the 6-month intervention. Only children with all measurements (0, 3 and 6 months) 
are included in the analysis.
Probiotic
n=94–96
%
Placebo
n=126
%
Probiotic vs. Placebo
OR*         95 % CI                     p-value
Rhinovirus
       Baseline
       3 months
       6 months 
20
3
16
29
8
18
0.27  0.05 to 1.37                    0.11
0.93  0.43 to 2.01                   0.86
Enterovirus
       Baseline
       3 months
       6 months
55
34
26
22
22
11
1.70   0.85 to 3.38                 0.13
2.09   0.91 to 4.78                 0.08
 * Adjusted for age, gender, form of day care, number of AOM during preceding 6 months, and virus positivity at baseline. 
5.2.3 Interaction of virus positivity and probiotic treatment on 
the occurrence of ARI (II, unpublished results)
In order to examine whether the eff ect of probiotic treatment on the occurrence of ARI was 
diff erent among children who were virus positive or virus negative, the interaction between 
virus positivity/negativity and the probiotic treatment was tested by the Mantel-Haenszel 
method. No interaction was observed when it was a question of 1-3 respiratory infections 
(data not shown). However, probiotic treatment reduced the recurrence of ARI episodes 
(≥ 4 ARI episodes) more if the children were negative to both rhinovirus and enterovirus 
(44% in the probiotic vs. 85% in the placebo group) than if they were positive (78% vs. 83%) 
(p=0.02, Table 14). Correspondingly, a signifi cant interaction (p=0.04) was observed in 
the number of ARI episodes. Probiotic treatment reduced the mean number of ARI 
episodes more among the virus-negative children (3.5 vs. 4.6) than among the virus-positive 
(4.5 vs. 4.7). 
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Table 14. Interaction between virus positivity/virus negativity,  probiotic treatment and
the occurrence of acute respiratory infections in otitis-prone children (II).
Virus-negative1 Virus-positive1 Interaction
(virus x treatment)
Probiotic Placebo Probiotic Placebo p-value
Rhino-negative Rhino-positive
n=63 n=71 n=33 n=55
≥ 4 ARI (%) 68 83 79 84 0.47
Entero-negative Entero-positive
n=24 n=72 n=72 n=54
≥ 4 ARI (%) 58 82 76 85 0.39
Rhino and Entero-negative Rhino or Entero-positive
n=18 n=40 n=78 n=86
≥ 4 ARI (%) 44 85 78 83 0.02
1 negative if all the measurements (0, 3, 6 months) negative;
  positive if at least one positive measurement
5.2.4 ARI with complications (I-III)
Th e occurrences of ARI episodes with complications are shown in Table 15, and the 
corresponding adjusted odds ratios for the occurrences are presented in Figure 7. In healthy 
children (I), probiotics reduced the occurrence of at least one episode of complication: of 
bronchitis, pneumonia, sinusitis or otitis media combined (probiotic: 39% vs. placebo: 47%, 
p=0.05; adjusted OR=0.75, 95% CI 0.52 to 1.09, p=0.13). No signifi cant diff erences in the 
occurrence of bronchitis, pneumonia or sinusitis separately were seen in either study (I-III). 
Table 15. Occurrence of ARI with complications other than AOM during interventions in Studies I-III. 
Only subjects who completed the study are included in the analysis.
     Study I
      Healthy children 
     Study II
  Otitis-prone children 
   Study III
 Institutionalised elderly 
   subjects
Probiotic
n=252
% 
Placebo
n=261
% 
p* Probioticn=135
% 
Placebo
n=134
% 
p† Probiotic
n=117
% 
Placebo
n=109
% 
p‡ 
Bronchitis 5.6 7.3 0.54 3.0 3.7 0.55 5.1 5.5 0.31
Pneumonia 1.2 1.5 0.81 0.7 1.5 0.94 6.0 7.3 0.40
Sinusitis 3.2 3.8 0.75 0.7 0.7 0.96 0.0 0.9 NA
≥1 complication 9.5 11.5 0.50 4.4 6.0 0.70 9.4 11.0 0.41
Adjusted for
     *age
     † age, gender, form of day care, number of AOM episodes during preceding 6 months
     ‡ number of chronic diseases, type of care, Barthel index 
NA = not analysed
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Figure 7. Adjusted odds ratios (with 95% confi dence intervals) for the occurrence of acute respiratory 
infections with complications other than AOM, in healthy children (I), otitis-prone children (II), 
and in institutionalised elderly subjects (III) are shown on a logarithmic scale
5.3 Th e eff ect of probiotics on acute otitis media (AOM) (I-II)
5.3.1 Occurrence of AOM episodes (I-II)
In healthy children (I), at least one AOM episode occurred in 31% of the probiotic group and 
in 39% of the placebo group, corresponding to a relative reduction of 21% in the prevalence 
(p=0.08). When age-adjusted, the relative reduction was 22% (OR=0.78, 95% CI 0.53 to 1.14, 
p=0.19, Table 16). Probiotic treatment postponed the fi rst AOM episode by an average of 12 
days: the mean infection-free time was 171 days (95% CI 163 to 179) in the probiotic group 
compared to 159 days (95% CI 150 to 167) in the placebo group (Log-rank test p=0.04, adjusted 
HR=0.78, 95% CI 0.59 to 1.05, p=0.09) (Figure 8). 
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In the otitis-prone children (II), probiotics did not aff ect the occurrence or recurrence of AOM 
episodes in the group as a whole (Table 16). However, in the allergic children (those with a 
history of allergic diseases or a current allergic disease), probiotics reduced the occurrence of 
recurrent AOM episodes: none of the allergic children in the probiotic group vs. 14% (6/42) of 
those in the placebo group experienced recurrent AOM episodes (p=0.03). Probiotic treatment 
did not postpone the fi rst otitis episode (85 vs. 99 days; Log-rank test p=0.23) (Figure 8). No 
diff erences were seen in the need for tympanostomy: 8.5% in the probiotic group and 8.8% in 
the control group needed tympanostomy during the study. 
Table 16. Occurrence and duration of AOM episodes in Studies I-II. Only children who completed 
the study are included in the analysis.
    Study I
   Healthy children 
 
      Study II
    Otitis-prone children 
Probiotic
n=252
Placebo
n=261
p Probiotic
n=135
Placebo
n=134
p
≥ 1 AOM (%)
≥ 3 AOM  (%)
31
4.4
39
6.9
0.19*
0.31*
72
18
65
17
0.15†
0.91†
Number of episode,
Median (IQR) 
0
(0, 1.0)
0
(0, 1.0)
0.10 1.0
(0, 2.0)
1.0
(0, 2.0)
0.39
Duration of episodes, days 
Median (IQR) 
NA NA 5.6
(3.5, 9.4)
6.0
(4.0, 10.5)
0.29
≥ 1 one antimicrobial 
course for AOM (%)
30 36 0.13 69 60 0.15
Adjusted for
     * age 
     † age, gender, form of day care, number of AOM episodes during preceding 6 months 
NA = not analysed
Figure 8.  Cumulative incidence of the fi rst AOM episode during the 7-month intervention with 
healthy children (I), and during the 6-month intervention with otitis-prone children (II).  
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5.3.2 Carriage of otitis pathogens (II)
Probiotic treatment did not have any significant effect on the carriage of Streptococcus 
pneumoniae or Haemophilus influenzae compared to the placebo (Table 17). During the 
study, the prevalence of S. pneumoniae increased slightly in both intervention groups, and 
the prevalence of H. influenzae decreased slightly in both groups. However, at 6 months, 
the prevalence of Moraxella catarrhalis was signifcantly higher in the probiotic group. 
Probiotic treatment increased the prevalence of M. catarrhalis, particularly in children 
under 3 years of age (OR= 2.44, 95% CI 1.34 to 4.44, p=0.004). However, in children of 
over 3 years, the odds ratio was in favour of the probiotic group (OR=0.54, 95% CI 0.16 to 
1.82, p=0.32). The overall carriage of at least one potential otitis pathogen (S. pneumoniae 
or H. influenzae or M. catarrhalis) was 76% in the probiotic group at baseline and 75% 
at the end, and 68% in the placebo group both at baseline and at the end. At the end of 
the treatment, the difference between the groups was  non-signifcant (adjusted OR=1.42, 
95% CI 0.80 to 2.53, p=0.23).
Table 17. Prevalence of potential otitis pathogens in the nasopharynx of otitis-prone children, 
at baseline and at the end of the 6-month intervention. Only children with both measurements 
(0 and 6 months) are included in the analysis.
  Baseline 6 months Probiotic vs. Placebo
Probiotic
n=128
%
Placebo
n=126
%
Probiotic
n=128
%
Placebo
n=126
%
  OR*  
       
         
            95% CI p-value
S. pneumoniae 41 39 47 47  1.02  0.61 to 1.70 0.94
H. infl uenzae 27 26 23 17  1.43 0.76 to 2.70 0.27
M. catarrhalis 43 40 52 39  1.79  
    
1.06 to 3.00 0.03
* Adjusted for age, gender, form of day-care, and pathogen carriage at baseline. 
5.3.3 Interaction of pathogen carriage and probiotic treatment on 
the occurrence of AOM  (II, unpublished results)
In order to examine whether the eff ect of probiotic treatment on the occurrence of AOM 
was associated with bacterial pathogen carriage, the interaction between bacterial pathogen 
positivity/negativity and probiotic treatment was tested by the Mantel-Haenszel method. Th e 
probiotic treatment reduced the occurrence of AOM among pathogen-negative children (63% 
in the probiotic group vs. 83% in the placebo group), but increased the occurrence among the 
pathogen-positive (74% vs. 62%) (p=0.05, Table 18). No interaction was observed in recurrent 
AOMs. 
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Table. 18. Interaction between bacterial pathogen positivity/pathogen negativity, probiotic treatment 
and the occurrence of acute otitis media in otitis-prone children (II).
Pathogen-negative1 Pathogen-positive1 Interaction
(pathogen x treatment)
Probiotic Placebo Probiotic Placebo p-value
S. pneumoniae-
negative
S. pneumoniae –
positive
n=50 n=49 n=84 n=84
≥ 1 AOM (%) 72 78 73 57 0.08
≥ 3 AOM (%) 18 20 18 14 0.53
H. infl uenzae-
negative
H. infl uenzae-
positive
n=81 n=85 n=53 n=48
≥ 1 AOM (%) 69 68 77 58 0.12
≥ 3 AOM (%) 17 21 19 8 0.10
M. catarrhalis-
negative
M. catarrhalis-
positive
n=38 n=59 n=96 n=74
≥ 1 AOM (%) 71 68 73 62 0.54
≥ 3 AOM (%) 24 20 16 14 0.97
Pathogen-
negative1
Pathogen-
positive1
n=16 n=18 n=118 n=115
≥ 1 AOM (%) 63 83 74 62 0.05
≥ 3 AOM (%) 25 33 17 14 0.45
1negative, if all potential pathogens negative at 0 and 6 months; 
  positive, if at least one positive pathogen at 0 or 6 months.
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5.3.4 Pneumococci-specifi c antibodies  (II, unpublished results)
Th e most prevalent pneumococcal serotypes found among a whole group of otitis-prone children 
during the study were serotypes 19F (ranging from 13-18% of the positive samples), 15 (10-15%), 
23F (10-13%), 6A (9-12%) and 6B (7-13%). No signifi cant changes between the probiotic and 
placebo groups were seen in the total prevalence of serotypes 19F, 15, 23 F, 6A and 6B: these 
serotypes accounted for 59% of the positive samples in the probiotic group at baseline and 60% 
at the end. Th e corresponding fi gures for the placebo group were 64% and 54%. 
According to the logistic regression analysis, the proportion of subjects with IgA-positive 
samples to pneumococcal serotype 6B tended to increase in the probiotic (62%) compared to 
the placebo group (51%) in the middle of the study (p=0.08). Th e proportion of IgA-positive 
samples to serotype 19F or to protein antigens PspA1 and PhtD did not diff er signifi cantly 
between the groups (Table 19). 
Table 19. Proportions of samples with detectable salivary IgA antibodies to pneumococcal polysaccharide 
(6B and 19F) and protein (PspA-1 and PhtD) antigens in otitis-prone children, at baseline, in the middle 
(3 months) and at the end (6 months) of the intervention. Only children with all the three measurements 
are included in the analysis. 
Probiotic
n=105-119
%
Placebo
n=106-115
%
Probiotic vs. Placebo
   OR*                        95 % CI                p-value            
6B          Baseline 58 54
6B          3 months 62 51 1.73 0.93 to 3.20 0.08
6B          6 months 63 57 1.26 0.70 to 2.28 0.44
19F         Baseline 65 63
19F         3 months 63 61 0.99 0.52 to 1.86 0.96
19F         6 months 65 64 1.00 0.55 to 1.80 0.99
PspA-1   Baseline 64 68
PspA-1   3 months 70 67 1.46 0.71 to 3.01 0.31
PspA-1   6 months 74 70 1.36 0.72 to 2.57 0.34
PhtD       Baseline 74 65
PhtD       3 months 86 77 1.50 0.65 to 3.47 0.34
PhtD       6 months 91 85 1.37 0.55 to 3.44 0.50
* Corresponding baseline value included as a covariate.
In addition, the level of the anti-6B-IgA concentration aft er 3 months was 1.3 times higher in 
the probiotic group (5.4 ng/mL) than in the placebo group (4.3 ng/ml) (p=0.04). When the 
anti-6B-IgA concentrations at 3 months and 6 months were combined by repeated measures 
of ANOVA and the baseline concentration was included as a covariate, the corresponding ratio 
probiotic/placebo was 1.25 (95% CI 1.00 to 1.58, p=0.06). No signifi cant diff erences in the 
levels of anti-19F-IgA, anti-PspA1-IgA, and anti-PhtD-IgA concentrations were seen between 
the groups. 
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5.4 Th e eff ect of probiotics on diarrhoea and gastrointestinal 
infections (I, III) 
Probiotic treatment did not reduce the occurrence of diarrhoea or GI infections (including 
diarrhoea and/or vomiting) either in healthy children (I) or in the institutionalised elderly (III) 
(Table 20). Th e adjusted odds ratios (with 95% confi dence intervals) resulting from logistic 
regression models for the occurrence of diarrhoea and GI infections are shown in Figure 9. In 
the elderly (III), the duration of diarrhoea seemed to be 3.7 days shorter in the probiotic group, 
but the diff erence did not reach statistical signifi cance. 
Table 20. Occurrence and duration of diarrhoea and gastrointestinal infection episodes during 
probiotic treatments in Studies I and III. Only subjects who completed the study are included 
in the analysis.
Study I
Healthy children
Study III
Institutionalised elderly subjects
Probiotic
n=252
Placebo
n=261
p Probiotic
n=117
Placebo
n=109
p
Diarrhoea
≥ 1 episode (%) 33 38 0.25* 19 19 0.80†
Duration, median (IQR) 2.0
(1.0,  3.7)
2.0
(1.0,  3.0)
0.59 5.0
(1.0, 14.8)
8.7
(1.0,  16.9)
0.72
Gastrointestinal infection
≥ 1 episode (%) 69 67 0.75* 37 38 0.68†
Duration, median (IQR) 1.2
(1.0,  2.6)
1.5
(1.0,  2.5)
0.57 1.5
(1.0, 7.3)
1.8
(1.0,  10.5)
0.57
Adjusted for
     *age, gender, number of diarrhoea or GI infections during preceding 12 months
     † number of chronic diseases, type of care 
Figure 9. Adjusted odds ratios (with 95% confi dence intervals) for the occurrence of 
diarrhoea and gastrointestinal infections in healthy children (I), and in the institutionalised elderly 
(III) are shown on a logarithmic scale.  
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Probiotic treatment did not postpone the fi rst episode of diarrhoea (Figure 10). Th e mean 
diarrhoea-free time in children (I) was 168 days in the probiotic and 162 days in the placebo 
group (Log-rank test p= 0.18). Th e corresponding fi gures for the elderly (III), were 122 vs.119 
days (Log-rank test p=0.57).
Figure 10. Cumulative incidence of the fi rst diarrhoea episode during the 7-month intervention with 
healthy children (I) and during the 5-month intervention with the institutionalised elderly (III). 
5.5 Th e eff ect of probiotics on oral yeast (IV) 
5.5.1 Prevalence of high Candida carriage
At baseline, a total of 74% of all the randomised subjects (n=276) carried yeast; 41% carried low 
counts (< 104 cfu/mL), and 33% high counts (≥ 104 cfu/mL). Salivary secretion, low buff ering 
capacity and denture wearing were associated with the baseline yeast count. Th e prevalence of 
a high yeast count was 49%, 38%, 25% and 16% in the quartiles of salivary secretion, from the 
lowest to the highest secretion (p<0.001). Th e prevalence of high yeast counts was 24%, 35% 
and 51%, when the buff ering capacity was high, medium and low respectively (p=0.003), and 
36% and 25% respectively in subjects with and without dentures (p=0.09). Th us, the results were 
adjusted for salivary secretion, buff ering capacity and denture wearing. It was also noted that 
those who had regularly used lactic acid bacteria-containing products before the intervention 
carried high yeast counts less oft en than those who had not (25% vs. 38%; p = 0.03). 
Th e prevalence of high yeast counts (≥ 104 cfu/mL) in the probiotic group at baseline was 
30%, and 28% in the control group. Aft er 2 and 4 months of the intervention, the prevalence 
of high yeast counts in the probiotic group had diminished  to 25% and 21% respectively. 
In the placebo group the prevalence increased to 31% and 34% respectively. At the end 
of the intervention, the risk of having high yeast counts was reduced by 61% in the 
probiotic group compared to the placebo group (OR=0.39, 95% CI 0.18 to 0.83, p=0.01), 
and by 75% when adjusted for other explanatory factors (adjusted OR=0.25, 95% CI 0.10 
to 0.65, p=0.004). 
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The changes occurring between the low and high yeast carriage during the 4-month 
intervention are shown in Figure 11. Among subjects belonging to the low yeast group 
(< 104 cfu/mL) at baseline, yeast counts increased in 9% of the probiotic group and in 19% 
of the placebo group, thus the risk of yeast increase tended to be reduced in the probiotic 
group (OR=0.43, 95% CI 0.15 to 1.19, p=0.10). Among those subjects who carried high 
yeast counts (≥ 104 cfu/mL) at baseline, the counts were reduced in 54% of the probiotic 
group compared to 29% of the placebo group. The risk of belonging to a high yeast group 
at the end was reduced by 65% in the probiotic group (OR=0.35, 95%CI 0.12 to 1.05, 
p=0.06). 
Figure 11. Changes (between baseline and the end of the intervention) in yeast carriage among those 
with low (< 104 cfu/mL, total n=184) and high (≥ 104 cfu/mL, total n=92) yeast counts at baseline. 
An increase indicates a change from low counts to high counts, and a decrease indicates a change 
from high counts to low counts.
Probiotic treatment did not aff ect the distribution of the diff erent yeast species; Candida 
albicans was the most dominating species, found in 94% of the positive subjects at the beginning 
of the study and in 90% at the end. In the control group, two subjects carried C. glabrata at 
the beginning, and seven at the end. In the probiotic group, C. glabrata was found in two 
subjects at the end. Saccharomyces cerevisiae was found in two subjects in the control group and 
C. tropicalis in only one subject in the probiotic group.  
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5.5.2 Salivary secretion and oral mucosal lesions 
Th e prevalence of hyposalivation decreased in the probiotic group and increased in the control group 
(Table 21). Probiotic treatment reduced the risk of hyposalivation by 56%, and tended to reduce the 
subjective feeling of dry mouth and high buff ering capacity. Oral mucosal lesions were clinically 
diagnosed as erythroplakia, leukoplakia, hyperplasia, ulceration and pigmentation. No signifi cant 
diff erences between the groups were seen in mucosal lesions or the subjective feeling of oral pain.  
Table 21. Eff ect of probiotics on hyposalivation, dry mouth, buff ering capacity, mucosal  lesions and 
oral pain aft er a 4-month intervention. Only subjects with both measurements (baseline and 4 months) 
are included in the analysis.
Variable
Probiotic 
n=85–92
%
Placebo 
n=88-100
%
Probiotic vs. Placebo
           OR*                      95 % CI             p-value 
Hyposalivation
Baseline
4 mo
24
18
19
27
0.44 0.19 to 1.01 0.05
Dry mouth
Baseline
4 mo
52
53
62
69
0.54 0.27 to 1.06  0.07
High buff ering capacity
Baseline
4 mo
65
62
59
71
0.51 0.24 to 1.09 0.08
Mucosal lesions
Baseline
4 mo
25
26
24
27
0.35 0.04 to 3.44 0.37
Oral pain
Baseline
4 mo
11
12
15
20
0.58 0.25 to 1.34 0.20
* Corresponding baseline value included as a categorical covariate. 
5.6 Compliance (I-IV)
 
Compliance, according to the consumption of milk, cheese or capsules, was good in all the 
studies. Th e average milk consumption by the healthy children (I) was 260 ml/day, the aim 
having been 200 ml/day. Mean compliance was 60% in both groups. Compliance was also 
measured by the faecal recovery of Lactobacillus GG. At the beginning, 12% of the children in 
the probiotic group and 4% in the placebo group carried Lactobacillus GG-like bacteria (p=0.29). 
Aft er four months and at the end of the study the respective percentages were 97% and 9% 
(p<0.0001), and 91% and 15% (p<0.0001). Th e median Lactobacillus GG count in the probiotic 
group was 5-8 x 104 cfu/ml (range 0-1x107).
In the independent elderly (IV), 61% of the subjects in both intervention groups showed cheese-eating 
compliance of at least 80%, while the median cheese-eating compliance was 93%. Th e mean compliance 
of eating capsules among the otitis-prone childen (II) was 96% in both intervention groups; in the 
institutionalised elderly (III), it was 98% in the probiotic and 99% in the placebo group. 
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5.7 Summary of results (I-IV) 
Table 22 summarises the main results of the eff ect of probiotics on acute respiratory 
infections, acute otitis-media, diarrhoea and oral Candida. 
Table 22. Summary of the main results in Studies I-IV. 
Study I
Healthy 
children
Study II
Otitis-prone 
children
Study III
Institutionalised 
elderly subjects
Study IV
Independent
elderly subjects
Acute respiratory  infections ΝΑ
Occurrence/
Recurrence
↔ (↓)
in atopics ↓
↔
Duration ↔ ↔ ↑ 
Symptoms (↓) ↔ ΝΑ
Day of absence (↓) ΝΑ ΝΑ
Infection-free time (↓) ↔ ↔
Complications (↓) ↔ ↔
Virus positivity ΝΑ ↔ ΝΑ
Antimicrobials (↓) ↔ ↔
Acute otitis media ΝΑ ΝΑ
Occurrence /
Recurrence
↔ ↔
in atopics ↓
Duration ΝΑ ↔
Infection-free time (↓) ↔
Pathogen carriage ΝΑ ↑
Diarrhoea ΝΑ ΝΑ
Occurrence ↔ ↔
Duration ↔ ↔
Infection-free time ↔ ↔
Oral Candida ΝΑ ΝΑ ΝΑ
High carriage ↓
Mucosal lesions ↔
Hyposalivation ↓
↑ = Increased risk  (adjusted p < 0.05) 
↓ = Decreased risk (adjusted p < 0.05)
(↓ ) = Marginally decreased risk (crude p < 0.05; adjusted 0.05 < p < 0.20) 
↔ = No evidence of eﬀ ect
NA = not analysed
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6   DISCUSSION
Th is series of studies comprised four independent clinical trials performed as randomised, 
double-blind, placebo-controlled interventions with two parallel groups. Th e study designs 
thus fullfi lled the quality criteria for clinical trials. Th e total number of subjects included in the 
studies was 1421, and 1200 subjects completed them. On the basis of sample size estimations, 
the sample sizes in Studies I, III and IV, even aft er the drop-outs, were suffi  cient for the 
expected diff erencies between the groups in the primary outcomes to be detected. However, 
in Study II, 380 children completing the study would have been needed in order to show the 
statistically signifi cant diff erence between the groups. Unfortunately, possibly due to very strict 
inclusion criteria, we were able to recruit only 309 children, of whom 269 completed the study. 
Th us, the results approaching statistical signifi cance (p ≤ 0.05) in Study II should be evaluated 
by taking into account the insuffi  cient sample size. 
6.1 Prevention of respiratory infections and acute otitis media 
Th e hypothesis that probiotics might reduce the risk of respiratory infections was partly 
confi rmed among children, but no eff ect was seen in the institutionalised elderly. It was seen in 
healthy children (I), that although probiotics did not reduce the total occurrence of respiratory 
infections, they postponed the fi rst ARI episode by one week, and reduced the number of days 
with fever and the rate of complicated infections. Th is led secondarily to reduced child-care 
absences and less need for antibiotic treatment, suggesting that probiotics might reduce the 
severity of respiratory infections. However, these eff ects were weakened when the results were 
age-adjusted. Our fi ndings accord with a previous study showing that the 12-week consumption 
of an infant formula containing either Lactobacillus reuteri or Bifi dobacterium lactis BB-12 did 
not reduce the rate of respiratory illnesses but reduced febrile episodes, child-care absences 
and antibiotic prescriptions in 4-10-month-old infants (Weizman et al., 2005). Th e same eff ects 
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have also been observed in basically healthy adults: a combination of Lactobacillus gasseri with 
Bifi dobacterium longum and B. bifi dum given in capsule form reduced the number of days with 
fever and the total symptom score (Winkler et al., 2005), as well as the duration of infections 
(de Vrese et al., 2005b), although the incidence of ARI was not reduced during an intervention 
lasting 3-5.5 months. 
Otitis-prone children (II) suff ered an average of 4-5 respiratory infections during the 6-month 
study. Due to their greater susceptibility to infections (almost all the children suff ered at least 
two ARI episodes and nearly 80%, at least 3 episodes) probiotics could not reduce the overall 
occurrence of ARI. However, when there were extremely recurrent infections (at least 4 or 6), 
probiotics tended to reduce recurrences, suggesting again that they might reduce the severity of 
infections. In addition, it was noted that the protective eff ect was more pronounced in children 
with a history of allergic diseases. Th is observation is extremely interesting, since Lactobacillus GG 
has also prevented early atopic diseases (Kalliomäki et al., 2001), and alleviated atopic eczema in 
IgE-sensitised infants (Viljanen et al., 2005c), through the augmentation of the Th 1 cytokine, IFN-
γ, secretion in peripheral blood mononuclear cells (Pohjavuori et al., 2004). However, a probiotic 
combination, the same as that used with otitis-prone children (II), has not been eff ective in 
alleviating present atopic diseases (Viljanen et al., 2005c), probably because of a slightly diff erent 
cytokine profi le; the combination induced the production of IL-4 along with IFN-γ, which may 
have deviated immunity towards a Th 2 response (Pohjavuori et al., 2004). However, the same 
combination has prevented the development of atopic eczema when the supplementation was 
started before the birth (Kukkonen et al., 2007), suggesting that the eff ect of probiotics depends 
on the immunological status of the subject. It is also known that oral treatment with probiotic 
LGG modulates the immune response diff erently in healthy subjects than in hypersensitive 
ones (Pelto et al., 1998). It can thus be hypothesised that the probiotic treatment prevented 
recurrent respiratory infections in the children whose immune system was skewed towards a 
Th 2 response. Th is assumption is supported by a previous study in which a combination of LGG 
and Bifi dobacterium lactis BB-12 reduced the incidence of recurrent respiratory infections during 
the fi rst 7 months of age when probiotics were given to infants from the age of one month, at a 
time when the neonatal Th 2 reponse still dominates (Rautava, 2005). 
In healthy children (I), probiotics also reduced the total occurrence of complicated infections, the 
majority of these being otitis media. However, no benefi cial eff ects on the occurrence of individual 
complications such as bronchitis, pneumonia and sinusitis were seen in either study (I-III). Th is is 
understandable, since the prevalence of complications was low (0-7.3% depending on the study). 
In healthy children (I), probiotics also showed a tendency to reduce the occurrence of otitis 
media and prolonged the otitis-free time. As viral respiratory infections usually precede bacterial 
otitis and otitis can be of viral origin (Kleemola et al., 2006; Ruohola et al., 2006), presumably 
the reduced occurrence of AOM was a secondary consequence of the reduced severity of ARI. 
However, although probiotics tended to reduce recurrent ARIs in otitis-prone children (II), the 
eff ect was insuffi  cient to prevent the development of AOM in children with a history of recurrent 
AOMs and a high carriage of bacterial pathogens. Th e duration of respiratory symptoms has been 
shown to increase among children carrying bacterial pathogens (Kristo et al., 2006), suggesting 
that infections might be more severe in children carrying pathogenic bacteria. To be eff ective 
against the development of AOM, probiotics should have reduced the nasopharyngeal carriage 
of bacteria, which was not the case in the present study. 
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However, in contrast to the results obtained in children, probiotics showed no benefi cial eff ect 
on respiratory infections in the institutionalised elderly, and the duration of ARI episodes 
actually increased in the probiotic group. Th is fi nding is also the opposite of that of a previous 
study which showed that probiotic L. casei reduced the duration of winter infections by 1.7 
days in free-living elderly subjects (Turchet et al., 2003). One major diff erence between Study 
III and the study by Turchet and colleagues (2003) is the health status of the subjects. Th e 
institutionalised elderly (III) were very frail, suff ered an average of three chronic diseases, 
and regularly used an average of six medications. Compared to the independent elderly, the 
institutionalised elderly are more susceptible to infections because of multiple co-morbid 
underlying diseases, the use of several medications, and diff erent invasive procedures such as 
catheters, feeding tubes or tracheostomies (Garibaldi, 1999). Probiotics thus seem ineff ective in 
subjects with high vulnerability to infection. In addition, irrespective of the random allocation 
to the treatment groups, the prevalence of chronic respiratory diseases, mainly asthmatic 
disorders, was more common in the probiotic group. Th is uneven distribution may have 
increased the susceptibility of the probiotic group to infections. When subjects with chronic 
respiratory diseases were excluded from the analyses, the occurrence of ARI in the probiotic 
group was slightly reduced, but the duration of ARI was not aff ected. Th us the reason for the 
extended duration of ARI remains unclear. 
6.1.1 Methodological considerations
Th e diagnoses of ARI in Studies I-III were based on the subjective evaluation of infection 
symptoms, and thus the method cannot be independently validated. Measuring can be diffi  cult 
when a carer evaluates a child’s symptoms or nurses evaluate symptoms of the elderly, who 
may be unable to communicate their own symptoms or whose symptoms may be atypical, 
diminished or even absent (Garibaldi, 1999). It is thus possible that the prevalence of infections 
among the elderly may have been underestimated. In children, on the other hand, the symptoms 
of allergic rhinitis can sometimes mimic the common cold, leading to an overestimation of the 
respiratory symptoms. However, the prevalences of respiratory infections in Studies I-III seem 
to give a fair representation of the average disease prevalence in children and the elderly, on 
the basis of  population-based cross-sectional studies (Pönkä et al., 1991; Nafstad et al., 1999; 
Engelhart et al., 2005). 
Defi ning the exact duration of an infection episode is also vague, because there is no valid defi nition 
of an episode. Th ree asymptomatic days between two separate ARI episodes is quite commonly 
used as a defi nition in intervention trials (Uhari and Möttönen, 1999), although in cohort studies 
even 30 asymptomatic days have been used (Nokso-Koivisto et al., 2002b). We defi ned an ARI 
episode as lasting as long as the subjects had respiratory symptoms, and 7 asymptomatic days 
were needed to separate two episodes. Th e duration of an AOM episode was also defi ned on the 
basis of the presence of respiratory symptoms aft er AOM diagnosis, and one asymptomatic day 
separated two episodes. Th e diagnostic accuracy of otitis media among paediatric residents has 
shown only moderate correlation to the diagnoses of otolaryngologists (Steinbach et al., 2002; 
Blomgren et al., 2004), suggesting that the incidence of otitis media is frequently overdiagnosed. 
Because AOM diagnoses among healthy children (I) were made by both municipal and private 
doctors, again, overdiagnosing, which is common among general physicians, is possible. However, 
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even though there may have been misdiagnoses, it can be assumed that these occurred equally in 
both intervention groups. Among the otitis-prone children (II), the diagnosis was made mainly 
by one study physician, which increases the reliability of the diagnosis. 
6.1.2 Eff ect on respiratory viruses
Th e primary end-points in the clinical trials were the occurrences of infections. An attempt was 
also made to hypothesise on the possible mechanisms of probiotics by examining their eff ects 
on the prevalence of two common respiratory viruses. Th ese eff ects were evaluated only in the 
infection-prone children (II), because these children were supposed to be frequently virus-
positive. Although the prevalence of both viruses decreased during the six-month study, the 
changes seemed to follow seasonal patterns. Th e prevalence of rhinovirus decreased from the 
baseline (measured in the autumn) to the middle of the study (winter), and increased again at 
end of the study (spring), corresponding to rhinovirus predominance in the early autumn and 
spring (Nokso-Koivisto et al., 2006). Th e reduction of enterovirus positivity from baseline to 
the end of the study can also be explained by an enterovirus peak in the autumn and winter 
(Nokso-Koivisto et al., 2006). 
Probiotics did not reduce the presence of rhinovirus or enterovirus. Th ere are no comparative 
clinical data available, but animal studies have shown that oral and intranasal administration of 
probiotic Lactobacillus casei Shirota has reduced viral titres in nasal washings of mice infected 
with an infl uenza virus (Hori et al., 2001; Yasui et al., 2004). Th is eff ect has been postulated 
as being due to the activation of innate immunity, as shown by the production of IL-12, TNF-
α and IFN-γ from medistinal lymph node cells (Hori et al., 2001), and the enhancement of 
pulmonary NK-cell activity (Yasui et al., 2004). Oral feeding with B. breve has also augmented 
antibody response to an oral infl uenza vaccination (Yasui et al. 1999). In humans, an oral 
consumption of fermented milk containing Lactobacillus GG or L. acidophilus accompanied 
by a polio vaccine increased the poliovirus neutralizing antibody titres and the formation of 
poliovirus-specifi c IgA and IgG (de Vrese et al., 2005a). 
A signifi cant interaction between probiotics and viruses on recurrent ARI episodes was 
seen. Probiotics reduced both the recurrence and the number of recurrent ARI episodes in 
the virus-negative children, but did not have any eff ect on the virus-positive children. Th is 
fi nding is astonishing, because ARIs are of viral origin, and it could be expected that probiotic 
eff ects would be seen particularly in the virus-positive subjects. However, the most reasonable 
explanation might be that other viruses, in addition to rhino- and entero-virus, may have been 
involved. Overall, the only possible way for probiotics to reduce viral respiratory infections 
is by immunological means. However, we did not measure any immunological parametres, 
leaving the immunological mechanisms to be merely speculated on. 
6.1.3 Antagonism to otitis pathogens
Nasopharyngeal colonisation by S. pneumoniae, H. infl uenzae or M. catarrhalis is associated 
with increased risk of AOM (Aniansson et al., 1994). It also seemed clear in our study that 
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these bacterial pathogens played an important role in the development of AOM in the otitis-
prone children (II), since the pathogen carriage was high, reaching up to 75%, while in 
healthy children the prevalence has varied from 20 to 50% (Ejlertsen et al., 1994; Gunnarsson 
et al., 1998; Principi et al., 1999). Th e probiotic combination did not reduce the carriage of 
pathogens, in contrast to a previous study in which a 3-week consumption of fermented milk 
containing L. rhamnosus GG, Bifi dobacterium, L. acidophilus  and S. thermophilus reduced the 
growth of potential pathogens on nasal mucosa in healthy adults (Glück and Gebbers, 2003). If 
probiotics reduced the growth of pathogens by direct antagonism, by producing antimicrobial 
compounds or by blocking adhesion, the method of administering probiotics would be of great 
importance. To achieve a local eff ect on the oro/nasopharyngeal microbiota, probiotics should 
be taken in the form of food. Th e administration of the probiotics in capsules in Study II may 
thus partly explain their ineff ectiveness. Although it was also permissable to mix the probiotic 
powder with food or drink, the older children at least may have swallowed the capsules whole, 
and no direct contact between the probiotics and the oropharyngeal microbiota will have 
occurred. Animal studies also show that intranasally-inoculated Lactobacillus strains have 
enhanced the clearance of S. pneumoniae (Cangemi de Gutierrez et al., 2001; Villena et al., 
2005) and of Pseudomonas aeruginosa (Alvarez et al., 2001) from the respiratory tract of mice. 
However, these eff ects were mediated through the induction of broncho-alveolar antibody 
production, and through the increased number and capacity of alveolar macrophages. In 
humans, consumption of fermented milk containing L. johnsonii La1 for 5 weeks, in addition 
to vaccination against H. infl uenzae, also showed the enhancement of  the antibody titre against 
H. infl uenzae (Yamori, 2004). 
Another factor aff ecting the effi  cacy of probiotics might derive from the use of multispecies 
probiotics. It is widely believed that combining several probiotic species will show 
synergistic eff ects against pathogen adhesion (Timmerman et al., 2004). However, the 
immunomodulatory eff ects of probiotics are highly strain-dependent (Moineau, 1991), and 
the interference of immunomodulating eff ects between individual strains might also take 
place (Hart et al., 2004). Although probiotics did not aff ect the carriage of S. pneumoniae or 
H. infl uenzae in Study II, the prevalence of M. catarrhalis increased in the probiotic group, 
which might have resulted from the possible antagonistic eff ects of the probiotic strains in 
the combination. On the other hand, the prevalence of Moraxella increased, particularly in 
the children of under 3 years of age, but not in the older children. Th is might also result from 
age-dependent factors, since the colonisation rate of Moraxella is highest among 1-4-year-
old children (54%), while it is relatively low (7%) in children of 4-15 years of age (Ejlertsen 
et al., 1994). 
To evaluate whether probiotics may enhance mucosal immunity in otitis-prone children 
(II), salivary IgA-antibodies against the most common otitis pathogen, S. pneumoniae (Kilpi 
et al., 2001), were measured. On the basis of diff erent capsular polysaccharides, at least 90 
diff erent pneumococcal serotypes are known. In Study II, the most frequent serotypes were 
6A, 6B, 15, 19F and 23F, which are also known to be the most prevalent serotypes in Finnish 
children, and to be related to the majority of cases of AOM (Syrjänen et al., 2001). Antibodies 
formed against the capsule are type-specifi c, and we measured antibodies against serotypes 
6B and 19F. Th e level of anti-6B-IgA concentration was higher in the probiotic group and the 
proportion of IgA-positive samples to serotype 6B also tended to be higher, suggesting that 
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probiotics might have enhanced mucosal immunity. However, no eff ect was seen on the level 
of anti-19F-IgA. Several surface proteins of Pneumococcus can also be used as immunogens, 
such as pneumococcal surface protein A (PspA), which is a virulence factor of S. pneumoniae, 
expressed on the surface of most clinical isolates (Crain et al., 1990). Th e oral and intranasal 
immunisation of mice with PspA with an adjuvant toxoid conjugate has induced mucosal 
and systemic antibody responses and protected against pneumococcal carriage and infections 
(Wu et al., 1997; Yamamoto et al., 1997). In healthy humans, the intranasal inoculation of 
pneumococcal 23F isolate has also induced the development of serum IgG and sIgA to PspA 
(McCool et al., 2002). However, in Study II, probiotics did not aff ect the levels of salivary 
IgA to the pneumococcal surface proteins, PhtD or PspA -1. Th us the results do not provide 
convincing evidence of the enhancement of mucosal immunity by probiotics, although anti-6B 
antibodies suggested a positive infl uence. 
Although probiotics did not reduce the overall occurrence of AOM, a signifi cant interaction 
was found between the probiotics and pathogen carriage on the occurrence of AOM. Probiotics 
increased the occurrence of AOM in the pathogen-positive subjects. Th is again highlights the 
strong infl uence of otitis pathogens on the occurrence of AOM, and that probiotics cannot 
compete with pathogen carriage in children who are highly susceptible to AOM because of 
disturbances in the nasopharyngeal microbiota. However, probiotics reduced the occurrence 
of AOM when the child was free of all bacterial pathogens. Th is indicates that probiotics may 
reduce the risk of AOM, which is of viral origin.  
6.2 Prevention of diarrhoea 
Probiotic treatment did not prevent diarrhoeal illnesses in healthy day-care children (I).Th is 
fi nding partly confl icts with the results of previous prevention studies. A slight decrease in 
the incidence of diarrhoea was seen when small infants and toddlers were supplemented with 
yoghurt containing Lactobacillus casei (Pedone et al., 2000). However, most of the prevention 
studies with children have not reduced the incidence of diarrhoea, although the severity of the 
diarrhoea, in terms of dehydration (Th ibault et al., 2004), the duration of diarrhoea (Pedone et 
al., 1999; Chouraqui et al., 2004; Weizman et al., 2005) and the number of diarrhoeal episodes 
(Oberhelman et al., 1999) has been reduced. One possible explanation for the ineff ectiveness 
of probiotics in Study I might be the age of the children. Th e children in previous studies who 
found benefi cial eff ects on diarrhoea, were 4 months to 2 years old (Oberhelman et al., 1999; 
Pedone et al., 2000; Chouraqui et al., 2004; Th ibault et al., 2004; Weizman et al., 2005), while 
the children in Study I were older - 1-6 years. Our fi nding also accords with another preventive 
study performed among older day-care children: a 6-month consumption of L. casei did not 
reduce the incidence of diarrhoea, either (Pedone et al., 1999). It can be speculated that the 
microbiota of infants and toddlers can be infl uenced more eff ectively (Guerin-Danan et al., 
1997; Waligora-Dupriet et al., 2007) than those of older children. Th e duration of diarrhoea 
among the healthy children (I) was short, lasting an average of only two days, while the average 
duration of diarrhoea among Finnish day-care children was 3.6 days (Pönkä et al., 1991). Th e 
short duration probably refl ects the mild nature of the diarrhoeal episodes, which could also 
explain the ineff ectiveness of the probiotics. 
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As with the children in Study (I), no benefi cial eff ect of probiotics on the prevention of diarrhoea 
was seen in the instutionalised elderly (III). However, the average duration of diarrhoea was 
3.7 days shorter in the probiotic group than in the placebo group. Th is diff erence might have 
clinical relevance, although it did not reach statistical signifi cance because of the low incidence 
of diarrhoea (only 22 subjects in the probiotic and 21 in the placebo group experienced 
diarrhoea). According to a recent meta-analysis, the treatment eff ect of probiotics has been 
found to be more evident in children than among adults, which may result from the diff erences 
between the gut microbiota of children and adults, and the diff erences in the colonisation 
ability of probiotics (Sazawal et al., 2006). On the other hand, it can also be speculated that 
the gut microbiota of frail elderly subjects (III) suff ering from several chronic diseases and 
consuming a wide range of medicines may have been severely unbalanced (Hebuterne, 2003) 
and therefore more responsive to benefi cial changes induced by probiotics. In healthy, elderly 
subjects it has been possible to induce benefi cial changes in the intestinal microbiota (refl ected 
by an increase in bifi dobacteria, lactobacilli and enterococci,  and a decrease in enterobacteria 
counts) by the 4-week consumption of a milk containing bifi dobacteria (Ahmed et al., 2007). 
However, there are only very limited data on the preventive eff ects of probiotics on community- 
or hospital-acquired diarrhoea in adults, and it is surprising that no previous data exist on the 
elderly, apart from data on antibiotic-associated diarrhoea, against which probiotics have been 
ineff ective (Lewis et al., 1998). 
On the basis of a recent meta-analysis of preventive studies, the eff ective size of probiotics 
seems to vary accordingly to the type of diarrhoea, being highest for antibiotic-associated 
diarrhoea and lowest for traveller’s diarrhoea (Sazawal et al., 2006). Th is indicates that the 
eff ect of probiotics is dependent on the causal pathogens: LGG has been found to be eff ective 
against viral gastroenteritis, but not against invasive agents such as Salmonella, Shigella, 
Campylobacter, Yersinia or Entamoeba (Guandalini et al., 2000). Th ere are no data available 
on the causative agents in Studies I and III, and therefore we cannot confi rm that the origin 
of the diarrhoeal episodes was infectious. It is well known that stress and changes in diet or 
medication may also cause diarrhoea. If these non-infectious causes had confounded the 
results, it would have lessened the eff ect of the probiotics. Th e probiotic eff ects are also known 
to be strain- and species-dependent. Combining two or more probiotic strains/species has 
been marginally more eff ective than using single strains in preventing diarrhoea (Sazawal et 
al., 2006). Th is might also explain why a single strain of Lactobacillus GG was not eff ective in 
preventing mild diarrhoea in children (I), but a combination of four probiotic strains showed 
a clinical diff erence in the duration of diarrhoea in the elderly (III). Th e specifi c combination 
seems to be especially benefi cial in gastrointestinal disorders, since it has reduced IBS-induced 
gastrointestinal symptoms (Kajander et al., 2005), as well as symptoms caused by Helicobacter 
pylori eradication treatment (Myllyluoma et al., 2005).
6.2.1 Methodological considerations
Th e defi nition of diarrhoea might have aff ected the outcome. Among the healthy children 
(I), diarrhoea was defi ned as ”abnormally loose stools compared to the child’s normal stool 
consistency”. We thought that this defi nition would be understandable to parents, and that the 
parents would be reliable observers in distinguishing changes in the usual stool consistency of 
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their own children. However, in most of the diarrhoea treatment studies (e.g. Guarino et al., 
1997; Szajewska et al., 2001; Mastretta et al., 2002; Costa-Ribeiro et al., 2003; Salazar-Lindo et 
al., 2004; Pereg et al., 2005), diarrhoea has been defi ned as “three or more loose or watery stools 
per 24 hours” following the World Health Organization (WHO) criteria, although diff erent 
modifi cations, e.g. “three or more bowel movements looser than normal” (Szymanski et al., 2006) 
or “two or more loose stools” (Rosenfeldt et al., 2002a), have also been used. It is, however, 
possible that such things as changes in the diet may have caused looser stools, and this may 
have been wrongly interpreted as infectious diarrhoea. Th is would have led to overestimation 
of the incidence of diarrhoea, which seems unlikely, because in our study the prevalence of 
diarrhoea was even lower than the average prevalence among day-care children (Hjelt et al., 
1987b; Rosenfeldt et al., 2005). 
In the institutionalised elderly (III), the defi nition of diarrhoea was more accurate: stool 
consistency was recorded as hard, normal/soft , loose, watery. Because the use of laxatives is 
extremely common among the instutionalised elderly and may cause functional diarrhoea 
on the same or the following day, the defi nition included abstention from laxatives on the 
same or the previous day. Personal nurses were responsible for recording stool frequency and 
consistency, which makes the results more reliable. However, the incidence of diarrhoea in 
the elderly was even lower than in the children. It is thus possible that diarrhoeal episodes 
of very short duration may have gone unnoticed. Th ere might also be some methodological 
weaknesses in reporting the duration of diarrhoea. All the treatment studies have measured 
the duration in hours, in order to detect diff erences of less than one day (e.g. Guandalini et 
al., 2000; Rosenfeldt et al., 2002a; Rosenfeldt et al., 2002b). Th e duration in Studies I and III 
was counted in whole days, and we might therefore have missed small diff erences in duration 
between the groups. 
6.3 Prevention of oral carriage of Candida 
Th e mouth represents the initial part of the gastrointestinal tract. It could therefore be 
hypothesised that probiotic antagonism to pathogens could act the same way in the mouth as 
in other distal parts of the gastrointestinal tract. During the past few years, evidence has been 
accumulating on the ability of probiotics to infl uence the composition of oral microbiota in 
adults and children, in terms of increasing the salivary Lactobacillus population (Montalto et al., 
2004), or reducing Streptococcus mutans counts (Näse et al., 2001). However, Study IV was the 
fi rst study to show that probiotics may modify the oral microbiota of the elderly by suppressing 
the growth of Candida. Probiotics reduced the risk of high Candida carriage by 75%, which can 
be considered a remarkable reduction. Th e overall prevalence of yeast carriage was 74%, which 
is a fair representation of the average yeast carriage among the elderly (Wilkieson et al., 1991; 
Meurman et al., 1997; Budtz-Jørgensen et al., 2000; Fanello et al., 2006), and thus the results 
can be generalised for an average elderly population.  
Only a very few clinical studies have been performed to study probiotic eff ects on Candida 
overgrowth, either in the oropharyngeal area or in the gastrointestinal tract. In an open, 
non-randomised clinical study, consumption of both fermented milk containing L. casei 
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Shirota and buttermilk containing L. lactis cremoris as a control product, decreased the 
quantity of yeasts in the voice prosthesis (Schwandt et al., 2005). An 8-week consumption of 
traditional yogurt containing S. thermophilus and L. bulgaricus did not aff ect the amount of 
salivary Candida in young adults, although the amount of S.mutans was reduced compared 
to the control ice-cream (Petti et al., 2001). However, cheese containing Lactobacillus 
GG and L. rhamnosus LC705 showed a tendency to reduce salivary Candida in healthy 
young adults (Ahola et al., 2002). In Study IV, L. rhamnosus GG and LC705 strains were 
combined with a Propionibacterium strain, because a combination of L. rhamnosus LC705 
and Propionibacterium freudenreichii ssp. shermanii JS has previously been shown eff ectively 
to prevent the growth of food spoilage yeasts and moulds in fermented milk products 
(Suomalainen and Mäyrä-Mäkinen, 1999). Th us, the addition of Propionibacterium 
probably improved the eff ectiveness of the probiotic mixture. Candida albicans was the 
most common species found, followed by C. glabrata and C. tropicalis, which accords with 
several other studies (Wilkieson et al., 1991; Paillaud et al., 2004; Fanello et al., 2006). No 
signifi cant switches between diff erent Candida species were found during the intervention. 
However, the probiotic treatment did not aff ect the subjective feeling of oral pain or the 
prevalence of mucosal lesions. Previous data on the eff ects of probiotics on oral mucosal 
disorders are very limited, though a few studies have reported some benefi cial eff ects of 
lactobacilli and bifi dobacteria on gingivitis and periodontal diseases - the infl ammations 
of the gum tissue caused by plaque (Morozova et al., 1996; Grudianov et al., 2002; Volozhin 
et al., 2004). 
6.3.1 Methodological considerations 
Several possible confounding factors which might have aff ected the yeast growth should 
be considered. No major diff erences in denture wearing, number of chronic diseases or 
medication were seen between the groups, but the prevalence of diabetes and the use of 
antibiotics were slightly more common in the probiotic group. However, no association 
between diabetes and yeast carriage was detected. Th e prevalence of yeast was slightly more 
common among antibiotic-users compared to non-users. However, when antibiotic use 
was introduced into a stepwise multivariable regression model, it did not reach statistical 
signifi cance, suggesting that antibiotics did not confound the treatment eff ect of probiotics. 
Low salivary secretion and buff ering capacity, in addition to denture wearing, are known 
risk factors for oral candidiasis (Närhi et al., 1993; Ikebe et al., 2006), and the results were 
therefore adjusted to these factors. Hyposalivation, on the basis of unstimulated secretion, 
was exhibited in 27% of the subjects, and in 45% when based on stimulated secretion, which 
accords with previous studies (Närhi et al., 1993; Ikebe et al., 2006). Interestingly, probiotics 
reduced the risk of hyposalivation, which may indirectly have aff ected the yeast growth. Th e 
mechanism behind this fi nding is unclear. It can be hypothesised that probiotics might have 
aff ected the composition of the saliva - such as the concentrations of mucins or salivary 
immunoglobulins, as has been shown in animal (Negretti et al., 1997), and  in in vitro studies 
(Mack et al., 2003) - and thereby aff ected the amount of saliva secreted. Saliva plays an 
important role in the preservation of oral health. Salivary proteins, such as histatin, defensins 
and secretory IgA, protect the soft  tissue of the oral cavity (Shay et al., 1997). Th us, alterations 
in the quality or quantity of saliva might aff ect the host resistance to candidal infection. 
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6.3.2 Antagonism to Candida 
Antifungal activity is a relatively common characteristic of many bacterial species, including 
lactobacilli (for review, see Kerr, 1999). Several Lactobacillus species (e.g. L. acidophilus, 
paracasei and rhamnosus), isolated from milk products, the female genital tract or the oral 
cavities of healthy volunteers, produce diff erent metabolites, such as organic acids, bacteriocins, 
hydrogen peroxide (Strus et al., 2005) and antifungal cyclic peptides (Ström et al., 2002), which 
inhibit the in vitro growth of yeasts. It has been suggested that hydrogen peroxide, together with 
peroxidase and hypothiocyanite, may be involved with the inhibition of Candida by lactobacilli 
(Jack et al., 1990) It has also been postulated that lactobacilli, in the presence of the peroxidase 
system, converts thiocyanate to hypothiocyanate, which is toxic to microorganisms. However, 
the mechanism of the probiotics in this clinical trial (IV) remains uncertain. Direct antagonism 
to Candida might partly explain the eff ects, especially since the probiotics were given in cheese. 
Lengthy chewing of cheese has, without doubt, prolonged the persistence of probiotics in the 
mouth, and thereby facilitated their functional ability in the oral cavity. In addition, lactobacilli 
are known to suppress the adhesion of oral micro-organisms such as Streptococcus mutans on 
saliva-coated hydroxyapatite (Wei et al., 2002), and several Lactobacillus strains can also inhibit 
C. albicans hyphal transformation, which is a key step towards epithelial invasion (Noverr and 
Huff nagle, 2004b). However, there are no comparative data available on the ability of probiotics 
to reduce the adhesion of Candida in the mouth, although in vitro studies have proved the 
ability of lactobacilli to displace Candida and prevent its adhesion to uroepithelial or vaginal 
cells (Reid et al., 1995; Strus et al., 2005). Coaggregation of probiotics with Candida may also 
explain the probiotic eff ect, as has been shown to happen between Candida and oral microbes, 
such as Fusobacteria (Jabra-Rizk et al., 1999).
Th e prolonged persistence of probiotics in the mouth may also have promoted the adhesion of the 
probiotics themselves to the mucosal surface, although previous colonisation studies fail to show 
any persistent colonisation of Lactobacillus GG in the mouth (Meurman et al., 1994; Yli-Knuuttila 
et al., 2006). LGG can be found in the saliva two weeks aft er the cessation of consumption 
(Meurman et al., 1994), but a recent study shows that even one third of the subjects do not carry 
LGG on the fi rst follow-up day aft er consumption (Yli-Knuuttila et al., 2006). Th e presence of 
probiotics in the saliva or oral mucosa was not determined in Study IV. 
If probiotics have the ability to colonise the oral cavity only temporarily, it is again tempting to 
assume that in addition to straight antagonistic mechanisms, systemic eff ects might also play 
a role in reducing Candida - a hypothesis supported by several animal studies. For example, 
the administration of live L. acidophilus and fermentum by a feeding tube straight into the 
stomach has shortened the duration of oral Candida colonisation in mice (Elahi et al., 2005). 
Because of the method of administration, the enhanced clearance of Candida did not involve 
direct interference by lactobacilli. In fact, the clearance was only detected two weeks aft er the 
treatment with lactobacilli, and it correlated with an early mRNA gene expression for IL-4 and 
IFN-γ, and with high levels of IFN-γ and NO in the saliva (Elahi et al., 2001). NO is involved 
in controlling the colonisation of Candida in the oral mucosa (Elahi et al., 2001), and Candida 
infections are associated with increased systemic and local NO production induced by the 
NO-synthase isoform (NOS2). NOS2, on the other hand, can be stimulated by TNF-α and 
IFN-γ, or by bacterial cell wall components, such as LPS, peptidoglycan and lipoteichoic acid 
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(Fang, 1997). Lactobacilli, including Lactobacillus GG, are known to induce the production 
of TNF-α and IFN-γ (Miettinen et al., 1996; 1998) and also of NO in murine macrophages 
and human colon epithelial cells (Korhonen et al., 2001). In addition, heat-killed Lactobacillus 
GG and L. acidophilus have been able to inhibit systemic candidiasis in mice, suggesting that 
the eff ect is mediated through the systemic stimulation of the immune system (Wagner et al., 
2000). It thus seems that probiotics may exert their Candida-inhibiting eff ect by producing 
antifungal metabolites, by inhibiting the adhesion of Candida, through the displacement of 
already existing Candida, and by enhancing host immunity. 
95
7  CONCLUSIONS  
On the basis of the results presented in this thesis, the following conclusions as to the effi  cacy 
of Lactobacillus GG and the combination of four probiotic bacteria in reducing common 
infections, can be drawn:
1. Specifi c probiotics may alleviate the severity of acute respiratory infections and prevent 
recurrent infections in certain subgroups of children. In healthy children, Lactobacillus GG 
slightly attenuates respiratory infections by postponing their appearance and by reducing 
complicated infections. Reduction of the complications may lead to reduced need for 
antimicrobial treatments, and to the reduction of child-care absences. In infection-prone 
children, the probiotic combination relieves infections by reducing recurrent episodes, 
especially in children with allergic diseases. Presumably, these eff ects are mediated through 
the stimulation of the immune system. In frail elderly subjects, a probiotic combination does 
not reduce respiratory infections. 
2. In healthy children, the alleviation of acute respiratory infections by Lactobacillus GG 
may lead to a marginal reduction in the occurrence of acute otitis media. In children prone 
to recurrent otitis media and with disturbed nasopharyngeal microbiota, the probiotic 
combination is not eff ective in preventing otitis, except in the case of children with allergic 
diseases. Probiotics taken in capsules do not reduce the carriage of bacterial pathogens, 
suggesting that no direct antagonism between probiotics and pathogens occurs in the 
nasopharynx. Specifi c probiotics may be eff ective against viral but not against bacterial acute 
otitis media. 
3. Th e long-term consumption of Lactobacillus GG or a probiotic combination, either taken 
in food or as capsules, is not eff ective in preventing acute diarrhoea in healthy children or in 
frail, institutionalised elderly subjects. Th is result, which is contrary to previous fi ndings, needs 
to be clarifi ed in further studies with a suffi  cient number of subjects and diarrhoea events with 
known causative pathogens.
4. Th e long-term consumption of specifi c probiotics in a food matrix modifi es the oral 
microbiota of elderly subjects by reducing the prevalence of high oral yeast carriage, possibly 
related to the reduced risk of hyposalivation. Probiotics can thus be considered benefi cial to 
the oral health of the elderly. 
Th e specifi c probiotic, Lactobacillus GG, and a probiotic combination containing LGG both 
seem to be benefi cial for children in terms of alleviating the severity of respiratory infections, 
and for elderly subjects, in balancing their oral microbiota. Since probiotics are considered to 
be food and are easy to include in the everyday diet, they can be considered a suitable, easy and 
safe method for balancing the body’s natural defences against infections.
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